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SUMMARY  
 
Due to the large amount of pollutants produced by the chemical industry, the 
European Union (EU) approved in 2007 the regulation on Registration, Evaluation, 
Authorisation and Restriction of Chemicals (REACH). This aims at improving the 
identification and knowledge of up to 30,000 existing chemical substances. Among them, 
1,500 compounds are considered “substances of very high concern” due to their 
environmental and human health risk. Animal experimentation is the classical approach 
to test the harmful effects of chemicals. However, due to the huge amount of chemicals, 
expensive cost and ethical reasons, alternatives testing methods are being implemented 
nowadays. According to REACH, the experimentation in animals should be used as a 
“last resort”. In this framework, in silico computational methods are promising tools, being 
physiologically-based pharmacokinetic (PBPK) models specially relevant. PBPK models 
are mathematical representations of the human body, where human tissues are 
considered as compartments linked by the blood flow. These tools allow estimating the 
concentration and behaviour of environmental contaminants in the human body. The use 
of PBPK models is still incipient in human health risk assessment. Therefore, there is a 
lack of validated PBPK models. Polychlorinated dibenzo-p-dioxins and dibenzofurans 
(PCDD/Fs) and perfluoroalkyl substances (PFASs) are two of the most harmful groups 
of chemicals for the human health. These environmental pollutants are well known for 
their high persistence, bioaccumulation and toxicity (PBT), exhibiting also a long-range 
transport capacity. Furthermore, PCDD/Fs as well as perfluorooctane sulfonic acid 
(PFOS), the mostly studied PFAS, are included in the list of persistent organic pollutants 
(POPs) in the Stockholm Convention. 
The objective of the present thesis was to develop a PBPK model to study the 
behaviour and concentration of POPs in human tissues. PCDD/Fs and PFASs, two 
notably different POPs, were selected. Since late 1970s, PCDD/Fs have been posing 
special concern for the regulatory agencies. In contrast, PFASs have not been so 
extensively studied yet. To identify the potential risk of PFASs, a PBT-based ranking was 
developed to confirm their potential human health risk in front of other environmental 
contaminants. Because of their easy pharmacokinetics, the PBPK model was firstly 
developed for PCDD/Fs. Afterwards, the model was adapted to estimate the 
accumulation of PFASs in human tissue.  
In Chapter I, a ranking to prioritize the risk of chemical compounds in river water 
was developed. Up to 205 compounds, including pharmaceutic compounds, illicit drugs, 
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endocrine disruptors, UV filters, pesticides as well as PFASs, were selected. The index 
was based on the PBT properties of the chemicals and the water concentration of 4 
Spanish rivers. Self-organizing maps (SOM) were used to cluster the compounds 
according to their PBT characteristics, and the final result was a hazard index (HI), where 
pollutants were prioritized according to their harmful effects. With a HI of 5.58 over 10, 
PFASs were identified among the most harmful group of compounds for the human 
health. Afterwards, an integrated risk index for the chemical aquatic pollution (IRICAP) 
was obtained by multiplying the HI of each compound by its concentration found in river 
water. The IRICAP was applied to 77 sampling points located in the basins of Ebro, 
Júcar, Guadalquivir and Llobregat.  
Chapter II and III developed the PBPK model for PCDD/Fs, highlighting their 
presence in blood and adipose tissue, respectively. The main characteristics of the PBPK 
model were: 1) PCDD/Fs are not metabolized in the human body, 2) the ingestion may 
be considered only through food and water intake, and 3) the elimination occur only 
through feces. The simulated compartments were blood, muscle, skin, richly perfused, 
fat, kidney, and liver. Experimental data on PCDD/F levels in blood and adipose tissue 
samples from the adult population in Tarragona County (NE of Spain), were collected. 
The model was validated comparing the simulated and experimental results, which were 
highly coincident. In plasma, the modelled mean level of PCDD/Fs was 7.95 pg I-TEQ/g 
lipid, while the experimental concentration was 6.18 pg I-TEQ/g lipid. In adipose tissue, 
the simulated and experimental levels of PCDD/Fs were also of the same order of 
magnitude (4.77 vs 11.15 pg I-TEQ/g lipid). Due to the reasonable coincidence between 
the experimental and simulated results, the PBPK model developed was considered as 
validated. The PBPK model was simulated in four temporal scenarios, for which 
experimental data were available: 1998, 2002, 2007, and 2012. 
Chapter IV adapted the previously developed PBPK model to perfluorooctanoic 
acid (PFOA) and PFOS. In this case, the elimination mechanism was considered to occur 
only through urine by a mechanism of resorption, according to chemicals in urine are 
resorbed back to plasma through a saturable process. Furthermore, the binding to 
plasma albumin was also considered in the model equations. The PBPK model simulated 
the concentration of PFOS and PFOA in humans for a non-occupationally exposed 
population in Tarragona County. Nine body compartments were considered: plasma, 
liver, brain, lungs, kidney, gut, filtrate, rest of the body, and fat. Data of PFOS and PFOA 
in 5 autopsy tissues (liver, brain, lung, kidney and bone marrow) were used to validate 
the PBPK model. In liver, the target tissue of PFOS and PFOA, the simulated 
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concentration of PFOA was 3.33 ng/g, while the experimental concentration was 
13.6±35.2 ng/g. For PFOS, the concentrations found were 36.4 ng/g and 102.3±122.9 
ng/g according to simulated and experimental results, respectively. Because simulated 
concentrations were within the range of the measured levels of PFOS and PFOA, the 
model was considered as validated. 
Chapter V extended the previous model to other 9 PFASs. The model followed 
the same structure, and only parameterization data were modified according on each 
specific compound. Values of partition coefficient (Pks), elimination constants and 
binding to albumin protein were assessed by using experimental data of biological 
tissues from residents in Tarragona County. Parameterization data were assessed by 
fitting the PBPK simulation with the experimental data. For validation purposes, the 
PBPK model was applied in a case-study. Andøya Island (Norway) was used as a 
scenario because data on human intake and plasma concentration of PFASs were 
available for a non-occupationally exposed population. Validation consisted on 
comparing the range of the simulations and the experimental results. The model was 
considered validated for PFHxS, PFOS, PFHpA, PFOA and PFNA, due to the important 
coincidence between the ranges of the simulated and measured concentrations. For 
instance, for PFNA the simulated concentration ranged from 0.02 to 1.14 ng/g, whereas 
the mean experimental concentration was 0.95 ng/g, ranging from 0.26 to 2.9 ng/g. 
Given the importance of uncertainty, Chapter VI was focused on quantifying the 
influence of uncertainty in the PBPK model for PFOS and PFOA. The uncertainty 
analysis was focused on the parametric uncertainty, which is the study of the error 
associated to the experimental parameters used in the PBPK model. The objective of 
this chapter was to study the validation process of PBPK models and to mathematically 
assess their validity. Therefore, the minimum and maximum concentrations for the PBPK 
simulations were assessed by using the range of data of the most uncertain parameters 
(elimination parameters, protein binding, and daily intake) to obtain a range of simulated 
concentrations. The model was considered as visually validated if the experimental 
results were in the same range of the simulated range. Moreover, the validity of the PBPK 
model was mathematically studied by using the Student’s t-test. Finally, the visual and 
the statistical validation were compared to analyze the influence of the uncertainty in the 
process of model validation. For few tissues, the model was not statistically validated, 
indicating that the inclusion of the statistical analysis should be incorporated in the 
development of PBPK models to ensure the validity of the final outcomes.  
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The here developed PBPK model has been demonstrated to be a reliable tool to 
simulate the levels of PCDD/Fs and PFASs in human tissues. The simulations were 
highly coincident with the experimental results for most of the PCDD/F congeners, 
whereas for PFASs, the simulated and experimental concentrations were also of the 
same order of magnitude. Moreover, the statistical study of the uncertainty in the PBPK 
models was incorporated into the process of model development to ensure the validity 
of the PBPK models. As a general conclusion, PBPK models are not only a promising 
tool, but also a reality to simulate the concentrations of environmental pollutants in 
human tissues, for their subsequent use in human health risk assessment.  
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RESUM 
 
Degut a la gran quantitat de productes contaminants produïts per la indústria 
química, la Unió Europea va aprovar a l’any 2007 la regulació sobre registració, 
avaluació, autorització i restricció de productes químics (REACH), amb l’objectiu de 
millorar la identificació i coneixement de més de 30,000 compostos químics. Entre 
aquests, 1,500 son considerats “compostos de molt alt perill” degut al seu risc per la 
salut humana i pel medi ambient. L’aproximació clàssica per mesurar els efectes 
perjudicials sobre la salut dels compostos químics és l’experimentació en animals. No 
obstant, degut a la gran quantitat de compostos químics que es necessiten estudiar i 
degut al seu cost i raons ètiques, s’estan implementant mètodes alternatius. Segons 
REACH, l’experimentació en animals hauria de ser l’“última alternativa”. En aquest 
context, les eines computacionals o in silico son una bona alternativa. Entre elles, es 
troben els models farmacocinètics o PBPK (·physiologically-based pharmacokinetic 
models”). Els models PBPK són representacions matemàtiques del cos humà on els 
teixits es consideren compartiments units pel flux de sang. L’ús de models PBPK és 
encara incipient en l’avaluació de risc per a la salut, i per tant hi ha una falta de models 
per calcular la concentració i el comportament de contaminants ambientals en el cos 
humà. Les dibenzo-p-dioxines policlorades i dibenzofurans policlorats (PCDD/Fs) i 
compostos perfluorats (PFASs), són dos dels grups de contaminants més perillosos per 
a la salut humana. Aquest compostos són ben coneguts per la seva alta persistència, 
bioacumulació i toxicitat (PBT), a més d’una alta capacitat pel transport a llarga distància. 
A més a més, les PCDD/Fs i l’àcid perfluorooctà sulfònic (PFOS), que és el PFASs més 
estudiat, estan inclosos a la llista de compostos orgànics persistents (COPs) en la 
Convenció d’Estocolm.  
L’objectiu de la present tesis va ser el desenvolupar d’un model PBPK per 
estudiar el comportament i concentració de compostos orgànics persistents (COPs) en 
teixits humans. Es van seleccionar dos grups de compostos notablement diferents, com 
son els PCDD/Fs i PFASs. Des de finals dels 70, les PCDD/Fs han tingut una 
preocupació especial per les agencies reguladores. Però, per altra banda, els PFASs 
encara no han estat gaire estudiats. Per conèixer amb exactitud la perillositat dels 
PFASs es va desenvolupar un índex de risc humà enfront a contaminants ambientals. 
Després, el model PBPK va ser primerament desenvolupat per PCDD/Fs degut a la seva 
relativament simple farmacocinètica en el cos humà. A continuació, el model es va 
adaptar per estimar l’acumulació de PFASs en teixits humans.  
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En el Capítol I es va desenvolupar un índex de risc per prioritzar compostos 
químics en aigua fluvial. Es van estudiar més de 205 compostos incloent farmacèutics, 
drogues, disruptors endocrins, filtres ultraviolats, pesticides i PFASs. L’índex es va basar 
en les propietats PBT dels químics i en la concentració en aigua en 4 conques fluvials 
Espanyoles. Els mapes autoorganitzats (SOM) van ser utilitzats per agrupar els 
compostos segons les seves característiques PBT. El resultat final va ser un índex de 
perillositat (HI), on els compostos es van prioritzar en funció dels seus efectes nocius. 
Els PFASs es van identificar entre els compostos més perillosos per a la salut humana 
amb un HI de 5.58 sobre 10. A continuació, es va calcular l’índex de risc integrat per la 
contaminació aquàtica (IRICAP) multiplicant el HI de cada compost per la seva 
concentració en aigua. L’IRICAP es va aplicar a 77 punts localitzats a l’Ebre, Xúcar, 
Guadalquivir i Llobregat.  
Els Capítols II i III van desenvolupar un model PBPK per PCDD/Fs en sang i en 
teixit adipós, respectivament. Les principals característiques del model PBPK van ser: 
1) els compostos PCDD/Fs no es metabolitzen en el cos humà, 2) la ingestió es va 
considerar exclusivament per ingestió d’aliments i aigua, 3) l’eliminació és exclusivament 
per femta. Els compartiments estudiats van ser la sang, múscul, pell, grassa, ronyó, 
fetge i resta del cos. En aquest estudi, les dades sobre la població adulta es van extreure 
a l’àrea de Tarragona (NE d’Espanya). El model es va validar comparant dades 
simulades i experimentals. Es va trobar una gran similitud entre les simulacions i les 
dades experimentals. En plasma, les dades del model per PCDD/Fs van ser 7.95 pg I-
TEQ/g greix, mentre les concentracions experimentals van ser de 6.18 pg I-TEQ/g greix. 
En teixit adipós els valors simulats i experimentals van ser igualment del mateix ordre 
de magnitud (4.77 vs 11.15 pg I-TEQ/g greix). Degut a la raonable coincidència entre 
els resultats experimentals i simulats, el model PBPK es va considerar com a validat per 
simular les concentracions de PCDD/Fs en sang i en greix per població no ocupacional. 
Les simulacions amb el model PBPK es van calcular en 4 escenaris on hi havia dades 
experimentals disponibles: 1998, 2002, 2007 i 2012. 
El Capítol IV va adaptar el model PBPK desenvolupat prèviament, a àcid 
perfluorooctanoic (PFOA) i a PFOS. En aquest cas el mecanisme d’eliminació es va 
considerar només a través de l’orina, mitjançant un procés de reabsorció, on des del 
plasma els compostos es reabsorveixen a l’orina, seguint un procés saturable. A més, 
es va considerar que hi havia una forta unió a l’albúmina del plasma. El model PBPK va 
simular la concentració de PFOA i PFOS per població no ocupacional de l’àrea de 
Tarragona. Els teixits que es van estudiar van ser plasma, fetge, cervell, pulmons, ronyó, 
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estomac, veixiga, resta del cos i teixit adipós. Per validar el model es van utilitzar dades 
de teixits humans en autòpsia. En el fetge, que és l’òrgan diana per PFOA i PFOS, la 
concentració simulada de PFOA va ser de 3.33 ng/g, mentre que la concentració 
experimental va ser de 13.6±35.2 ng/g. Per PFOS les concentracions van ser de 36.4 
ng/g i de 102.3±122.9 ng/g, per valors simulats i experimentals, respectivament. Degut 
a la coincidència entre els valors simulats i els rangs dels valors experimentals, el model 
es va considerar com a validat. 
En el Capítol V es va estendre el model previ a 9 compostos PFASs més. El 
model va seguir la mateixa estructura i només les dades paramètriques es van modificar 
en funció del compost. Els coeficients de partició (Pks), les constants d’eliminació i la 
unió a l’albúmina es va calcular utilitzant dades experimentals de residents de l’àrea de 
Tarragona. Les dades paramètriques es van calcular ajustant les simulacions del model 
PBPK amb les dades experimentals. A continuació, per tal de validar el model, el model 
PBPK es va aplicar en un cas d’estudi. L’illa d’Andøya (Noruega) es va utilitzar com 
escenari degut a la disponibilitat de dades de concentracions en plasma i d’ingesta en 
població no ocupacional. El model es va validar per simular les concentracions de 
PFASs en teixits humans per població sota exposició no ocupacional. Per considerar el 
model com a vàlid, es va considerar que el rang entre els valors simulats i experimentals 
havien de ser coincidents. Per exemple per PFNA, la concentració simulada va ser 
d’entre 0.02 i 1.14 ng/g (mínim i màxim), i el valor experimental va ser de 0.95 ng/g (rang 
entre 0.26 i 2.9 ng/g). El model es va considerar com a validat per PFHxS, PFOS, 
PFHpA, PFOA i PFNA degut a la coincidència entre el rang dels valors simulats i els 
valors experimentals 
Donada la gran importància de la incertesa, en el Capítol VI es va estudiar la 
incertesa en els models PBPK per PFOS i PFOA. L’anàlisi de incertesa es va enfocar 
en la incertesa paramètrica, que és l’estudi de l’error associat als paràmetres 
experimentals utilitzats en el model PBPK. Per tant, l’objectiu d’aquest capítol és l’estudi 
del procés de validació dels models PBPK i calcular matemàticament la seva validesa. 
Conseqüentment, els valors màxim i mínim dels valors simulats pel model PBPK es van 
calcular utilitzant el rang de concentració dels paràmetres amb més incertesa 
(eliminació, ingesta i unió amb proteïnes), per obtenir un rang de concentracions 
simulades. El model es va considerar com a vàlid quan els resultats experimentals 
estaven dins del rang dels resultats simulats. A més a més, la validesa del model PBPK 
es va estudiar utilitzant el test estadístic de la t de Student. Finalment les validacions 
visual i estadística es van comparar per analitzar la influència de la incertesa en el procés 
UNIVERSITAT ROVIRA I VIRGILI 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF PCDD/FS AND PFASS IN HUMANS. 
Francesc Fabrega Bonadona 
Dipòsit Legal: T 1660-2014
Resum 
 
XXVI 
de validació. Per alguns pocs teixits el model no es va poder considerar com a validat. 
És per això que la inclusió d’anàlisis estadístic hauria de ser incorporat en el 
desenvolupament dels models PBPK com una pràctica habitual per assegurar la 
validesa dels resultats finals.  
El model PBPK ha demostrat ser una eina fiable per simular la concentració de 
PCDD/Fs i PFASs en teixits humans per població no ocupacional. Les simulacions de 
PCDD/Fs van ser altament coincidents amb els resultats experimentals per la major part 
del congéners, mentre que per PFASs les concentracions simulades i experimentals van 
ser raonablement coincidents. A més a més l’estudi estadístic de la incertesa en el model 
PBPK va ser incorporat en el procés de validació del model. Com a conclusió, els models 
PBPK son no només una eina prometedora, sinó una realitat per simular les 
concentracions de contaminants ambientals en teixits humans, pel seu posterior ús en 
l’avaluació de risc per a la salut humana.  
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INTRODUCTION 
1. New computational methods: In silico tools 
 
Classic approaches to estimate the toxicity of chemical compounds for human 
health have involved the usage of animal testing. However this is a relatively slow 
technique, subject to a big variability and expensive costs, besides obvious ethical 
reasons (Robson and Toscano, 2007). Furthermore there is a huge amount of chemicals 
which required to be tested, making terribly difficult their assessment by means of animal 
experimentation studies. The European Commission (EC) has estimated that over 
30,000 chemicals in 11 years will be regulated under REACH (Registration, Evaluation 
and Authorisation of Chemicals). Given the impressive number of chemicals, new testing 
methods have emerged on powerful, reliable and cheaper alternatives. One of these are 
in silico methods, whose main objective is to reduce the usage of animal experimentation 
(Roncaglioni et al., 2013). In silico techniques may be either Expert Systems (ES) or 
Data Driven Systems (DDS) (Bakhtyari et al., 2013). ES attempts to emulate the decision 
making ability of the human experts, while DDS are methods to extract and predict 
models directly from experimental data. DDS vary in sophistication from simple methods 
(Read-across methods) to more complex methods (QSAR: Quantitative structure-activity 
relationship). 
In silico techniques can extract information easier and quicker than with in vivo 
experiments. Mathematical models are relatively simple to build and with the additional 
advantage that validated models can be applied to a number of different hypothetical 
scenarios including new routes, dose, species and the involvement of new chemicals. In 
silico tools also allow to replacing in vivo animal studies by extrapolating results between 
species with a relatively high degree of reliability. Furthermore, modeling seems to be a 
better technique to extrapolate kinetic or toxicological results from animals to humans, 
thus increasing confidence in health risk assessment (Bouvier et al., 2007). Despite, 
modeling is a useful tool, it must be highlighted that they are an oversimplification of the 
real processes of the body, as was pointed out by Suresh Moolgavkar, and eminent 
professor of toxicology and risk assessment: “No model can be said to be ‘correct’. The 
role of any model is to provide a framework for viewing known facts and to suggest 
experiments”. 
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2. Physiologically-based pharmacokinetic (PBPK) models 
2.1. Introduction and needs  
Human health risk assessment is a fundamental step to estimate the impact of 
chemicals emitted to the environment, and to estimate the exposure. Dose and time of 
exposure have been considered traditionally as the most important parameters to 
perform evaluation of the human health risk. However, when a chemical enters the 
human body, there are complex processes which must be taken into account: absorption, 
distribution, metabolism and elimination (ADME). Physiologically-based pharmacokinetic 
(PBPK) models provide a tool to predict these ADME processes inside the body along 
time. Physiologically-based pharmacokinetic (PBPK) models are mathematical 
representations of the human body where the tissues are represented as compartments 
linked by the blood flow. The final result is a set of ordinary differential equations that can 
be solved using computational software. These models can be used for pharmacological 
research, health risk assessment and other fields in medicine. 
 
2.2. History of PBPK models  
The first PBPK model including a multi-compartmental structure and PK/PD data 
was introduced by Teodorell (1937). Unfortunately, the lack of mathematical tools to 
solve differential equations made PBPK models a difficult problem to solve in that time. 
Moreover, there was a lack of methods to predict the parameters needed for the PBPK 
model parameterization (Jones and Rowland-Yeo, 2013). The proliferation of PBPK 
models started in the 1980s due to the improvement of the new in vitro technologies, and 
computational tools (Edginton et al., 2008). Bischoff et al. (1971), published an early 
report that established the basis for the current PBPK models incorporating metabolism 
mechanisms in a PBPK model for methotrexate. Another seminal report of the early 
development of PBPK modeling was developed by Ramsey and Andersen (1984) that 
applied a PBPK model to assess styrene in rats for several routes of administration. 
Since the eighties, the PBPK model started to proliferate increasing its complexity and 
being used in pharmaceutical research and in environmental risk assessment. Over the 
last two decades, the number of scientific publications about PBPK modeling has 
gradually increased, demonstrating its utility in drug development and risk analysis 
(Huang et al., 2013) (Figure 1).  
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Fig. 1. Annual rate of publications whose title contains the phrase 
“Physiologically-based pharmacokinetic”; Source: ISI Web of Knowledge. 
 
2.3. Development of PBPK models  
The development of PBPK models involves three main steps: 1) definition of the 
model, 2) data collection and 3) mathematical simulation (Figure 2). Subsequently, the 
model is compared with experimental data available for calibration and validation 
purposes, and the model is finally modified according to new suppositions and 
presumptions.  
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Fig. 2. Steps on the PBPK model development (Reddy et al., 2005). 
 
The first step on the PBPK model building is to identify the organs or tissues 
involved in the ADME processes. Models generally simplify the biological complexity by 
subdividing the body in discrete compartments (Bouvier et al., 2007). The construction 
of the model can be done by considering previously available information about the 
distribution of the compound inside the body, and the biochemical information on 
chemicals metabolism. For instance, if a compound is strongly lipophobic, it is senseless 
to include fat tissues. Realism and simplification must be balanced. 
Each organ or tissue is considered a compartment, characterized by its own initial 
concentration, tissue volumes, solubility, metabolic constants, etc. The different tissues 
are connected by the arterial and venous blood flow. To maintain the mass balance, the 
sum of arterial blood flows must to be equal to the venous flow. It is also important to 
distinguish between interstitial and intracellular space because the compartments are 
separated from membranes that act as a barrier with a limiting distribution (permeation 
limiting kinetics), and this distribution can be a limiting step (von and Huisinga, 2007). 
Usually, metabolism is considered only in liver, although this may also occur in lungs, 
kidney or gut (Beaudouin et al., 2010). The administration of the compound can be by 
gastric intake, dermal exposure or inhalation, and therefore all the possible human 
exposures can be simulated (Di Muria et al., 2010). A model can be as complex as the 
modeler wants, including all the organs of the body, but the simplicity of the model can 
avoid unnecessary waste time. In this first step, an overestimation or oversimplification 
is possible, becoming one of the most problematic steps. If the model does not run well, 
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a new adjustment will be necessary in the future. In this way, models are useful not only 
to simulate the behaviour of a chemical, but also to determine the metabolic and 
biochemical processes inside the human body (Edginton et al., 2008). 
Once the conceptual model is created, the next step is to make a mathematical 
representation of each compartment or tissue. Generally, mass-balance ordinary 
differential equations are used to explain the change of a chemical in a tissue over the 
time, describing the transfer between compartments, as well as metabolism and 
excretion processes. The PBPK compartments are usually defined as a well-stirred tank 
or two-subcompartment tissues, being defined by flow-limited and permeability-limited 
equations (Thompson and Beard, 2011; Thompson et al., 2012). These equations 
establish the rate at which molecules enter and leave a tissue, and the speed of 
metabolism in the same tissue. Once a set of equations is obtained, the resolution is 
done by specific computational software (e.g., Berkley Madonna, AcslX) or by 
programming the equations with generic mathematical programs (e.g., Matlab, Fortran 
95) (Schmitt and Willmann, 2004). The building of the model also involves the collection 
of parametric data. Pharmacokinetic data are available in medical literature, where have 
been compiled (Brown et al., 1997; Price et al., 2003). In turn, information can be 
calculated through different algorithms (Peyret et al., 2010; Poulin and Theil, 2009). 
Sometimes there exist gaps in human body data, and then extrapolation from 
experimentation on animal data is necessary. There are three kinds of parameters that 
are necessary to build PBPK models: physiological (e.g., ventilation rate, body weight, 
blood rate), thermodynamic (e.g., tissue partition coefficients), and biochemical (e.g., Km 
and Vmax) (Mumtaz, 2010). 
Once the model is created, it can be compared with experimental data for 
calibration and validation purposes. If the model is not in agreement with the 
experimental observations, some possibilities arise: either a wrong estimation was done 
in some step of the process or some information had been misunderstood. Then, it is 
necessary to check which the mistake is and solve the problem or refine much more the 
model. Sometimes PBPK models are created as a hypothesis-testing in toxicology to 
conduct in silico experiments to know much more about some toxicological processes. 
Once a model is correctly validated, then it is ready to be used in other scenarios. 
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2.4. PBPK in human health risk assessment  
Firstly, it is important to distinguish between tissue dose or target dose in front of 
the exposure dose. Exposure dose is the administrated dose via food intake, dermal 
exposure or air inhalation, while target dose is the dose in a tissue or organ after different 
ADME processes in the body (Leahy, 2006). Beneficial or adverse effects are not related 
only to the exposure but also with the different processes inside the body. 
Pharmacokinetic models allow to evaluating the chemical distribution and to making 
much more precise approximations than exposure-based models.  
PBPK models vary in complexity according to their purpose, while there are not always 
necessary for human risk assessment. Traditionally, cancer and noncancer risk 
assessment rarely considers chemical-specific pharmacokinetic information, but PBPK 
models may improve risk assessment. There are four important uses of PBPK models in 
risk assessment (Clark et al., 2004; Clewell et al., 2002):  
1) Cross-species extrapolation. Classical risk assessment assumes the 
same mode of action for both animals and humans. PBPK models may be used to 
extrapolate from animals to humans when the mode of action is different between 
species.  
2) Cross-route extrapolation. It consists on extrapolating data between 
different exposure pathways. For instance, PBPK modeling can be used to assess the 
tissue-dose associated to a target tissue in animals through one route, and then 
assessing the equivalent exposure in human by using another exposure pathway.  
3) Dose extrapolation. This incorporates the dose-response of a chemical. 
As for instance, the toxicity of the vinyl chloride is not lineal due to the saturation of its 
metabolism. By using PBPK models, the response in the metabolism may be estimated 
and the accuracy of the model improved.  
4) Time extrapolation. PBPK modeling provides more accuracy to 
extrapolate exposure frames than other methods such as average daily dose. For 
instance, exposure to one chemical to a single dose is not the same than a repeated 
exposure to multiple low doses. Moreover, PBPK models may simulate the dosimetry 
under pregnancy, lactation and developmental age. 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF PCDD/FS AND PFASS IN HUMANS. 
Francesc Fabrega Bonadona 
Dipòsit Legal: T 1660-2014
Introduction 
 
7 
3. POPs 
Persistent organic pollutants (POPs) are organic compounds intentionally or 
unintentionally released to the environment. They are characterized by a high 
persistence in the environment, high bioaccumulation in the human body, high toxicity 
for both humans and wildlife, as well as long-range transport capacity (Boethling et al., 
2009). The Stockholm convention (SC) on POPs is a global treaty for the regulation of 
such compounds that was adopted in May 2001 and came into force in 2004. The SC 
aims to reduce or eliminate the use and production of these compounds. The initial SC 
list included 12 compounds, but this list has increased in recent years. Currently, up to 
22 compounds are included. 
 
4. PCDD/Fs 
Polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans 
(PCDFs) are a group of halogenated organic compounds, constituted by two rings of 
benzene linked by two or one oxygen atoms, respectively. This family of compounds is 
generally known as “dioxins or furans”. It family includes 210 congeners, which depend 
on the position of the chlorine atom: 75 are dioxins (PCDD), and 135 furans (PCDFs). 
The general structure of dioxins and furans is depicted in Figure 3.  
 
 
Fig. 3. Chemical structure of PCDDs and PCDFs. 
 
4.1. Sources of exposure 
PCDD/Fs are unintentional by-products of industrial and burning processes, 
being human activities the main emission source. In turn, this can be divided into 
regulated and non regulated or diffuse source (Fiedler, 1996; Kulkarni et al., 2008). The 
former group includes municipal solid waste incinerators, chemical waste incinerators, 
clinical waste incinerators, cement kilns, sinter plants and sewage sludge incinerators 
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(Alcock et al., 2001). Non regulated emissions come from traffic, domestic combustion 
and accidental fires. In the last decades, important legislation efforts to reduce the 
environmental emissions of PCDD/Fs have give place to a substantial reduction of the 
emissions and the atmospheric concentrations (Hassanin et al., 2006). Consequently, a 
reduction in human exposure and in body burdens of PCDD/Fs has also been observed 
(Nadal et al., 2013).  
Scientific studies, have indicated that the main source of human exposure to 
PCDD/Fs is food ingestion, over the >95% of the total intake (Linares et al., 2010; Martí-
Cid et al., 2008; Nadal et al., 2011). In general, food from animal origin contains more 
dioxins that the food coming from vegetal origin (Chan and Wong, 2013), while relatively 
high levels of PCDD/Fs have also been found in fish and seafood.  
 
4.2. Toxicity 
The toxicity of the different PCDD/F congeners may vary in a 1000-folder 
magnitude depending of the congener. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (2,3,7,8-
TCDD) is considered the most toxic of the dioxins congeners and a toxic factor of 1 has 
been assigned to this congener. All the other congeners of PCDD/Fs have a relative 
toxicity that ranges from 0 to 1 (Table 1). This scale of toxicity is called the Toxicological 
Equivalent Factor (TEF). It is agreed that the most toxic congeners for the human Health 
risk are those that contains Cl in the positions 2, 3, 7 and 8 in the ring (Linden et al., 
2010). Up to 17 toxic congeners have been selected: 7 dioxins and 10 furans. For the 
remaining 193 PCDD/F congeners, the toxicity for the human health may be considered 
as negligible (TEF=0). The most and more extensively used TEF values for human 
toxicity are I-TEF and WHO-TEF. I-TEF was set up by NATO in 1989 and after that was 
extended and validated (Kutz et al., 1990). WHO-TEF where set up by the World Health 
Organization (WHO) in 1998, and reevaluated in 2005 (Van den Berg et al., 2005). I-TEF 
and WHO-TEF values are summarized in table 1.  
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Table 1. I-TEF and WHO-TEF valued for the 17 PCDD/Fs congeners 
Compound I-TEF WHO-TEF 
PCDDs 
  
2,3,7,8-TCDD 1 1 
1,2,3,7,8-PeCDD 0.5 1 
1,2,3,4,7,8-HxCDD 0.1 0.1 
1,2,3,6,7,8-HxCDD 0.1 0.1 
1,2,3,7,8,9-HxCDD 0.1 0.1 
1,2,3,4,6,7,8-HpCDD 0.01 0.01 
OCDD 0.001 0.0003 
PCDFs 
  
2,3,7,8-TCDF 0.1 0.1 
1,2,3,7,8-PeCDF 0.05 0.03 
2,3,4,7,8-PeCDF 0.5 0.3 
1,2,3,4,7,8-HxCDF 0.1 0.1 
1,2,3,6,7,8-HxCDF 0.1 0.1 
1,2,3,7,8,9-HxCDF 0.1 0.1 
2,3,4,6,7,8-HxCDF 0.1 0.1 
1,2,3,4,6,7,8-HpCDF 0.01 0.01 
1,2,3,4,7,8,9-HpCDF 0.01 0.01 
OCDF 0.001 0.0003 
 
 
In order to assess the toxicity of a mixture of dioxins the toxic equivalents (TEQ) 
is used. TEQ is calculated as a summation of the multiplying the toxicity (WHO-TEQ or 
I-TEQ) for the concentration of each congener, according the equation 1. 
 
TEQ=∑ (TEFi · Ci)      (1) 
 
4.3. Health effects 
The International Agency for Research on Cancer (IARC) classified the 2,3,7,8-
tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) as a carcinogen for the human health 
(Group 1), and recently, the 2,3,4,7,8-pentachlorodibenzofuran (2,3,4,7,8-PeCDF) was 
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also included (IARC, 2012). In turn, other PCDD/F congeners, such as 1,2,3,7,8-PeCDD, 
1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD have been included in the Group 3 by the 
IARC, therefore not being classifiable as to its carcinogenicity to humans (IARC, 1997). 
In turn, USEPA considers there is sufficient evidence in animals but insufficient in 
humans (carcinogenic B2) to classify PCDD/Fs as carcinogenic, when considered alone 
(U.S.EPA, 2000). However, in complex mixtures, dioxins and related compounds were 
classified as likely to be carcinogenic for humans (Group B1) (U.S.EPA, 2000). In spite 
of these classifications, of some authors point out there is important lack of conclusive 
data to consider PCDD/Fs as a carcinogenic (Boffetta et al., 2011; Cole et al., 2003).  
The hallmark of non-carcinogenic toxicity of PCDD/Fs in humans is chloracne 
that may be manifested after occupational exposure or high acute exposure (Linden et 
al., 2010). Children are more sensitive to chloracne than the adult population, according 
to the experience of the accident of Seveso (Italy) in 1976 (Mocarelli et al., 1991). 
Moreover, harmful effects on the reproductive system, hepatoxicity, development, 
immunology, neurotoxicity and endocrine systems have been observed (Linden et al., 
2010; Sweeney and Mocarelli, 2000). The aryl hydrocarbon receptor (AhR) seems to be 
implied in the mode of action (MoA) of PCDD/Fs. Thus, the MoA is similar to the 
hormonal biochemistry, and PCDD/Fs are considered endocrine disruptors (ED) 
(Vasseur and Cossu-Leguille, 2006; Wang et al., 2006). 
In 1990, the World Health Organization (WHO) established a tolerable daily 
intake (TDI) of 1-4 pg-TEQ/kg-day for PCDD/Fs (Van et al., 2000). However, it was 
indicated that human intake should be less than 1 pg-TEQ/kg-day. In 2001, the Joint 
FAO/WHO Expert Committee on Food Additives (JECFA) concluded that, due to the long 
half-lives in blood, the human doses of PCDD should be evaluated in a monthly period, 
establishing a Provisional Tolerable Monthly Intake (PTMI) of 70 pg WHO-TEQ/kg BW 
per month (WHO, 2002). In 2012, a RfD of 0.7 pg/kg-day for TCDD was suggested by 
U.S.EPA (2012). Such dose was derived based in two previous studies: a study that 
related the sperm concentration and mobility on men exposed to TCDD, and a second 
study that related the concentration of TCDD with thyroid hormone levels on newborns 
(Baccarelli et al., 2008; Mocarelli et al., 2008). 
 
4.4. Pharmacokynetics and Pharmocodynamics (PK/PD) 
The absorption of PCDD/Fs is mainly through oral intake, being the inhalation 
another important route of exposure. In contrast, dermal intake seems to be a minor 
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pathway according to previous reports (McLachlan, 1993; Schlummer et al., 1998). 
PCDD/Fs may be absorbed in a range of 80%-90% by oral route. The limiting factor of 
the absorption is the passage across the intestinal wall, decreasing in relation to 
molecular size (ATSDR, 1998). 
The distribution and disposition of PCDD/Fs is dependent of the congener, dose, 
route of administration and age. The main storage compartments of dioxins for mammals 
are the liver and the adipose tissue (mesentery fat), due to the high lipophilicity of these 
compounds. Furthermore, the blood compartment also works as a storage compartment 
and correlation between the levels found in blood and other tissues has been established 
(Iida et al., 2007). The distribution of PCDD/Fs in the lipid fraction of the tissues, and 
specially for the highly chlorinated compounds, is not equal depending of the depot 
(ATSDR, 1998). Quantifiable concentration of dioxins have been found in the liver of 
neonates, suggesting a transplacental transfer in gestational mothers (Schecter et al., 
1990). Moreover, detectable concentrations of several PCDD/Fs congeners have been 
found in breast milk samples (Schuhmacher et al., 2009, 2013). 
The half-life of 2,3,7,8-TCDD have been estimated in 7.1 years, according to data 
from a group of Vietnam veterans highly exposed to TCDD in the Ranch Hand operation 
of herbicide warfare (Pirkle et al., 1989). After that, in a more recent study, the same 
value of half-life elimination of 7.1 years was reported in a cohort of women exposed to 
2,3,7,8-TCDD in a highly residential exposure in Seveso (Italy) (Warner et al., 2013). 
Other studies of Vietnam veteran subjects suggested higher values of half-lives, ranging 
from 8.7 and 11.3 years (Michalek et al., 1996; Wolfe et al., 1994). A correlation between 
the percentage of adipose content in the human body and the human half-lives has been 
established in several studies (Flesch-Janys et al., 1996; Wolfe et al., 1994).  
PCDD/Fs are poorly metabolized in humans (Hu and Bunce, 1999; Wendling et 
al., 1990), and the slow metabolism of PCDD/Fs is hypothesized to be the responsible 
of the long half-lives elimination in humans (Reddy et al., 2005). The major elimination 
routes of PCDD/Fs are feces, and in a smaller quantity, the urine. In feces, the 
mechanism of TCDD was proposed to be a passive diffusion into the intestinal lumen 
from blood to feces and subsequently excreted (Olson, 1986). In urine, detectable 
amounts of metabolites of TCDD were found in a study conducted in rats after a bolus 
injection of 2,3,7,8-TCDD (Weber et al., 1993). Furthermore, breast milk can be also an 
important source of PCDD/Fs elimination. High-chlorinated dioxins are more present in 
milk, decreasing the concentration with the chlorination of the aromatic rings (ATSDR, 
2008). OCDD is usually the main PCDD/F congener found in milk samples, with 
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percentages over 50% of the total (ATSDR, 1998). The highest concentration in milk is 
in the first weeks of lactation, with a sharp decline after that (Takekuma et al., 2011). 
Some studies have demonstrated that dioxins in breast milk may be quickly absorbed by 
nursing babies (McLachlan, 1993).  
 
4.5. PBPK models for PCDD/Fs 
PBPK models have been demonstrated to be useful to predict the distribution of 
TCDD body burdens. The first PBPK model for TCDD was developed in 1983 by King et 
al. (1983) using rats, mice and monkeys. Some years later, Leung et al. (1988) improved 
the model including the hepatic CYP1A2 binding in the PBPK model of TCDD. Currently, 
more than 25 PBPK models have been elaborated to predict the tissue distribution of 
TCDD in rats, humans or other animals (Reddy et al., 2005).The degree of complexity in 
the model for TCDD in rodents has been increasing over the time. Four levels of 
complexity of PBPK models have been described for TCDD in rodents depending of the 
protein binding, binding to AhR, the CYP1A1/2 induction, extrahepatic biochemical 
responses, etc (Figure 4) (Reddy et al., 2005). In summary, Level 1 models feature two 
binding proteins in liver that are cytosolic AhR and microsomal CYP1A2 (Lawrence and 
Gobas, 1997; Leung et al., 1988). Level 2 models include the interaction between AhR-
TCDD complex and DREs and the induction of CYP1A1/2 (Andersen et al., 1993; 
Santostefano et al., 1998). Level 3 models features the nonuniform induction of enzymes 
in liver (Andersen et al., 1997). Level 4 model include extrahepatic responses, like 
induced effects on thyroid hormones (Kohn et al., 1996). Most of these models were only 
applicable and validated for acute and subchronic exposure, but not for chronic 
exposure. 
Chronic exposure to PCDD/Fs in humans is obviously in much lower levels than 
exposure in experimentation animals. At chronic concentrations, TCDD do not induce 
protein binding, and most of the models do not induce CYP1A1 binding, with some 
exceptions (Carrier et al., 1995a, b). Thus, the level of complexity is lower than in rodent 
studies. Most of the human PBPK models have been developed only for TCDD, and only 
few works developed PBPK model for the 17 PCDD/F congeners (Carrier et al., 1995a, 
b; Maruyama et al., 2002, 2003). Furthermore, few PBPK models were have been 
developed to consider the distribution of TCDD from mother to fetus, and to newborns 
via pregnancy and breast milk feeding (Gentry et al., 2003; Maruyama et al., 2003).  
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Fig. 4. Diagram of the four levels of PBPK models of TCDD in rats. Adapted from 
Reddy et al. (2005). 
 
5. Perfluoroalkyl substances (PFASs) 
Perfluoroalkyl substances (PFASs) are a group of fluorinated compounds, 
constituted by a carbon backbone where all the hydrogen atoms are substituted by 
fluorine, with the exception of those hydrogen atoms that are part of a functional group. 
The most common PFASs includes carboxylic acid (-COOH) or sulfonic acid (-SO3H) as 
functional groups (Buck et al., 2011), being perfluorooctane sulfonic acid (PFOS) and 
perfluorooctanoic acid (PFOA) the foremost studied PFASs. The structure of PFOS and 
PFOA is depicted in Figure 5.  
UNIVERSITAT ROVIRA I VIRGILI 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF PCDD/FS AND PFASS IN HUMANS. 
Francesc Fabrega Bonadona 
Dipòsit Legal: T 1660-2014
Introduction 
 
14 
 
Fig. 5. Chemical structure of PFOS and PFOA. 
 
5.1. Sources of exposure 
PFASs are a group of manmade organic environmental pollutants. The sources 
of emissions are defined as either direct (manufacture, use and consumption) or indirect 
(impurities, degradation products and precursors) (Prevedouros et al., 2006). More than 
80% of the PFASs emitted to the environment come from fluoropolymer manufacture 
and the use of products such as stain repellent treated carpets, waterproof apparel and 
aqueous firefighter foams (Paul et al., 2009; Prevedouros et al., 2006). Indirect sources 
are not well understood yet due to the lack of information about their degradation (Paul 
et al., 2009). PFASs have been detected in water and biota worldwide (Falk et al., 2012; 
Rotander et al., 2012). Specifically, PFOS is the most predominant PFAS found 
worldwide, being detected in animal wildlife like fish, birds and mammals (Giesy and 
Kannan, 2001). A general decrease of PFASs in the environment has been observed 
(Paul et al., 2009), since the phase-out of the PFOA production by the 3M company in 
2002 (Wang et al., 2009). 
The main source of human exposure to PFASs is the oral intake through food 
and water ingestion (Domingo, 2012; Ericson et al., 2008; Vestergren and Cousins, 
2009). PFASs are also present in food packaging materials for oil resistance, and 
migration of PFASs from packaging materials to food may also occur (Llorca et al., 2010; 
Zafeiraki et al., 2014). Dust intake of PFASs is negligible in the adult population, whereas 
in toddlers it is also low (Ericson et al., 2012). Furthermore, inhalation exposure is 
negligible even in the indoor areas, due to the low volatility of PFASs (Schlummer et al., 
2013). In newborn infants, exposure from breast milk may be notable source of exposure 
(Karrman et al., 2010; Karrman et al., 2007; Llorca et al., 2010). Recently, a decrease of 
PFASs concentration in food items and drinking water has been observed (Calafat et al., 
2007; Ericson et al., 2008; Johansson et al., 2014), in parallel to the environmental 
reduction of their environmental burdens. As a result of the declining of human intake, 
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decrease of PFASs concentration in human blood has also been observed in individuals 
of Western countries (D’eon and Mabury, 2011; Olsen et al., 2008).  
 
5.2. Toxicity and Health effects  
The potential toxicity of some PFASs has been characterized in animal studies. 
On general, the toxicity of PFASs is relatively similar among congeners, being the liver 
the target tissue (Yeung et al., 2013). PFASs cause hepatotoxicity, reproductive toxicity, 
toxic effects on body weight (BW), development, cholesterol, thyroid hormone and 
immunotoxicity (Lau et al., 2007; Stahl et al., 2011). Acute toxicities of PFASs have been 
studied in animals, but studies have been mainly focused on PFOS and PFOA. The lethal 
dose [LD50] of PFOS is estimated in 251 mg/kg BW, and that of PFOA in a range between 
430 and 680 mg/kg BW in PFOA (EFSA, 2008). The lethal concentration [LC50] in rats 
for 1h of inhalation of contaminated airbone dust was assessed estimated in 5.2mg/L for 
PFOS, and 0.98 mg/L for PFOA. In studies of LD50 in fresh water organisms such as flea, 
planaria, snail or shrimp, PFOS has showed to be more toxic than PFOA (Ji et al., 2008; 
Li, 2009). 
Acute exposure to PFOS in mice causes developmental effects like reduction of 
fetal weight, edema, cardiac abnormalities, delayed ossification and behavioral effects 
(Fuentes et al., 2006; Fuentes et al., 2007a; Fuentes et al., 2007b; Lau et al., 2004). 
Exposure to PFOA has been suggested to cause kidney and testicular cancer in human 
population (Barry et al., 2013). Subchronic and subacute toxicities in rats induce 
hepatotoxicity, reduction of body weight, reduction of the levels of triglycerides, reduction 
of cholesterol in serum, liver hypertrophy, thyroid hormones reduction and damage on 
the neuroendocrine system for PFOS (Austin et al., 2003). 
 
5.3. Pharmacokynetics and Pharmocodynamics (PK/PD)  
The pharmacokinetic and pharmacodynamic characteristics of PFASs have been 
studied in animals (Lau et al., 2007). In general, PFASs are well absorbed in oral intake, 
not metabolized and poorly eliminated (Cui et al., 2009; Hundley et al., 2006). The main 
tissues of distribution are plasma and liver, being the concentration in liver several times 
higher than plasma concentration. In rats, the concentration of PFOA and PFOS in liver 
is between 3 and 5 higher than in plasma in animals, and between 1.3 and 2 times higher 
in humans (Hundley et al., 2006; Seacat et al., 2003). The distribution of PFOS is mainly 
extracellular (Noker and Gorman, 2003). PFOS and PFOA have a high affinity to bind to 
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β-lipoproteins, plasma albumin and fatty acid liver proteins (Han et al., 2003; Luebker et 
al., 2002). The fraction of binding of PFASs to plasma albumin is estimated to be over 
the 90% in rats and humans (Han et al., 2003). Detectable concentrations of PFASs 
have been found in umbilical cord suggesting that PFASs can cross the placenta 
exposing the fetus (Apelberg et al., 2007). Furthermore, PFASs have been detected in 
breast milk, exposing the neonate to PFASs (Karrman et al., 2007).  
PFASs half-lives in plasma have been studied in detail. The plasma/serum 
elimination in PFOA show notably differences among species, ranging 2-6 h, 17-19 days 
and 30-21 days in rats, mice and monkey, respectively (Lau et al., 2007). Regarding 
PFOS, half-lives have been set in 1-2 months, 4 months and 4.8 years in rodents, 
monkey and humans, respectively (Chang et al., 2012). Moreover, in animals PFOS and 
PFOA exhibits different elimination rates depending on the gender and the age of the 
individuals (Lau et al., 2007). For PFOA, the elimination half-lives in adult female rat was 
assessed in 2-4h, whereas in adult male rat was assessed in 4-6 days (Kemper, 2003). 
In monkey, the elimination rate of PFOA was assessed in 30 days for adult female and 
21 days for adult male (Butenhoff et al., 2004). On the other hand, in mouse and humans, 
sex differences on the elimination rate have not been observed yet. The explanations of 
the differences in the elimination rates in rats were not conclusive, but some studies 
suggested that the transporters in the proximal tube of the kidney may be the responsible 
(Andersen et al., 2006; Tan et al., 2008; Yang et al., 2009). In humans, blood half-lives 
of 5.4, 3.8 and 8.5 years have been estimated for PFOS, PFOA and perfluorohexane 
sulfonic acid (PFHxS), respectively (Lau, 2012). In contrast, half-lives of 32, 30 and 3 
days have been observed for perfluorohexanoic acid (PFHxA), perfluorobutane sulfonic 
acid (PFBS), and perfluorobutanoic acid (PFBA), respectively (Lau, 2012; Olsen et al., 
2009). The organic anion transporter proteins are compound, gender and chain length 
dependent (Han et al., 2011). PBPK models have been used in the past to successfully 
simulate the elimination of PFOS and PFOA via a resorption mechanism, that once the 
chemical is in the urine is resorbed back to plasma following a saturable mechanism 
(Andersen et al., 2006; Loccisano et al., 2011; Tan et al., 2008).  
 
5.4. PBPK models for PFASs 
Recently, a number of PBPK models have been developed for PFASs. However, 
most of them are limited to the study of PFOS and PFOA. One of the first PBPK model 
for PFOS and PFOA was developed by Andersen et al. (2006), who described the 
elimination of PFOS and PFOA in monkey. The model included three compartments 
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(central compartment, tissue and filtrate) and included two key features of the ADME 
characteristics of PFOS and PFOA. First, the elimination was mainly urinary, following a 
resorption mechanism, that when the chemicals are in the urine are resorbed back to the 
plasma following a saturable process. This kinetic is analogous to the Michaelis-Menten 
kinetics. The second feature of that PBPK model was the binding of PFOS and PFOA to 
plasma albumin. As a consequence, only a fraction of the total amount of PFASs present 
in urine was available to be distributed to other tissues. Afterwards, the PBPK model was 
extended to rats and humans, and the pharmacokinetics and pharmacodynamics 
properties of PFOS and PFOA were studied (Loccisano et al., 2012a; Lou et al., 2009; 
Tan et al., 2008). The model was applied in a case study of human individuals living in 
Little Hocking (Ohio, USA) and Arnsberg (Germany), and exposed to relatively high 
concentrations of PFOS and PFOA through consumption of drinking water. The result 
was a PBPK model reasonably capable to estimate the concentration of PFOS and 
PFOA in the human body. The model was firstly developed to study the pregnant and 
lactating concentrations of PFOS and PFOA in rats (Loccisano et al., 2012b) and after 
that, the model was scaled to humans to assess the pregnancy and lactational 
concentrations of PFOS and PFOA (Loccisano et al., 2013). 
Other PBPK models have considered other pharmacokinetic mechanisms, 
different from that firstly suggested by Andersen et al. (2006). A PBPK model was 
developed for PFOS by Harris and Barton (2008). In rats the structure of the model 
differentiated blood, liver, rest of the body, and two compartments for the gastrointestinal 
tract (GI), being tissues described as diffusion-limited compartments (Thompson and 
Beard, 2011). For validation purposes, experimental data of concentration of PFOS in 
rats were used, and the model was based on the elimination via urinary and biliary 
excretion. Sonne et al. (2009) developed a PBPK model to estimate the burdens of 
PFOS in Greenland polar bears (Ursus Maritimus). This PBPK model was based on a 
previous generic model applied to organohalogen contaminants (OHC) (Cahill et al., 
2003). Another approach was done for cows, for which PBPK model was developed to 
assess the transfer of PFOS from contaminated feed to milk (van Asselt et al., 2013). 
Two tissues were considered in the model (carcass and serum), while the elimination of 
PFOS occurred mainly in milk, instead of urine and feces. The estimated half-life of 
PFOS in milk was 56 days.  
It must be highlighted that most PBPK models have been exclusively developed 
for PFOS and PFOA. Unfortunately, pharmacokinetic information about other PFASs is 
particularly scarce. Instead of some PBPK models were elaborated for PFOS and PFOA 
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in animals and in humans, none of them were elaborated for other PFASs. Thus, there 
is a lack of PBPK models to describe the pharmacokinetics of PFAS in the human body. 
Due to the lack of knowledge of the pharmacokinetics of compounds different of PFOS 
and PFOA this is a challenging area of study. 
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HYPOTHESIS 
 
The human health risk assessment of exposure to environmental pollutants may 
be improved if the time course concentrations of these chemicals in the human body are 
well known. In silico tools are cheap, quick and reliable techniques to estimate the body 
burdens of chemicals, being a serious complement to in vivo or in vitro investigations.  
PBPK models may simulate and predict the distribution and accumulation of 
POPs in the human body. Therefore, they may be a good alternative to biological 
monitoring of PCDD/Fs and PFASs.  
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OBJECTIVES 
 
General objective 
To develop and validate a PBPK model to simulate and predict the time course 
concentration of PCDD/Fs and PFASs in human tissues.  
 
Specific objectives 
• To develop a Ranking Index to prioritize those environmental pollutants 
posing the highest health risk for humans. 
• To develop a PBPK model to predict the tissue concentration of 17 
PCDD/F congeners in human plasma and adipose tissue.  
• To determine the main biochemical parameters needed to develop a 
PBPK model for the estimation of PFASs in the human body.  
• To develop a PBPK model to predict the tissue concentration of 11 PFASs 
in human tissues, including plasma, liver, kidney, brain and lungs. 
• To study the parametric uncertainty of a PBPK model for PFOS and 
PFOA. 
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CHAPTER 1 
INTEGRATED RISK INDEX OF CHEMICAL AQUATIC POLLUTION 
(IRICAP): CASE STUDIES IN IBERIAN RIVERS 
 
Abstract 
The hazard of chemical compounds can be prioritized according to their PBT 
(persistence, bioaccumulation, toxicity) properties by using Self-Organizing Maps 
(SOM). The objective of the present study was to develop an Integrated Risk Index of 
Chemical Aquatic Pollution (IRICAP), useful to evaluate the risk associated to the 
exposure of chemical mixtures contained in river waters. Four Spanish rivers basins were 
considered as case-studies: Llobregat, Ebro, Jucar and Guadalquivir. A SOM-based 
hazard index (HI) was estimated for 205 organic compounds. IRICAP was calculated as 
the product of the HI by the concentration of each pollutant, and the results of all 
substances were aggregated. Finally, Pareto distribution was applied to the ranked lists 
of compounds in each site to prioritize those chemicals with the most significant 
incidence on the IRICAP. According to the HI outcomes, perfluoroalkyl substances, as 
well as specific illicit drugs and UV filters, were among the most hazardous compounds. 
Xylazine was identified as one of the chemicals with the highest contribution to the total 
IRICAP value in the different river basins, together with other pharmaceutical products 
such as loratadine and azaperol. These organic compounds should be proposed as 
target chemicals in the implementation of monitoring programs by regulatory 
organizations. 
 
1. Introduction 
Due to the massive use of chemicals in industrial and agricultural activities, as 
well as their content in home products, water pollution in rivers has been growing in 
recent decades. Detectable and quantifiable amounts of chemicals can be found in 
rivers, some-times at harmful concentrations for the environment and especially for the 
human health (Carafa et al., 2011; Fernández-Turiel et al., 2003). Furthermore, 
Mediterranean rivers are characterized by a strong rainfall and temperature seasonality, 
with periods of severe drought and floods (López-Doval et al., 2012; Petrovic et al., 
2011). Because of these special characteristics, climate change models conclude that 
Mediterranean regions will be among the most impacted regions in a near future (Giorgi 
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et al., 2008). Therefore, climate change and the anthropogenic manipulation of water 
resources in Mediterranean rivers may lead to enhance human health risks of river water 
exposure. 
As humans are exposed to chemical mixtures rather than individual substances, 
new realistic approaches have been developed to assess the risks associated to 
combined exposure to sets of pollutants (McCarty et al., 2006; Sumpter et al., 2006). 
Classically, two main approaches have been used to evaluate the toxicity of chemical 
mixtures: concentration addition (CA) and independent action (IA), which assume a 
similar or different mode of action (MoA), respectively. Although these approaches have 
been successfully applied in the past (Backhaus et al., 2012), mixtures of compounds 
can interact, modifying therefore the final toxicity (Boobis et al., 2011). In 2004, the 
Agency of Toxic Substances and Disease Registry (ATSDR) elaborated a guide manual 
for the evaluation of join action of chemical mixtures (ATSDR, 2004), which contained 
flows charts to help toxicologists (Wilbur et al., 2004). Nevertheless, proper schemes of 
the MoA considering possible interactions among pollutants, are clearly necessary 
(Teuschlet et al., 2007).  
Ranking systems allow the prioritization of chemicals according to their chemical, 
physical or toxicological properties. Ranking methods have become useful tools for 
stakeholders involved in water management. The European Union (EU) developed a 
combined monitoring-based and modeling-based priority settings (COMMPS) 
methodology (EC, 1999). COMMPS procedure is based on the exposure of pollutants in 
freshwater, as well as the effects of the pollutants on aquatic organisms and humans. 
Among ranking methods, an extended method to prioritize organic chemicals is the use 
of 3 basic properties: persistence, bioaccumulation and toxicity commonly known as PBT 
(Arnot et al., 2008; Pennington et al., 2001). The main outcome of this exercise was the 
list of 33 priority substances identified under the Water Framework Directive (Directive 
2000/60/EC) and its “daughter” specifically devoted to this issue (Directive 
2008/105/EC). However, PBT models cannot be used to study interactions among com-
pounds. Alternatively, Self-Organizing Maps (SOM) may be a good option. SOM are a 
kind of artificial neural network (ANN) extensively used in data analysis, which are able 
of friendly visualizing large amounts of information (Alvarez Guerra et al., 2008; Arias et 
al., 2008; Mari et al., 2008). Data can be analyzed and the extracted results studied in a 
two-dimensional grid. In addition to information visualization, SOM has been also used 
for environmental modeling (Kalteh et al., 2008). Due to the ability of the SOM algorithm 
to group data according to similar characteristics, it has been previously used to create 
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PBT-based rankings pollutants (Nadal et al., 2006; Nadal et al., 2008). Recently, SOM 
was also applied to elaborate an ecological hazard index of a series of pollutants found 
in Ebro River waters (Spain) (Ocampo-Duque et al., 2012). 
In recent years, some statistical and mathematical tools have been used to detect 
the chemicals with a higher contribution. Some examples are h-index (Hirsch index) and 
Zipf’s law, which were successfully applied in a recent study performed to prioritize 
pharmaceuticals in a wastewater treatment plant (Ginebreda et al., 2011). H-index is 
capable to identify the most relevant compounds in a list of ranked chemicals by means 
of a Pareto distribution, according to some specific parameters. In turn, Zipf’s law, based 
on the inverse proportion between the frequency of one event and its ranking position, 
has been also widely applied in different domains (Hisano et al., 2011). 
The objective of the present study was to rank the hazard of 205 organic 
compounds analyzed in water samples from 4 river basins in Spain (Llobregat, Ebro, 
Júcar and Guadalquivir), according to the PBT properties of the pollutants. Firstly, a 
hazard index (HI) was developed and applied to each individual compound by using 
SOM. Secondly, an Integrated Risk Index of Chemical Aquatic Pollution (IRICAP) was 
elaborated to rank the human health risks depending on the HI and the concentration of 
each individual chemical. Finally, the compounds with the highest contribution were 
characterized using the h index and the power law exponent of the Zipf’s law.  
 
2. Materials and Methods 
2.1. Data and study area 
As part of a large monitoring program (Navarro-Ortega et al., 2012), a total 
amount of 205 organic pollutants were analyzed in four Spanish rivers with different 
pressures and impacts: Llobregat, Ebro, Júcar and Guadalquivir. The former three are 
located in the Mediterranean catchment basin, while Guadalquivir waters discharge into 
the Atlantic Ocean (Fig. 1). A network of representative 77 sampling points was 
previously established to assess the main stressors of the river basins. The geographical 
distribution of the sampling sites is presented in Table S1 (Annex 1). 
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Fig. 1. Area of study. 
 
The list of analyzed compounds included pharmaceutical products, illicit drugs, 
endocrine disruptors (ED), pesticides, perfluoroalkyl substances (PFAS), and UV filters. 
Eighty-one pharmaceutics, including analgesics such as ibuprofen and acetaminophen, 
antibiotics such as ofloxacin and amoxicilin, and antihypertensives such as enalapril and 
losartam, were determined. Pharmacy products, like psychiatric drugs, diuretic or 
veterinary pharmaceuticals, were also analyzed. Nineteen illicit drugs including 
cannabinoids, and recreational drugs such as cocaine, LSD or amphetamine, were also 
studied. Thirty-one endocrine disruptors were added to the set of target pollutants, 
including diethylstilbestrol and nonylphenol. Forty-two different pesticides (insecticides 
and herbicides) were analyzed, including ethion and propanil, among others. Finally, 21 
perfluoroalkyl substances (PFASs) such as perfluorooctanoic acid (PFOA) and 
perfluorooctane sulfonate (PFOS), and 11 UV filters, including benzophenone and 
octocrylene, were also determined. Full names and abbreviations are summarized in 
Table S2 (Annex 1). Water samples were collected in Autumn of 2010 and 2011. 
The Llobregat river basin is located in the north-east of Spain. It has a drainage 
basin of 1948 km2 and a total length of 170 km, being the main drinking water resource 
of Barcelona and surrounding cities. Because of its proximity to Barcelona, the lowest 
course of the river receives strong anthropogenic pressures. Urban and industrial waste 
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water are discharged in the Llobregat river, in addition to the surface run off coming from 
agricultural and salt mining areas (Cabeza et al., 2012). Furthermore, the Mediterranean 
climate of this area usually changes the water flow, and consequently the natural 
capacity of the river water dilution. The Ebro river basin is the largest in Spain in terms 
of water flow, with a drainage basin of 85,550 km2 and a length of 928 km. Situated in 
the north of Spain, it is regulated by numerous dams and channels in all the river flow. 
At the end of the 20th century, approximately 30% of the river flow had decreased due 
to surface water extractions for irrigation, land use change (reforestation) and rainfall 
decrease as well as due to the impact of industrial activities, which are concentrated in 
the main cities along the river. An important “hot spot” of chemical pollution has been 
also identified in the Flix (Catalonia) reservoir, where thousands of tons of toxic 
substances (e.g., radio nuclides, heavy metals, organo chlorine compounds, etc.) have 
been accumulated (Ferré-Huguet et al., 2009a; Ferré-Huguet et al., 2009b; Mola et al., 
2011). These pressures have also altered the sediment regimes and the water quality. 
The Jucar river basin, located in the east of Spain, covers a drainage area of 21,632 km2, 
and the mainstream shows a length of 500 km. Agriculture pressures are located in the 
medium and lower parts of the river basin, where there is also a notable industrial activity. 
Since it flows in a semiarid zone, the most important problems of this basin are the 
hydrological modification of the river course, the aquifers overexploitation, and the river 
contamination. The Guadalquivir river basin is located in the south of Spain, with a 
drainage basin of 57,071 km2 and a length on the main stream of 657 km. This area 
covers a population of approximately 7 million inhabitants, and the river consequently 
receives many anthropogenic pressures. The total agriculture area of the river basin is 
700,000 ha (mainly rice, olives and fruit trees), with the consequent environmental 
effects. The regime of the river is highly modified by dams and reservoirs, especially in 
the lower course. Doñana National Park, a natural area severely affected by metal inputs 
after a mining accident (Gómez et al., 2004), is located at the mouth of the river. 
 
2.2. Hazard Index 
Originally developed by Kohonen (Kohonen, 1982), Self-Organizing Maps (SOM) 
use an unsupervised learning algorithm that reduces large amounts of input data 
(Kohonen, 2013). The results are generally visualized in two-dimension maps, allowing 
clustering the input information by grouping similar data. The final result is, on one hand, 
a Kohonen’s map showing the distribution of the input values on a two dimensional grid, 
and on the other hand, a set of component planes (c-planes) showing the clusters 
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created by the algorithm in the Kohonen’s grid. In previous studies, we successfully used 
SOM in order to create prioritization rankings of pollutants (Nadal et al., 2006; Nadal et 
al., 2008). 
A hazard index (HI) was elaborated for the whole set of 205 compounds, using 
the PBT properties of each individual chemical. Data of persistence, bioaccumulation 
and toxicity were gathered using Estimation Program Interface (EPI) SuiteTM for Microsoft 
Windows®, v 4.1 (EPI SuitTM). EPI SuitTM is a set of tools developed by the US 
Environmental Protection Agency (US EPA) to estimate physical and chemical 
properties, environmental fate and aquatic toxicology of chemicals. It uses a database 
of more than 41,000 chemical compounds, coming from the PHYSPROP© database. The 
predictive methods and the equation used for each calculation parameter have been 
described elsewhere (Boethling et al., 2004). Half-lives were assessed by using BiowinTM 
tool. Based on a previously developed model (Boethling et al., 1994), BiowinTM tool 
predicts the primary aerobic degradation of the organic compounds. The result is a semi-
quantitative rate of times with the following units: 5-h, 4-days, 3-weeks, 2-months and 1-
years. Bioaccumulation was estimated by using BCFBAFTM tool. The method was initially 
developed by Meyland et al., (1997; 1999), and subsequently improved by Arnot and 
Gobas et al., (2006), who added experimental values of bioconcentration factor (BCF). 
Finally, toxicity was estimated by applying the ECOSARTM tool, which let assess the 
aquatic (fish) toxicology based on Kow levels (Sanderson et al., 2003). As low levels of 
persistence and toxicity derive in a higher hazard, inverse values obtained from the 
BiowinTM and ECOSARTM tools, respectively, were considered in the HI building. Final 
data constituted a matrix of 205 compounds and 3 parameters (Table S2, Annex 1), 
which was run with the SOM toolbox for Matlab® (Alhoniemi et al., 1999). Values were 
normalized using the same toolbox to obtain a variance equal to one for each parameter. 
A linear initialization was applied. The learning phase consisted on 10,000 steps, while 
the tuning phase added other 10,000 steps. HI was considered as the sum of the PBT 
values for each compound, after the SOM training. Default range (from 0 to 3) was re-
scaled to 0–10. 
 
2.3. Integrated Risk Index of Chemical Aquatic Pollution (IRICAP) 
The Integrated Risk Index of Chemical Aquatic Pollution (IRICAP) was calculated 
by applying the following formula: 
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chemicalsofNumber
ionconcentratChemicalIndexHazard
IRICAP ∑ ×=    (1) 
The HI of each individual compound was multiplied by the normalized water 
concentration found in each sampling point (unpublished data), being the final sum 
divided by the number of pollutants (205). Concentrations were normalized to avoid any 
overestimation. They were re-scaled from 0 to 10, being the same as the HI. The 
concentrations were normalized for each chemical by using the following formula: 
minmax
min
CC
CiC
normC
−
−
=     (2) 
 
2.4. H-index and Zipf’s law  
The list of 205 compounds was initially ordered according to their IRICAP. The 
percentage of the product of the normalized concentration by the HI was obtained for all 
the individual compounds studied in each sampling point. Afterwards, data were 
distributed following a Pareto distribution, using h-index and Zipf’s law were used to study 
some of the characteristics of the distribution. The h-index was suggested by Hirsch 
(Hirsch et al., 2005) in order to evaluate the quality of the scientific and academic 
publications. In the academic area, the number h is the number of papers published by 
an author that have the same number (h) of citations. However, this can be translated to 
other research areas. In the present study, all compounds were ranked according to the 
HI and the subsequent h-index was obtained. Furthermore, the h-content or percentage 
of IRICAP covered by h-compounds, was assessed. The h-compounds are defined as 
those located in the first h positions of the list of compounds, ordered according to the 
HI. Finally, the number of compounds representing the 90% of HI (referred to as P 90) 
was assessed by means of Pareto distributions. 
The Zipf’s law was formulated for the first time by the linguist Zipf, and it has been 
extensively used in experimental and social sciences (Newman et al., 2005). It assumes 
that there is a relationship on the frequency of one event that varies depending of some 
attribute of the event. This mathematical relationship is called a power law. The power 
law usually follows this formula: 
α−×= xcxy )(
     (3) 
where y is the frequency of the event of rank x, c is a constant factor, and α is the power 
parameter. The α exponent is numerically determined by linear regression of the log–log 
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transformed experimental data (log y = −α·log x + log c). It may give a measure of the 
complexity of the distribution in the following sense: When α = 0, there is a situation of 
“minimum complexity”, as x0= 1. In contrast, when α = ∞ there is a situation of “maximum 
complexity”, because x∞= ∞. Because α gives important information about the curve 
shape, this power parameter was assessed in each sampling point. 
 
3. Results and Discussion 
3.1. Hazard Index 
The final result for the HI was a two dimensional grid of 96 hexagons (12 × 8), 
where the compounds are spread around the cells according to PBT similarities. 
Moreover, three c-planes maps were obtained, one for each of the PBT parameters (Fig. 
2). C-planes show the normalized values of half-lives, bioaccumulation and toxicity, 
obtained after the SOM training of the initial PBT data. The numerical values of the c-
planes were extracted for the HI calculation developing specific commands using the 
SOM Toolbox for Matlab® (Table S3, Annex 1). HI outcomes are summarized in Table 
1. Half-lives ranged from 0.04 to 2.48. A cluster of 16 PFASs was identified as the group 
of compounds with highest values of half-lives. The environmental persistence of some 
PFASs has been reported in previous studies (Thomas et al., 1990). Surprisingly, neither 
PFOS nor PFOA, two of the most known and well-studied PFASs, were among the 
perfluoroalkyl substances presenting a highest persistence. Half-life scores for other 
compounds were comparatively lower, being distributed in a list with no appreciable 
trends. 
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Fig. 2. Self-Organizing Map of the Hazard Index: a) Kohonen’s map, and b) c-
planes of PBT. 
(a) (b) 
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Table 1. SOM-based Hazard Index (HI) developed for 205 organic compounds. 
Compound HI Compound HI Compound HI Compound HI Compound HI Compound HI 
*PFHxDA 5.58 ¶NP 4.34 *PFDA 3.52 #Cocaethylene 3.02 *PFOA 2.30 ¥3-hydroxycarbofuran 1.76 
*PFODA 5.58 ¥Inazalil 4.34 *PFNA 3.52 ¥Diuron 3.02 ¥Fenoxon 2.29 ¥Dimethoate 1.76 
*PFTeDA 5.58 ¥Fenthion  4.26 ¥Metolachlor 3.46 ¥Azinphos methyl 2.96 ∆4DHB 2.29 ¥Fenoxon sulfone 1.76 
*PFTrDA 5.58 *I,p-PFNS 4.20 ¶E1 3.45 ¶NP1EC 2.92 ⊥Fluvastatin 2.21 ¥Fenoxon sulfoxide 1.76 
*PFDoA 5.58 *L-PFOS 4.20 ¥Molinate 3.45 ¶OP1EC 2.92 ⊥Ibuprofen 2.21 ⊥Acridone 1.75 
*PFUdA 5.58 ⊥Norfluoxetine 4.13 ¥Propanil 3.45 ∆BP1 2.92 ⊥Valsartan 2.21 #1S,2R(+)Ephedrine  1.75 
#THC 5.45 #Methadonehydrochloride 4.13 ⊥Azaperone 3.45 ⊥Propyphenazone 2.90 ¶BT 2.21 ⊥Ranitidine 1.69 
#Cannabidiol 5.45 ¥Prochloraz 4.13 ⊥Clarithromycin 3.40 ¶Etilparaben 2.80 ¶E2-17G 2.21 Trimethoprim 1.69 
#Cannabinol 5.45 ⊥Fluoxetine 4.06 ⊥Erithromycin 3.40 ¶TBEP 2.80 ¥Deisopropylatrazine 2.21 #2-oxo-3-hydroxy- 1.69 
∆4MBC 5.45 ¶E2 4.06 ⊥Olanzapine 3.40 ¥Carbofuran  2.80 ¥Desethylatrazine 2.21 ⊥Metoprolol 1.64 
∆OD-PABA 5.45 ¥Diazinon 4.06 ⊥Torasemide 3.40 #Metaamphetamine 2.72 ⊥Hydrocodone 2.15 ⊥Atenolol 1.64 
∆EHMC 5.45 ¥Paratión ethyl 4.06 ⊥Trazodone 3.40 ¶Metilparaben 2.72 ⊥Oxycodone 2.15 ⊥Ronidazole 1.64 
∆OC 5.45 *I,p-PFNA 3.99 ⊥Carazolol 3.32 ¶TCCP 2.72 *PFHxA 2.15 ⊥Sotalol 1.64 
¥Hexythiazox 5.32 ⊥Atorvastatin 3.98 ⊥Losartan 3.32 ¥Fenthion sulfone 2.72 ⊥Dimetridazole 2.14 ¶E1-3G 1.64 
*PFOSA 5.32 #11-nor-9-carboxy-9-THC 3.98 ⊥Warfarin 3.28 ¥Fenthion sulfoxide 2.72 ⊥Diclofenac 2.12 ⊥Famotidine 1.57 
⊥Irbesartan 5.26 ¶NP1EO 3.98 ∆BP3 3.28 ∆4HB 2.72 ¶TCEP 2.12 ⊥Hydrochlrothiazide 1.57 
¥Pyriproxyphen 5.26 ¶OP 3.98 ⊥Albendazol 3.27 ∆BP2 2.72 ¥Simazine 2.12 ⊥Tetracyclin 1.57 
⊥Loratadine 5.13 ¥Terbutryn 3.94 ⊥Amlodipine 3.27 ¶E3 2.71 #6-acetylmorphine 2.10 ¶E1-3S 1.57 
⊥Sertraline 5.13 ⊥Azithromycin 3.90 ¶Propilparaben 3.27 #MDMA 2.68 #Heroin 2.10 ⊥Acetaminophen 1.53 
¥Dichlofenthion 5.13 ⊥Citalopram 3.90 ¥Methiocarb 3.27 ¥Malathion 2.68 ⊥Codeine 2.06 ⊥Tenoxicam 1.53 
*L-PFDS 5.06 ⊥Clopidogrel 3.90 Azaperol 3.23 Indomethacine 2.66 ¶TT 2.06 ¶Caffeine 1.53 
⊥Glibenclamide 4.91 ¶EE2 3.90 #LSD 3.23 Phenazone 2.66 ⊥Dexamethasone 2.02 ¥Omethoate 1.53 
#EDDPperchlorate 4.91 ¥Alachlor 3.90 ⊥Diazepam 3.17 ¥Imdacloprid 2.66 ⊥Pravastatin 1.99 *PFBA 1.53 
¶Triclocaraban 4.91 ¶NP2EO 3.74 ⊥Propranolol 3.17 *PFPeA 2.66 ⊥Cimetidine 1.91 *L-PFBS 1.46 
¶Triclosan 4.91 ¶OP2EO 3.74 ¥Isoproturon 3.17 ¥Atrazine  2.60 ⊥Furosemide 1.91 ⊥Amoxicillin 1.41 
¥Chlorpyriphos 4.91 ¶OP1EO 3.74 ¥Chlorfenvinphos 3.17 #Cocaine  2.55 ⊥Sulfamethoxazole 1.91 ⊥Cefalexin 1.41 
¶DES 4.86 ¥Acethochlor 3.74 ⊥Alprazolam 3.16 ⊥Bezafibrate 2.42 #Morphine 1.91 ⊥Metronidazole-OH 1.41 
#11-hydri-9-THC 4.85 ⊥Meloxicam 3.62 ¥Propazine 3.16 ⊥Gemfibrozil 2.42 ⊥Nadolol 1.86 ⊥Ciprofloxacin 1.24 
¥Ethion 4.85 ¶Benzilparaben 3.62 ¥Paratión methyl 3.08 ⊥Levamisol 2.35 ⊥Naproxen 1.86 ⊥Enalaprilat 1.24 
⊥Paroxetine 4.64 ¶BPA 3.62 ⊥Carbamazepine 3.02 #Amphetamine 2.35 ⊥Enalapril 1.76 ⊥Iopromide 1.24 
¥Tolclofos methyl 4.64 ¥Azynphos ethyl 3.62 ⊥Diltiazem 3.02 ∆Et-PABA 2.35 ⊥Ketoprofen 1.76 ⊥Metformin 1.24 
⊥Desloratadine 4.57 ¥Fenitrothion 3.62 ⊥Lorazepam 3.02 *L-PFHpS 2.30 ⊥Metronidazole 1.76 ⊥Ofloxacin 1.24 
⊥Xylazine 4.57 ∆DHMB 3.61 ⊥Tamsulosin 3.02 *L-PFHxS 2.30 ⊥Piroxicam 1.76 #Benzoilecgonine 1.24 
¥Buprofezin 4.37 ⊥Venlafaxine 3.58 ⊥Thiabendazole 3.02 *PFHpA 2.30 ⊥Salbutamol 1.76 ¶E3-16G 1.24 
          
¶E3-3S 1.24 
*PFCs, #Illicit drugs, ⊥Pharmaceutics, ¥Pesticides, ¶Endocrine disruptors, ∆UV filters
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Bioaccumulation scores ranged from 0.29 to 2.70. In contrast to persistence, 
PFASs were not especially found to be bioaccumulative compounds, excepting PFOSA. 
In turn, 3 illicit drugs (THC, cannabidiol and canabinol) and 4 UV filters (4MBC, OD-
PABA, EHMC, OC) presented the highest bioaccumulation factor (2.70).With regard to 
this, cannabinoids could present a high bioaccumulation potential due to their important 
lipophilicity (Thomas et al., 1990). Toxicity ranges were within 0.57 and 2.53. Two PFAS, 
PFDoA and PFUdA, seemed to be the most toxic compounds, with a toxicity score of 
2.53. Moreover, some cannabinoids (e.g., THC, cannabidiol, and cannabinol) and UV 
filters (e.g., 4MBC, OD-PABA, EHMC and OC) were also among the most toxic 
chemicals among the 205 com-pounds analyzed (2.40). In general terms, most 
pesticides, such as pyriproxiphen, ethion and anazalil, also presented relatively high 
levels of toxicity. By contrast, and with the exception of irbesartan, pharmaceutical 
products mostly were in the lowest part of the list. 
HI was obtained by summing the individual score of persistence, 
bioaccumulation, and toxicity, and re-scaling to 0–10. The final HI values ranged from 
1.24 to 5.58. Some trends and clusters can be visually established by means of the SOM. 
Six PFASs (PFHxDA, PFODA, PFTeDA, PFTrDA, PFDoA, and PFUdA) were identified 
as the most hazardous pollutants, in terms of PBT parameters, reaching a HI value of 
5.58. These perfluoroalkyl substances were characterized by a high environmental 
persistence and aquatic toxicity, but a relatively low bioaccumulation potential. However, 
PFOS and PFOA were not included in this set of hazardous pollutants, as their HI was 
lower (4.20 and 2.30, respectively). A group of cannabinoids (THC, cannabinol and 
cannabidiol) and UV filters (4 MBC, OD-PABA, EHMC, OC) showed also a high HI (5.45), 
given their high bioaccumulation and toxicity. Since pharmaceutical compounds 
generally have low half-lives and toxicity, most of them also showed a comparatively low 
HI. Bioaccumulation of each particular pharmaceutic determined its final position in the 
HI ranking. Thus, irbesartan, loratadine, and sertraline were identified as hazardous 
compounds (HI > 5), which agree with previous results (Roos et al., 2012). In turn, 
ciprofloxacin, enalaprilat, iopromide, metformin andofloxacin, were selected as 
pharmaceutical compounds with a low hazard (HI = 1.24). Illicit drugs did not show any 
special trend, being well distributed in the whole range of HI values. As abovementioned, 
cannabinoids were among the most hazardous com-pounds. In contrast, 
benzoilecgonine hazard was poor (HI = 1.24). In the group of pesticides, hexythiazox 
was the most hazardous (HI = 5.53), while Omethoate presented the lowest HI (1.53). 
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3.2. IRICAP: Case-studies 
An IRICAP value was estimated in each one of the 77 sampling points of the four 
Spanish rivers above described. IRICAP was estimated by the HI and the water 
concentration of each one of the 205 compounds (unpublished data). Final IRICAP 
values are summarized in Table 2, and also depicted for all the four river basins in Fig. 
3. A high value of IRICAP is an indicator of more hazard, while a small value of IRICAP 
indicates water hazardless in terms of risks. 
In the Llobregat area, sampling was performed in 14 points across the river basin, 
including the main course and two tributaries: Anoia and Cardener. In general, the water 
hazard in Cardener was lower than that in the 2 remaining rivers, as expected owing to 
its location in the upper basin. The IRICAP score for Cardener ranged between 5.26 
(CAR2) and 5.59 (CAR3). CAR1 is considered a reference station with no (or minimum) 
anthropogenic pressures. Water presented a low risk, with an IRICAP score of 5.58. 
CAR4, located after a wastewater treatment plant in Manresa, showed an IRICAP value 
of 5.88. In contrast, highest levels of IRICAP were found in the lowest part of the river 
basin. Specifically, ANO2, which receives agricultural pressures and the discharges of 
an industrial pole located in the town of Igualada, showed a high IRICAP value (10.29). 
ANO3, located at the mouth of the tributary river, is also impacted by the waste waters 
from a population living close to the river (IRICAP = 7.09). Finally, the Llobregat river had 
an IRICAP ranging from 6.03 (LLO2) to 11.62 (LLO7). The IRICAP showed a logical 
tendency in Llobregat, as values increased downriver. The up river area (LLO1 and 
LLO2) is a mountainous zone with no agricultural and industrial activities. In the mid part 
of the river course (from LLO3 to LLO6), there are urban and industrial areas, while the 
final point on the mainstream (LLO7) is located near the mouth of the river close to the 
Barcelona town area, with high urban, industrial and agricultural activities in the 
surroundings. The IRICAP value in this last site was 11.62. It is the highest value of all 
the river basins, indicating a high degree of risk. The Ebro is the largest river of Spain 
and water was sampled in 24 points across the whole river basin. IRICAP ranged from 
4.08 (GAL1) to 11.36 (ZAD). The Ebro river basin is constituted by several tributaries 
such as Arga, Cinca, Gallego and Matarranya, among others. GAL1 could be considered 
as a reference point (IRICAP = 4.08), whereas GAL2 is much more affected by 
agricultural activities (IRICAP = 5.93). The river mainstream, from EBR2 to EBR9, is 
severely affected by the anthropogenic activities of some cities located nearby: Miranda 
de Ebro (EBR2), Logroño (EBR4), Tudela (EBR5), and Tortosa (EBR8), all of them with 
important populations. Furthermore, some sites also receive the impact of agricultural 
and industrial activities, such as EBR3 (Haro) and EBR7 (Flix), respectively. Despite Flix 
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reservoir was previously identified as a “hot spot” of pollution due to accumulation of toxic 
sediments formerly discharged by an existing chloro-alkali industry, the sampling point 
presenting the highest risk was ZAD. It strongly receives the influence of the city of 
Vitoria, located a few kilometers upstream. It is important to highlight that the current 
IRICAP was exclusively developed taking into account the levels in the water 
compartment, while other environmental relevant compartment such as sediments or 
biota were disregarded. Pollutant levels of organic chemicals near Flix were not found to 
be of especial concern (Ferré-Huguet et al., 2009a; Ferré-Huguet et al., 2009b). 
 
Table 2. Values for the IRICAP in the 77 sampling points studied.  
Llobregat Ebro Júcar Guadalquivir 
Site IRICAP Site IRICAP Site IRICAP Site IRICAP 
LLO7 11.62 ZAD 11.36 JUC8 7.80 GUAA 6.32 
ANO2 10.29 HUE 8.47 JUC7 7.63 GUA3 5.93 
LLO5 8.35 ARG 8.35 JUC4 7.07 GEN1 5.93 
LLO6 7.75 EBR6 7.51 MAG1 6.97 GUA6 5.91 
LLO1 7.60 EBR1 7.26 JUC6 6.79 GUA4 5.84 
ANO3 7.09 EBR3 7.24 JUC1 6.52 HER 5.65 
LLO4 6.92 EBR4 7.17 JUC2 6.47 GUA2 5.64 
LLO3 6.88 EBR2 7.13 JUC5 6.43 GEN2 5.48 
ANO1 6.76 OCA 7.10 CAB1 6.09 COR 5.41 
LLO2 6.03 SEG 7.03 MAG2 6.04 GUAR 5.32 
CAR4 5.88 EBR5 6.92 CAB3 6.01 GUAL 5.32 
CAR3 5.59 EBR9 6.85 JUC3 5.79 CAC 5.26 
CAR1 5.58 EBR8 6.59 CAB4 5.74 GUAN 5.16 
CAR2 5.26 MAT 6.54 CAB5 5.64 GUA5 5.14 
  MAR 6.40 CAB2 4.41 PIC 5.13 
  EBR7 6.30   GUA8 5.11 
  NAJ 6.25   GUA7 5.06 
  CIN2 6.21   BOR 5.05 
  ESE 6.01   GUA1 5.03 
  GAL2 5.93   BEM 4.84 
  RS 5.78   MAG 4.82 
  ALG 5.53   GUAM 4.79 
  CIN1 5.41   GUA9 4.71 
  GAL1 4.08   YEG 4.69 
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Fig. 3. IRICAP score of 4 Spanish river basins: (a) Ebro, (b) Jucar, (c) Guadalquivir, and (d) Llobregat.
(a) (b) 
(c) (d) 
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Fifteen points were sampled in the Jucar river basin: 8 in the mainstream, 5 in 
Cabriel tributary, and the remaining 2 in Magro tributary. IRICAP ranged from 4.41 
(CAB2) to 7.80 (JUC8). Cabriel showed lower IRICAP values (range: 4.41–6.09), 
indicating the quality of its waters. Cabriel River is located in a semiarid area with a low 
industrial/agricultural pressure. In Magro River, MAG1 showed the highest IRICAP score 
(6.97). It corresponds to a point just located after a village with no wastewater treatment 
plant. Therefore, sewage is directly discharged to the river waters, influencing the 
environmental conditions of the river at that point. The Jucar has several scenarios in the 
mainstream with some agricultural and industrial areas. JUC1 should be considered as 
a reference point (IRICAP = 6.52), although the risk score was somehow higher than that 
obtained in reference sites of other river basins. This value does not really differ from the 
IRICAP in JUC2 (6.47), which his affected by the Cuenca city, whose population exceeds 
50,000 inhabitants. In JUC 3, the contamination from Cuenca city is diluted, resulting in 
a final IRICAP outcome of 5.79. From JUC4 to JUC 6, the IRICAP again increased 
(range: 7.07–7.63) as a consequence of the immediate affection of some small village 
and agricultural practices. Finally, JUC7 and JUC8 showed the highest IRICAP values 
(7.63 and 7.80, respectively) in the basin, which presents a high industrial activity in its 
mouth. In general terms, Guadalquivir was the river basin with the lowest IRICAP values, 
and consequently, with lower human health risks. The Guadalquivir river basin is 
constituted by other sub-river basins such as Yeguas, Bembézar, Guadaira or Genil, 
among others. Twenty-four sampling points were included. The IRICAP values ranged 
from 4.69 (YEG) to 6.32 (GUAA). Although notable high levels of metals were previously 
reported in Sanlcar de Barrameda (GUA9) (Kraus et al., 2006), a high degree of pollution 
is not reflected in our index, as only organic contaminants were considered in the 
development of the IRICAP. However, quantifiable amounts of some pharmaceutically 
active compounds have been recently reported in the waters of Doñana National Park 
(Camacho-Muñoz et al., 2010; Dowse et al., 2013).The most polluted area of the basin 
was GUAA (IRICAP = 6.32), a sampling point downstream a military area. On the other 
hand, the less polluted area corresponded to YEG (IRICAP = 4.69). 
The results obtained after application of h-index and Zipf’s law are summarized 
in Table 3. The h-index ranged between 2 and 3 in all the sampling points, except for 
ZAD, whose h-index was 1. This means that 2–3 compounds are the most important 
contributors to the IRICAP score, being the determination of their levels in river water 
sufficient as indicators of the total risk in terms of both hazard and pollutant 
concentration. More specifically, the contribution percentage of the 2–3 compounds with 
respect to the total IRICAP, defined as the percentage of h-values content, would range 
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from 1.74% to 13.68% (ZAD and CAB2, respectively). Between 35 and 96 compounds 
(CAB2 and ZAD, respectively) summed up to 90% of the IRICAP (Table 3, P90). The 
current results denote that more than one-half of the 205 compounds here assessed play 
a minor role, since their aggregated contribution to the risk is less than 10%. Finally, the 
specific h-compounds for each sampling point are given in Table 4. In 3 of the river 
basins, xylazine was identified as one of the h-compounds. Xylazine is a veterinary drug 
used for sedation, anesthesia, muscle relaxation, and analgesia in animals. Loratadine, 
pyriproxyphen and azaperol were also cataloged as h-compounds (in Ebro, Jucar and 
Guadalquivir, respectively). In contrast, the h-compounds in Llobregat river basin were 
loratadine and azaparone. According to this, we strongly suggest that xylazine, firstly, as 
well as other major pharmaceutical products (loratadine, azaperol, loratadine, and 
azaperone) and pesticides (pyriproxyphen) should be definitively included in the set of 
pollutants that are routinely measured in river waters. As top contributors to health risks, 
their levels should be controlled when implementing water monitoring programs in rivers 
with typical Mediterranean regimes. Power-law equations generally fitted well to the 
ranked list of compounds in each sampling site (regression coefficient R2 between 0.47 
and0.93). However, it must be also highlighted that ranges of the exponent (from 0.99 to 
2.44) were relatively small (Table 3). Values of α exponent obtained in all the sampling 
points denote relatively flat curves, thus indicating that there is a lack of compounds with 
a prominent dominating weight. Therefore, the IRICAP-based risk load is not clustered 
with a few compounds. 
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Table 3. Results of h-index and Zipf’s law applied on the IRICAP. 
Sampling 
site 
h-index h-content 
(%) 
P 90 α Sampling 
site 
h-index h-content 
(%) 
P 90 α 
ANO1 3 9.98 62 1.74 CAB1 3 10.86 50 2.37 
ANO2 2 4.66 90 1.25 CAB2 3 13.68 35 1.97 
ANO3 2 6.41 84 1.45 CAB3 3 11.80 52 2.19 
CAR1 2 6.48 56 1.87 CAB4 3 10.78 54 2.23 
CAR2 2 6.87 53 1.95 CAB5 3 11.26 52 2.28 
CAR3 2 6.46 57 1.88 JUC1 3 10.63 52 2.19 
CAR4 2 6.14 68 1.54 JUC2 3 10.32 52 2.19 
LLO1 3 10.36 60 2.00 JUC3 2 7.02 54 1.99 
LLO2 3 10.43 52 1.87 JUC4 3 9.62 58 1.97 
LLO3 2 6.72 63 1.67 JUC5 3 9.91 53 2.24 
LLO4 2 6.32 63 1.65 JUC6 3 9.79 55 2.09 
LLO5 2 6.52 76 1.38 JUC7 2 6.42 58 1.94 
LLO6 2 5.38 79 1.36 JUC8 2 6.36 63 2.07 
LLO7 2 4.36 95 1.11 MAG1 2 6.10 63 1.82 
ALG 3 9.61 52 2.00 MAG2 2 6.73 58 2.08 
ARG 2 4.13 83 1.34 BEM 3 11.10 50 2.20 
CIN1 3 10.95 50 2.05 BOR 3 9.61 53 2.04 
CIN2 2 6.69 56 1.88 CAC 2 8.18 48 2.40 
EBR1 3 9.63 59 1.88 COR 2 7.07 52 2.11 
EBR2 2 6.49 62 1.68 GEN1 2 6.70 61 1.84 
EBR3 2 5.75 68 1.42 GEN2 2 7.20 59 1.93 
EBR4 2 5.80 67 1.47 GUA1 3 10.68 50 2.22 
EBR5 2 6.01 65 1.53 GUA2 2 7.39 59 1.88 
EBR6 2 4.92 74 1.53 GUA3 2 7.09 60 2.02 
EBR7 2 6.15 56 1.69 GUA4 2 7.46 58 1.79 
EBR8 2 6.31 60 1.74 GUA5 3 10.42 55 1.99 
EBR9 3 8.65 61 1.79 GUA6 2 7.12 63 1.85 
ESE 3 9.87 51 1.96 GUA7 3 10.58 51 2.07 
GAL1 3 13.44 36 1.95 GUA8 3 10.52 53 2.06 
GAL2 2 6.19 59 1.86 GUA9 3 10.07 50 2.14 
HUE 3 6.99 78 1.45 GUAA 2 6.48 64 1.81 
NAJ 2 6.66 54 1.88 GUAL 2 9.18 53 2.13 
MAR 2 6.50 52 1.92 GUAM 3 11.22 48 2.23 
MAT 2 6.59 55 1.92 GUAN 3 10.41 59 1.89 
OCA 2 5.86 63 1.75 GUAR 2 7.89 51 2.16 
RS 3 10.26 49 2.14 HER 2 5.61 58 1.97 
SEG 2 5.91 68 1.50 MAG 3 11.39 56 2.33 
ZAD 1 1.74 96 0.99 PIC 3 10.49 52 2.03 
     YEG 3 11.40 49 2.15 
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Table 4. List of h-compounds according to the IRICAP in 77 sampling sites in Spanish 
river basins. 
Site h-compounds Site h-compounds 
ANO1 Triclocaraban Xylazine  CAB1 Pyriproxyphen Xylazine NP 
ANO2 Triclosan EDDPperchlorate  CAB2 Pyriproxyphen NP Dichlofenthion 
ANO3 Loratadine L-PFOS  CAB3 PFUdA Xylazine Pyriproxyphen 
CAR1 Loratadine Azaperone  CAB4 Xylazine Pyriproxyphen Hexythiazox 
CAR2 Loratadine Azaperone  CAB5 Xylazine Pyriproxyphen Buprofezin 
CAR3 Loratadine Azaperone  JUC1 Pyriproxyphen Xylazine Buprofezin 
CAR4 Loratadine Azaperone  JUC2 Pyriproxyphen Xylazine Desloratadine 
LLO1 OC EHMC Hexythiazox JUC3 NP Hexythiazox  
LLO2 Xylazine Paroxetine Atorvastatin JUC4 Dichlofenthion Pyriproxyphen Xylazine 
LLO3 Triclocaraban Xylazine  JUC5 Xylazine Pyriproxyphen Buprofezin 
LLO4 Xylazine Desloratadine  JUC6 Pyriproxyphen Xylazine Desloratadine 
LLO5 PFTrDA PFTeDA  JUC7 Dichlofenthion Chlorpyriphos  
LLO6 Xylazine Atorvastatin  JUC8 Hexythiazox Ethion  
LLO7 Irbesartan Sertraline  MAG1 Xylazine Pyriproxyphen  
ALG Triclocaraban Xylazine Paroxetine MAG2 Xylazine Pyriproxyphen  
ARG Meloxicam Azaperone  BEM Xylazine Azaperol Desloratadine 
CIN1 Xylazine Loratadine Meloxicam BOR Azaperone Warfarin Azaperol 
CIN2 Xylazine Loratadine  CAC Xylazine 4MBC  
EBR1 Triclocaraban Diethylstilbestrol Xylazine COR Xylazine Warfarin  
EBR2 Triclocaraban Xylazine  GEN1 Xylazine 4MBC  
EBR3 Xylazine Loratadine  GEN2 Xylazine PFNA  
EBR4 Xylazine Loratadine  GUA1 Xylazine Azaperol Desloratadine 
EBR5 Xylazine Loratadine  GUA2 Xylazine 11-nor-9-carboxy-9-  
EBR6 Loratadine Meloxicam  GUA3 Xylazine Estradiol (E2)  
EBR7 i,p-PFNA Loratadine  GUA4 Xylazine Desloratadine  
EBR8 Xylazine Loratadine  GUA5 Xylazine Azaperol Diazepam 
EBR9 Xylazine Loratadine Meloxicam GUA6 Xylazine Diazinon  
ESE Xylazine Loratadine Meloxicam GUA7 Xylazine Azaperol Diazepam 
GAL1 Xylazine Azaperone Azaperol GUA8 Xylazine Azaperol Desloratadine 
GAL2 Loratadine NP2EO  GUA9 terbutryn Desloratadine Alprazolam 
HUE Xylazine Loratadine Meloxicam GUAA Xylazine NP  
NAJ Xylazine Loratadine Meloxicam GUAL 4MBC Xylazine  
MAR Xylazine Loratadine  GUAM Xylazine Azaperol Desloratadine 
MAT Xylazine Fenthion  GUAN Xylazine Azaperol Desloratadine 
OCA Xylazine Loratadine  GUAR Xylazine NP  
RS Xylazine Loratadine Meloxicam HER Propilparaben Azaperol  
SEG Xylazine Loratadine  MAG Xylazine Estrone (E1) Azaperol 
ZAD Fluoxetine   PIC Xylazine Azaperol Desloratadine 
    YEG Xylazine Desloratadine Alprazolam 
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4. Conclusions  
IRICAP means an important effort to elaborate methods for assessing human 
health risks associated to exposure to chemical mixtures, or the aggregated exposure to 
chemicals. Although interactions have not been considered in the current study, this tool 
was able to easily integrate a large amount of compounds to establish similar patterns, 
with the ultimate goal of prioritizing contaminants in terms of health risks. IRICAP showed 
logical and reliable results in most sampling points, taking into account the chemical 
characteristics of each site. Furthermore, IRICAP considers the joint effect of the 
chemical mixture, but not single groups of pollutants. Consequently, although some 
places (e.g., agricultural areas) are known to have high concentrations of pesticides, this 
effect is not reflected in IRICAP because of their low weight vs. other contaminants with 
a higher HI or concentration. An important limitation of the IRICAP is the use of 
theoretical values as HI parameters. Data on persistence, bioaccumulation and toxicity 
for each one of the 205 compounds were derived by applying the US EPA EPI SuitTM 
software, which is a very powerful tool to get estimative values when experimental 
information is not available. However, the process of modeling PBT data may be 
inherently associated to a high uncertainty. This is especially remarkable in the variable 
“toxicity”. In this case, only fish toxicity values were used to build the HI by means of the 
ECOSARTM tool, which is in turn based on Kow levels. This approach may lead to a 
significant bias, as the impact on aquatic species of other steps in the food web, or even 
on the human health, is not taken into account. In this framework, further improvements 
of the IRICAP, in general, and the hazard index, in particular, should be focused on 
incorporating as many species as possible. Species Sensitivity Distributions (SSDs) are 
distributions of species’ responses to a given toxicant (Dowse et al., 2013). Using SSDs, 
instead of point toxicity values, could reduce the exclusion of key pollutants, for which 
fish toxicity is not significant, but the effects on other species may be notable. In order to 
solve other limitations of this index, as well as to improve the robustness of the model, 
further studies should include other groups of pollutants, such as heavy metals and 
POPs and include, if possible, other environmental compartments (sediments and biota). 
In addition, validation of the index should be considered in future studies by comparing 
IRICAP values with scores obtained by applying biological indices. Pareto distribution-
based indices have been proven to be a useful complement for risk assessment. In the 
current study, the final results allowed estimating the distribution of the compounds in 
the curve. Furthermore, the h-compounds, this is, those with a highest contribution on 
the hazard/concentration-based risk, were identified. Xylazine, as well as loratadine, 
azaperol, loratadine, azaperone, and pyriproxyphen, should be selected as key 
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pollutants when measuring the chemical pollution of fresh waters, at least in rivers of 
similar characteristics to those here evaluated. In conclusion, these chemicals must be 
priority pollutants in quality control monitoring networks of river basins. IRICAP may be 
a useful tool for stakeholders involved in water management, for its capabilities to 
evaluate and compare human risks in water river samples. 
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Discussion of Chapter I 
 
Up to 205 environmental contaminants were ranked according their Hazard Index 
(HI), which, in turn was basedon the PBT properties of the chemicals. The whole list 
included 81 pharmaceutical compounds, 19 illicit drugs, 31 endocrine disruptors (ED), 
42 pesticides, 11 UV filters and 21 perfluoroalkyl substances (PFASs). PBT data were 
derived by applying EpiSuitTM, due to the impossibility to found experimental data in the 
scientific literature. PFASs were characterized by a high environmental persistence and 
aquatic toxicity, but relatively low bioaccumulation potential. A cluster of 16 PFASs was 
identified as the group of compounds with the highest half-lives. PFASs were ranked as 
the most harmful familiy of compounds, with a HI of 5.58 in a scale from 0 to 10. PFASs 
were subsequently chose to develop the PBPK model, due to the harmful effects of the 
whole family of compounds, and the relatively similar behaviour with PCDD/Fs. The 
groups of cannabinoids (THC, cannabinol and cannabidiol) and UV filters (4 MBC, OD-
PABA, EHMC and OC) also showed a high HI (5.45).  
A specified risk ranking (IRICAP) was designed to identify the environmental 
pollutants posing the highest risk for the human health in freshwater. IRICAP was the 
product of the HI and the respective concentration of each chemical in water. This tool 
allows assessing the aggregated effect of chemical mixtures. IRICAP showed logical and 
reliable results in most sampling points, taking into account the chemical characteristics 
of each site. Although the interactions of chemical pollutants were not taken into account 
in the IRICAP, this index improved previous PBT-based rankings.  
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CHAPTER 2 
PCDD/Fs IN PLASMA OF INDIVIDUALS LIVING NEAR A 
HAZARDOUS WASTE INCINERATOR. A COMPARISON OF 
MEASURED LEVELS AND ESTIMATED CONCENTRATIONS BY 
PBPK MODELING 
Abstract 
The construction of the first and, until now, only hazardous waste incinerator 
(HWI) in Spain finished in 1998. To assess its potential impact on the population living in 
the vicinity, a surveillance program was established. It includes the periodical 
biomonitoring of PCDD/Fs body burden. On the basis of this program, in 2012 we 
determined the levels of PCDD/Fs in plasma of nonoccupationally exposed individuals 
living near the HWI. The results were compared with those of the baseline study, and 
with those of two previous surveys (2002 and 2007). A multicompartment, 
physiologically-based pharmacokinetic (PBPK) model was also applied to estimate the 
levels of PCDD/Fs in plasma. The model was validated by comparing the results with 
our experimental data (baseline, 2002, 2007, and 2012). The current mean concentration 
was 6.18 pg I-TEQ/g lipid, with a range between 2.03 and 18.8 pg I-TEQ/g lipid. In 1998 
(baseline), the mean concentration of PCDD/Fs in plasma was 27.0 pg I-TEQ/g lipid 
(reduction of 77%, p< 0.001). Significant reductions were also noted in our previous 2002 
and 2007 surveys, with mean concentrations of 15.7 and 9.36 pg I-TEQ/g lipid, 
respectively. However, the comparison between simulated (using the PBPK model) and 
experimental results was very successful, as PCDD/F values in plasma were very similar 
(7.95 vs 6.18 pg I-TEQ/g lipid). The levels of PCDD/Fs in plasma of nonoccupationally 
exposed individuals living near the HWI here assessed are comparatively lower than 
most recently reported values. 
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1. Introduction 
If not safely managed and disposed, hazardous waste (HW) may mean risk to 
human health and the environment. According to Eurostat (European Commission, 
2012) in 2010, a total of 94.5 million tons of HW were generated in the EU-27, that 
amount being higher than that generated in 2004 (89 million tons), but lower than the 
amounts generated in 2006 (101 million tons) and 2008 (98 million tons). For the 
treatment of HW, Eurostat indicates that about 9.8 million of tons (or 13.2% of all HW) 
were incinerated or used for energy recovery, while 29.1 million of tons (or 39.2% of all 
HW) were recovered (European Commission, 2012). Although waste combustion, 
including HW, offers a number of advantages (i.e., volume reduction and energy 
recovery) with respect to other waste management strategies (Domingo et al., 2002), the 
construction and/or operation of incinerators has been, and remains, an issue of 
considerable public concern. It is well-known that waste incinerators emit pollutants such 
as heavy metals and organic chemicals, whose potential toxicity at certain environmental 
concentrations is well-established. With respect specifically to HW incineration, although 
the number of HW incinerators (HWIs) is notably lower than that of municipal solid waste 
incinerators (MSWIs), and the volume of waste to be treated is remarkably different, 
special attention has been paid to those facilities (García-Pérez et al., 2013), as a 
consequence of the notable pressure that plants managing hazardous waste receive 
from the administration and the people living nearby. 
In 1999, the first HWI in Spain initiated its regular operations in Constantí 
(Tarragona County, Catalonia). This facility started its activities before the Waste 
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Incineration Directive (WID) entered into force in December 2000 (European 
Commission, 2000). However, since the construction of the facility generated an 
important concern among the local population, on behalf of the Catalan Agency of Waste, 
we initiated a wide environmental surveillance program during the construction of the 
HWI (baseline study, 1996−1998). This program was focused on evaluating the 
environmental impact of the stack emissions, particularly of metals and polychlorinated 
dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) on the environment, as well as 
assessing the health risks for the population living in the area under potential influence 
of the HWI. Although metals and PCDD/Fs are produced in many processes, incineration 
has received prolonged special attention by scientists and politicians (Domingo et al., 
2002; Mari et al., 2010; Tian et al., 2012). Our surveillance program is in addition to the 
requirements of the WID, which sets emission limit values and monitoring requirements 
for air pollutants such as dust, nitrogen oxides (NOx), sulfur dioxide (SO2), hydrogen 
chloride (HCl), hydrogen fluoride (HF), heavy metals, and PCDD/Fs. Since then, the 
program has been continuously maintained, measurements of the pollutants in different 
environmental and/ or biological matrixes being carried out annually (Bocio et al., 2005; 
Ferré-Huguet et al., 2005; Ferré-Huguet et al., 2009; Nadal et al., 2005; Nadal et al., 
2009; Schuhmacher et al., 2002a; Schuhmacher et al., 2002b; Schuhmacher et al., 
2004a; Schuhmacher et al., 2004b; Vilavert et al., 2010).  
The aim of the present study was to determine, after approximately 13 years of 
regular operations in the HWI, the concentrations of PCDD/Fs in plasma samples of 
individuals living in the neighborhood of the facility. In order to assess the temporal trend 
of these pollutants in the general, nonoccupationally exposed population of the area, the 
results of this survey have been compared with those of the baseline survey 
(Schuhmacher et al., 1999), and also with those of two previous campaigns carried out 
after the plant initiated its regular activities (2002 and 2007) (Agramunt et al., 2005; Nadal 
et al., 2008). We have also applied a multicompartment physiologically-based 
pharmacokinetic (PBPK) model in order to estimate the levels of PCDD/Fs in plasma. 
The model was validated by comparing the results with our experimental data, not only 
from the current, but also from our previous surveys (1998, 2002, and 2007) (Agramunt 
et al., 2005; Nadal et al., 2008; Schuhmacher et al., 1999). 
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2. Materials and Methods 
2.1. Area of Study 
The HWI herein studied is located in the industrial park of Constantí, relatively 
close to other significant industrial sources of environmental pollutants, such as a big oil 
refinery, an important complex of petrochemical industries, and a municipal solid waste 
incinerator among others. The plant is situated 5 km from the closest populated nuclei 
(Constantí and Reus), and 10 km from Tarragona city. Despite the presence of some 
chemical industries, the closest land to the plant is mainly used for agricultural purposes, 
in which hazel and olives are the predominant vegetal species. A few chicken farms are 
also sporadically situated in the surrounding zone. The number of farm workers is 
relatively reduced, as the main activities in the zone are oriented to the secondary and 
tertiary sectors of the economy. 
 
2.2. Sampling 
Blood collection was done in collaboration with the Joan XXIII and Santa Tecla 
Hospitals (Tarragona, Spain), where people living in the zone under the potential 
influence of the HWI emissions are mostly treated. Some samples were also obtained 
through blood donors of the area, with the collaboration of the Blood and Tissue Bank of 
the Vall d’Hebron Hospital (Barcelona, Spain). Plasma samples (80 mL per sample) were 
obtained from 40 individuals. All participants in the study had lived at least during the last 
10 years in zones near the HWI. All individuals with potential occupational exposure to 
PCDD/Fs, including welders and smelters, stations workers, PVC workers, and workers 
in waste incinerators, were excluded. No further consideration was done according to 
the eating habits of the subjects. People followed regular Mediterranean diets, 
characterized by a higher contribution of fruits, vegetables, and cereals. In turn, eggs 
and pulses showed the lowest values in the weekly intake. 
Blood samples were collected from individuals of both genders (20 men and 20 
women) and different ages (22−67 years). As in our previous surveys, 18−20 volunteers 
were also classified according to the specific place of residence: urban (living in 
Tarragona City) or industrial (living near incinerators and chemical/petrochemical 
industries) areas. Once collected, samples were kept at −20 °C until analysis. 
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2.3. Analytical Procedure 
PCDD/F concentrations in plasma samples were determined following a 
methodology derived from the U.S. EPA methods 1613 and 8290A. Forty mL of a 
standard solution containing a mixture of 13C12−PCDD/Fs was added to 75 g of plasma. 
Lipid extraction was carried out using a mixture of isopropanol/hexane through a solid 
phase (marine plankton diatomite). The concentrated lipids were calculated by 
gravimetry. For cleaning, extracts were passed through a column of acid/basic silica gel. 
Then, 40 mL of tetradecane was added as a control. After being concentrated to 1 mL, 
solutions were passed through a second column with activated Al2O3 and Na2SO4. 
Fractionation was performed with hexane. The third fraction, which contained PCDD/Fs, 
was immediately passed through a column of charcoal. A mixture (18%/82%) of 0.5 g of 
Carbopack C (Supelco Inc., Bellefonte, PA, U.S.) and Celite 545 (Fluka AG, Buchs, 
Switzerland) was used. Finally, the extract was evaporated to dryness with a stream of 
nitrogen, being redissolved with a solution containing 13C6-1,2,3,4- TCDD until a final 
volume of 20 mL with ultrasonic agitation. 
Cleaned extracts were analyzed by high resolution gas chromatography/high 
resolution mass spectrometry (HRGC/ HRMS), with selected ion recording at resolution 
>10000 and working with SIR mode (Selected Ion Recording). The calculation of the 
toxic native compounds was made by using the corresponding 13C12−PCDD/F internal 
standards, automatically correcting for any potential losses occurring during the 
processes of extraction, cleanup, and analysis. To check the reliability of the method and 
the apparatus, blanks and standards were set during the analytical procedure. The 
average recovery percentages ranged between 53% and 95%. 
 
2.4. Data treatment 
Toxic equivalents (TEQs) of the analyzed PCDD/Fs were calculated using both 
international NATO/ CCMS toxic equivalency factors (I-TEFs) and WHO-TEFs2005 (Van 
den Berg et al., 2006; Van Zorge et al., 1989). Data were statistically evaluated using 
the SPSS 19.0 software package. The Levene test was applied to study the equality of 
variances. Subsequently, statistical significance between groups was determined by 
using analysis of variance (ANOVA) or a Kruskal−Wallis test, respectively, depending on 
whether data followed a normal distribution or not. A probability lower than 0.05 (p < 
0.05) was considered as statistically significant. For calculations, the concentrations of 
those PCDD/F congeners with a value below the limit of detection (LOD) were 
considered to be one-half of the respective LOD (ND = 1/2 LOD). 
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3. Results and Discussion 
3.1. Concentration of PCDD/Fs in human plasma 
Table S1 (Annex 2) summarizes the individual concentrations of PCDD/Fs in 
plasma of 40 subjects living in the vicinity of the HWI here assessed. The mean 
concentration was 6.18 pg I-TEQ/g lipid (6.26 pg WHO-TEQ/g lipid), with a range 
between 2.03 and 18.8 pg I-TEQ/g lipid (2.16−25.4 pg WHO-TEQ/g lipid). Table 1 shows 
a general comparison between the results obtained in the baseline (1998) and the 
current surveys. In 1998, the mean concentration of PCDD/Fs in plasma was 27.0 pg I-
TEQ/g lipid (n = 20), which significantly decreased to 6.18 pg I-TEQ/g lipid (reduction of 
77%, p < 0.001) in the present study. Considerable and significant reductions in the 
PCDD/F levels in plasma were already noted in our previous 2002 and 2007 surveys, 
with mean concentrations of 15.7 and 9.36 pg I-TEQ/g lipid, respectively (Agramunt et 
al., 2005; Nadal et al., 2008). There was a significant (p < 0.001) reduction in the PCDD/F 
concentrations for both genders between the baseline survey (1998) and the current 
study. Pearson correlation was applied to analyze the influence of age on body levels of 
PCDD/Fs. A significant decrease in the levels of these pollutants was noted for all age 
groups. In contrast to other studies (Huang et al., 2007), no correlation between the 
concentrations of PCDD/Fs in plasma and age was found. However, in the present study, 
PCDD/F levels in plasma of the residents in urban zones were slightly higher than the 
mean level of subjects living in industrial areas (7.15 and 5.21 pg I-TEQ/g lipid, 
respectively). However, the difference did not reach a level of statistical significance (p 
> 0.05). A very notable and significant decrease in the mean concentrations of PCDD/Fs 
in plasma between the baseline (1998) and the current survey was found for the 
individuals living in both areas. The temporal evolution of the PCDD/F levels in plasma 
of the population living near the HWI is depicted in Figure S1 (Annex 2). 
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Table 1. Total concentration of PCDD/Fs (in pg I-TEQ/g lipid) in plasma of residents 
nearby the HWI, according to gender, age and specific area of residence (industrial or 
urban). 
  
No. 
Samples   Mean   
Standard 
deviation   Range   Variation % 
 
1998 2012  1998 2012  1998 2012  1998 2012  1998-2012 
Total 20 40  27.0 6.18  8.2 4.06  14.8-49.0 2.03-18.8  -77** 
Gender  
            
Male 13 20  26.7 6.48  2.5 4.52  14.8-49.0 2.11-18.8  -76** 
Female 7 20  27.8 5.88  2.7 3.63  14.9-34.7 2.03-17.5  -79** 
Age  
            
18-30 4 4  17.2 6.26  3.8 3.98  14.8-22.9 3.82-12.1  -64* 
31-45 4 10  25.2 4.93  5.0 2.85  17.9-29.2 2.04-9.21  -80** 
46-55 8 19  32.0 5.18  8.4 3.18  21.2-48.9 2.03-13.3  -84** 
>56 4 7  28.8 10.4  5.1 5.45  23.9-33.8 5.72-18.8  -64** 
Area  
            
Industrial 15 20  26.4 5.21  8.8 3.18  14.8-49.0 2.03-12.1  -80** 
Urban 5 20   28.7 7.15   7.1 4.66   16.5-34.7 2.04-18.8   -75** 
Significant differences at: *p < 0.01; **p < 0.001. 
 
Nowadays, it is well-known that for nonoccupationally exposed populations, diet 
is the main route of exposure to PCDD/Fs, being the percentages of the daily intake of 
PCDD/Fs through food consumption even higher than 95% (Domingo et al., 2007; 
Linares et al., 2010; Perelló et al., 2012). On the basis of this, we have also periodically 
measured the levels of PCDD/Fs in the most consumed food items in the zone under 
evaluation, and determined the dietary intake of these pollutants by the local population 
(Bocio et al., 2005; Domingo et al., 1999; Llobet et al., 2008). In the baseline survey 
(1998), the dietary intake of PCDD/Fs was 210.1 pg I-TEQ/ day, while the current dietary 
intake was estimated in 33.1 pg WHO-TEQ/day (Domingo et al., 2012). This intake was 
similar to that obtained in our previous survey (27.8 pg WHO-TEQ/day) (Llobet et al., 
2008), and lower than that found in the 2002 study (59.6 pg I-TEQ/day). It is evident that 
there is a parallel decrease and a direct relationship between the exposure to PCDD/Fs 
through the diet, and the concentrations of PCDD/Fs in the plasma of the population 
living in the area under the current evaluation. It has been suggested that there might be 
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some delay between the dietary intake of PCDD/Fs and the detection of these 
contaminants in biological tissues, such as plasma or breast milk (Nadal et al., 2008). 
The reduction in the levels of PCDD/Fs in foodstuffs and the corresponding decrease in 
the concentration of PCDD/Fs in human tissues and biological matrixes agree well with 
the results of other recent international studies (Consonni et al., 2012; Lakind et al., 2009; 
Lopez-Espinosa et al., 2008). Moreover, it is important to note that in an additional 
monitoring program, which we annually perform to determine the levels of PCDD/ Fs in 
blood of the workers at the same HWI, we have also observed a significant and continued 
reduction in these levels, which decreased from an initial (baseline values) mean 
concentration of 26.7 pg I-TEQ/g lipid to 4.6 pg I-TEQ/g lipid in 2011 (Domingo et al., 
2001; Mari et al., 2013). The profiles of the PCDD/F congeners in the 4 campaigns since 
the baseline (1998) study are depicted in Fig. 1. In the current (2012) survey, OCDD was 
the predominant congener, followed by 1,2,3,6,7,8 HxCDD and 1,2,3,4,6,7,8-HpCDD, 
while the lowest concentrations corresponded to 2,3,7,8-TCDD and 1,2,3,7,8,9-HxCDF. 
 
 
Fig. 1. PCDD/F congener profiles in plasma of non-occupationally exposed subjects living 
in the vicinity of a HWI. Temporal trends. 
 
Data on PCDD/F concentrations in blood of nonoccupationally exposed 
populations are rather scarce. While in the scientific literature, a number of reports 
concerning the levels of PCDD/Fs in human blood of populations living in the 
neighborhood of MSWIs has been published, information regarding PCDD/F levels in 
subjects living near HWIs and industrial incinerators is tremendously limited. In Missouri 
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(U.S.), Evans et al., (2000) assessed whether living in the vicinity of a HWI in Times 
Beach, which was burning 2,3,7,8-TCDDcontaminanted material, increased TCDD and 
toxicity equivalencies (TEQ) in individuals living near the facility. Subjects were randomly 
chosen from an area close to the HWI and compared to individuals outside the exposure 
area. TCDD and related compounds were measured in blood serum before incineration, 
four months after incineration started, and at the end of incineration. The results showed 
that incineration of TCDD did not result in any measurable exposure to the population 
surrounding the incinerator, as indicated by the biomarkers TCDD and TEQ serum 
levels. In Korea, Leem et al., (2003) analyzed blood samples of 45 subjects living near 
two MWSIs at Seoul, and an industrial waste incinerator at Pyongtaek, where high 
emissions of PCDD/Fs were suspected. The industrial waste incinerator began its 
operations in 1988 and ceased in 2001. The average TEQ concentration of PCDD/Fs in 
residents near the industrial waste incinerator was 53.4 pg I-TEQ/g lipid, whereas that in 
residents near MSWIs was 12.2 pg I-TEQ/g lipid. In a subsequent study performed in the 
vicinity of the same Korean incinerator, Park et al., (2004) assessed the spatial changes 
in the influence of that facility. A total of 47 soil samples (in continuous manner with 
distance) and 60 human blood samples (40 within 5 km, and 20 at 7 and 12 km) were 
collected and analyzed for the levels of PCDD/Fs. The mean PCDD/F value in the blood 
samples from the near-site zone was 12.2 pg I-TEQ/g lipid, while the mean concentration 
in the blood samples collected at the far-site zone was 11.0 pg I-TEQ/g lipid. Influence 
of the incinerator was not clearly observed both on soil and blood concentrations of 
PCDD/Fs, as the levels in the zone within 5 km were not significantly different from those 
at 7 and 12 km. However, the congener patterns of PCDD/Fs in both soil and blood 
changed with the distance to the facility. In the area under the potential influence of that 
same Korean incinerator, Leem et al., (2006) estimated whether blood levels and isomer 
patterns of PCDD/Fs in residents living near the facility were affected by its presence. 
Blood levels and homologue patterns of PCDD/Fs were determined in a group of 40 
residents living within 5 km of the industrial waste incinerator, and in a group of 20 
residents living 20 km away from the facility. The average concentration of PCDD/Fs in 
the near-site zone was 11.9 pg ITEQ/ g lipid, whereas that of the far-site zone was 11.2 
pg ITEQ/g lipid, the difference not being statistically significant. The authors observed 
that the group living next to the industrial incinerator presented the typical isomer pattern, 
in which the proportions of OCDDs were lower, while those of PCDFs were higher. These 
scarce international data, together with those obtained for the population living in the 
vicinity of the Spanish HWI here assessed, are summarized in Table 2. It can be seen 
that, among those reported, the current and previous mean PCDD/F levels (6.26 and 
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9.36 pg I-TEQ/g lipid, respectively) correspond to the lowest concentrations of these 
chemicals in human plasma of populations living near industrial or hazardous waste 
incinerators. Moreover, the continued decrease in the mean PCDD/F concentrations is 
well correlated with the reductions in the dietary intake of PCDD/Fs, which have been 
also noted in this same surveillance program. 
For comparison purposes only, we next summarize the results of some recent 
studies from different scenarios, in which the levels of PCDD/Fs were also determined 
in human blood. (Zubero et al., 2011) analyzed the concentrations of PCDD/Fs in 16 
“composite” samples of individuals living near a MSWI in Zabalgarbi (Bilbao, Spain), and 
established the temporal changes between 2006 and 2008. The average concentrations 
of PCDD/Fs were 13.4 and 13.2 pg WHO-TEQ/g lipid, respectively. No significant 
differences based on the specific place of residence, near or far from the facility, were 
found. In Germany, the Integrated Exposure Assessment Survey (INES) is designed to 
obtain data on exposure of the German population, including the analysis of several 
persistent organic pollutants (POPs) in biological matrixes. The latest campaign, 
conducted in 2005, showed an average PCDD/F concentration of 8.9 pg WHO-TEQ/g 
lipid (Fromme et al., 2009). Also in Germany, and specifically in the region of 
Baden−Württemberg, recently Link et al., (2012) observed a progressive reduction of the 
levels of PCDD/Fs in blood of children between 1996 and 2009. In that survey, PCDD/F 
levels ranged between 4.9 and 7.6 pg WHOTEQ/g lipid, depending on the type of 
breastfeeding. In turn, Turrio-Baldassarri et al., (2008) estimated in 22 pg WHO-TEQ/g 
lipid the average concentration of PCDD/Fs (assuming ND = LOD) in human serum of 
differently exposed population groups living in Brescia (Italy). In Japan, Arisawa et al., 
(2011) found a median concentration of 10 pg WHO-TEQ/g lipid in 1656 Japanese 
individuals, while in Australia, Staff et al., (2012) reported concentrations of PCDD/Fs 
between 9.5 and 10.1 pg WHOTEQ/g lipid in blood of a control group. Interestingly, the 
calculated concentration of PCDD/Fs in plasma samples of 43 workers who had been 
assigned to work in the vicinity of the World Trade Center (New York, U.S.) during the 
week after the collapse of the buildings was, on average, 41.2 pg WHOTEQ/g lipid (Horii 
et al., 2010). The levels of PCDD/Fs in plasma of the nonoccupationally exposed 
population, and living near the HWI here assessed, were lower than all of the above 
recently reported values. 
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Table 2. Summary of studies reporting PCDD/F levels in plasma of non-occupationally 
exposed populations living near industrial or hazardous waste incinerators. 
 
n.a.: not available. 
 
3.2. Multicompartment physiologically-based pharmacokinetic (PBPK) model 
PBPK models are mathematical representations of the human body, where 
organs are considered as compartments (Spear et al., 1994). These models allow 
prediction of the theoretical concentration of chemicals along the time in different human 
tissues (Fàbrega et al., 2011), taking into account species-specific physiological, 
chemical, and biochemical parameters. PBPK models are based on a system of 
differential equations which estimate the concentration or amount of individual 
substances of sets of chemicals in each body compartment. These tools are increasingly 
used in the field of human health risk assessment, particularly in quantifying the 
relationship between measures of external exposure and internal dose (Thompson et al., 
2008). In the present study, a multicompartment PBPK model developed by Maruyama 
et al., (2003) was applied to estimate the levels of PCDD/Fs in plasma. The model was 
validated by comparing the results with experimental data, not only from the current 
survey, but also from our previous surveys (1998, 2002, and 2007) (Agramunt et al., 
2005; Nadal et al., 2008; Schuhmacher et al., 1999). As mentioned above, dietary intake 
is the most important pathway of exposure to PCDD/Fs, with contribution percentages 
higher than 95%. Therefore, we assumed that: (1) food intake was the only source of 
PCDD/F exposure, and (2) this route of exposure was constant along time. Data about 
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dietary intake of PCDD/Fs were obtained from previous studies conducted in the same 
area (Bocio et al., 2005; Domingo et al., 1999; Domingo et al., 2012; Llobet et al., 2008). 
The conceptual representation of the PBPK model, which included 7 individual 
compartments, is depicted in Figure S2 (Annex 2). Fat, liver, kidney, skin, muscle, and 
richly perfused tissues (lung, spleen, and brain) were considered as independent 
compartments, while blood was the only matrix interrelated with the others. The predicted 
concentration of PCDD/Fs in fat, kidney, skin, muscle, and richly perfused tissues was 
based on the following mass balance equation: 

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    (1) 
where Vi is the volume of the tissue i (L), Ci is the concentration of PCDD/Fs in 
the tissue i (pg/L), Qi is the blood flow (L/h), Pi is the tissue i:blood partition coefficient 
(unitless), and Ca is the arterial concentration (pg/L). In turn, the predicted level of 
PCDD/Fs in blood was determined by applying the following expression: 
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where Vi is the volume of blood (L), Cblood is the PCDD/F concentration in blood 
(pg/L), Ci is the PCDD/F concentration in the tissue i (pg/L), Qi is the blood flow (L/h), Pi 
is the tissue i:blood partition coefficient (unitless), Ca is the arterial concentration (pg/L), 
D is the daily intake of PCDD/Fs (in pg/day), and Abs is the gastrointestinal absorption 
factor (unitless). In order to estimate the blood concentration of PCDD/Fs (pg/g lipid), the 
lipid percentage (weight:weight) of each sample was analyzed (mean: 0.79%; range: 
0.39%− 1.39%). As liver was considered as an elimination organ, the predicted 
concentration of PCDD/Fs in this tissue was estimated by the following equation: 
KiVliverCliver
Pliver
CliverCaQliver
dt
dCliverVliver +×−





−×=×
  (3) 
where Vliver is the liver volume (L), Cliver is the PCDD/F concentration in liver 
(pg/L), Qliver is the blood flow (L/h), Ca is the arterial concentration (pg/L), Pliver is the 
liver:blood partition coefficient (unitless), and K1 is the elimination constant. Values of 
tissue volume, cardiac output, partition coefficient, absorption rates, and elimination 
constant were obtained from Maruyama et al., (2003). As the model was restricted to a 
simulation period of 4 years and applied to an adult population, no variations in volumes 
and cardiac output along the time were considered. The final system of differential 
equations was coded in Matlab using the Stiff method. Calculations were made for the 
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17 toxic 2,3,7,8-chlorinated PCDD/Fs, being the total levels estimated according to I-
TEF values. 
Simulated concentrations of PCDD/Fs in each one of the 7 compartments, taking 
into account intake data of 2012, are summarized in Table 3. The highest levels were 
found in fat and blood (17.6 and 7.95 pg I-TEQ/g lipid, respectively). In contrast, kidney 
and skin showed the minimum levels (0.14 and 0.24 pg I-TEQ/g tissue, respectively). 
Adipose tissue is considered an accumulation reservoir of PCDD/Fs in the human body 
(Moon et al., 2011), while plasma is also a good biomarker of PCDD/Fs, given its 
distribution capacity. When comparing the modeled and experimental concentrations of 
PCDD/Fs in plasma, very similar values were observed: 7.95 vs 6.18 pg ITEQ/g lipid, 
respectively. This corroborates the validity and suitability of this particular model to 
predict the PCDD/F burdens in plasma. Moreover, the simulation was also performed on 
the basis of the dietary intake of PCDD/Fs in previous monitoring campaigns. The results 
are depicted in Fig. 2, together with experimental values of PCDD/Fs in plasma and the 
dietary intake. Because food intake was assumed to be the only single exposure 
pathway, a significant reduction of plasma concentrations of PCDD/Fs was noted, which 
is in agreement with the significant decrease in the dietary intake of PCDD/Fs. In our 
preoperational study (1998), the dietary intake of PCDD/F ingestion through food 
consumption by the general population was 210.1 pg I-TEQ/day (Domingo et al., 1999), 
while in subsequent surveys (2002 and 2007) the intake decreased to 27.8 pg WHO-
TEQ/day (Bocio et al., 2005; Llobet et al., 2008). In our last assessment period 
(2007−2012), the dietary intake slightly increased, reaching 33.1 pg WHO-TEQ/day. The 
increase was attributed to the inclusion of a new food group (industrial bakery), whose 
incidence had not been previously evaluated. The daily intake of PCDD/Fs, exclusively 
due to the consumption of industrial bakery, was estimated in 3.49 pg WHO-TEQ (10.5% 
of the total). Considering only the food groups evaluated in both 2007 and 2012 surveys, 
it was noted that the dietary intake had remained nearly constant, from 27.8 to 29.4 pg 
WHO-TEQ/ day (Domingo et al., 2012). 
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Fig. 2. Dietary intake of PCDD/Fs, and comparison between measured and 
simulated PCDD/F concentrations in plasma, between 1998 (baseline survey) and 2012 
(current data). PCDD/F intake in 1998 is given as pg I-TEQ/day. 
 
Table 3. PBPK modeling results: Simulated concentrations of PCDD/Fs in 7 human 
compartments according to dietary intake data of 2012. 
Blood Liver Fat Kidney Muscle Richly perfused Skin 
2,3,7,8-TCDD 1.06 0.08 2.09 0.03 0.14 0.03 0.02 
1,2,3,7,8-PeCDD 3.78 0.51 13.1 0.09 0.57 0.14 0.06 
1,2,3,4,7,8-HxCDD 1.10 0.26 1.03 0.01 0.04 0.02 0.02 
1,2,3,6,7,8-HxCDD 6.78 2.96 12.0 0.16 0.71 0.15 0.09 
1,2,3,7,8,9-HxCDD 0.27 0.61 3.32 0.02 0.29 0.06 0.01 
1,2,3,4,6,7,8-HpCDD 18.5 5.01 21.3 0.34 5.78 2.07 2.07 
OCDD 16.3 7.22 7.18 0.36 3.38 2.08 1.82 
2,3,7,8-TCDF 4.08 0.59 1.79 0.03 0.15 0.08 0.31 
1,2,3,7,8-PeCDF 1.49 0.23 1.55 0.02 0.12 0.08 0.11 
2,3,4,7,8-PeCDF 4.11 1.47 11.1 0.07 1.25 0.12 0.09 
1,2,3,4,7,8-HxCDF 3.45 0.69 2.07 0.04 0.30 0.17 0.06 
1,2,3,6,7,8-HxCDF 1.41 0.50 1.47 0.02 0.28 0.02 0.03 
1,2,3,7,8,9-HxCDF 3.95 0.06 5.44 0.01 0.09 0.12 0.35 
2,3,4,6,7,8-HxCDF 3.80 0.12 1.46 0.03 0.09 0.11 0.19 
1,2,3,4,6,7,8-HpCDF 13.2 2.32 14.7 0.09 0.77 0.24 1.16 
1,2,3,4,7,8,9-HpCDF 3.58 0.25 3.23 0.01 0.09 0.05 0.31 
OCDF 17.2 2.06 19.8 0.23 0.76 0.62 1.92 
I-TEQ 7.95 1.75 17.6 0.14 1.33 0.26 0.24 
Concentrations in plasma are given in pg I-TEQ/g fat, while those of the remaining tissues 
are shown in pg I-TEQ/g tissue. 
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4. Conclusions 
In conclusion, the PBPK model has demonstrated to be a very reliable tool to 
predict the levels of PCDD/Fs in plasma. The comparison between simulated and 
experimental results was very successful, as PCDD/F values in plasma were very similar 
(7.95 vs 6.18 pg I-TEQ/g lipid). For validation purposes, modeling results for other 
compartments may also be compared with the levels of PCDD/Fs found in different 
human tissues. In this sense, it must be highlighted that, in addition to plasma, 
periodically we also use other biological monitors, such as breast milk and adipose 
tissue, as biomonitors of accumulation of PCDD/Fs in subjects living in the zones under 
potential influence of the HWI. In previous studies, the concentrations of PCDD/Fs in 
samples of adipose tissue of autopsied subjects living in these zones were 40.1, 9.89, 
and 14.6 pg I-TEQ/g lipid in 1998, 2002, and 2007, respectively (Nadal et al., 2009). 
These values are very similar to those obtained after executing the model (31.0, 9.27, 
and 14.0 pg I-TEQ/g lipid, respectively). As part of the current biological surveillance 
program of the HWI, the concentration of PCDD/Fs will again be determined in adipose 
tissue during 2013. The outcomes of that survey will be fundamental in the design and 
implementation of future monitoring programs of the HWI. If the PBPK model results are 
sufficiently effective in adipose tissue, as they already seem to be in plasma, then the 
cost of surveillance studies might be notably reduced by minimizing the number of 
biological samples, something critical in the context of the current economic crisis. 
 
References  
Agramunt, M.C., Schuhmacher, M., Hernandez, J.M, Domingo, J.L., 2005. Levels of 
dioxins and furans in plasma of nonoccupationally exposed subjects living near 
a hazardous waste incinerator. Journal of Exposure Analysis and Environmental 
Epidemiology 15, 29−34. 
Arisawa, K., Uemura, H., Hiyoshi, M., Kitayama, A., Takami, H., Sawachika, F., Nishioka, 
Y., Hasegawa, M., Tanto, M., Satoh, H., Shima, M., Sumiyoshi, Y., Morinaga, K., 
Kodama, K., Suzuki, T.I., Nagai, M., 2011. Dietary patterns and blood levels of 
PCDDs, PCDFs, and dioxin-like PCBs in 1656 Japanese individuals. 
Chemosphere 82, 656−662. 
Bocio, A., Domingo, J.L., 2005. Daily intake of polychlorinated dibenzo-p-
dioxins/polychlorinated dibenzofurans (PCDD/PCDFs) in foodstuffs consumed in 
Tarragona, Spain: A review of recent studies (2001−2003) on human 
PCDD/PCDF exposure through the diet. Environmental Research 97, 1−9. 
Bocio, A., Nadal, M., Domingo, J.L., Human exposure to metals through the diet in 
Tarragona, Spain: Temporal trend. Biological Trace Element Research 104, 
193−201. 
UNIVERSITAT ROVIRA I VIRGILI 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF PCDD/FS AND PFASS IN HUMANS. 
Francesc Fabrega Bonadona 
Dipòsit Legal: T 1660-2014
Chapter 2. A PBPK model to estimate PCDD/F levels in plasma 
 
60 
Consonni, D., Sindaco, R., Bertazzi, P.A., 2012. Blood levels of dioxins, furans, dioxin-
like PCBs, and TEQs in general populations: A review, 1989−2010. Environment 
International 44, 151−162. 
Domingo, J.L., Schuhmacher, M., Granero, S., Llobet, J.M., 1999. PCDDs and PCDFs 
in food samples from Catalonia, Spain. An assessment of dietary intake. 
Chemosphere 38, 3517−3528. 
Domingo, J.L., Schuhmacher, M., Agramunt, M.C., Müller, L., Neugebauer, F., 2001. 
Levels of metals and organic substances in blood and urine of workers at a new 
hazardous waste incinerator. International Archives of Occupational and 
Environmental Health 74, 263−269. 
Domingo, J.L, 2002. Human health risks of dioxins for populations living near modern 
municipal solid waste incinerators. Reviews on Environmental Health 17, 
135−147. 
Domingo, J.L., Agramunt, M.C., Nadal, M., Schuhmacher, M., Corbella, J., 2002. Health 
risk assessment of PCDD/PCDF exposure for the population living in the vicinity 
of a municipal waste incinerator. Archives of Environmental Contamination & 
Toxicology 43, 461−465. 
Domingo, J.L., Bocio, A., 2007. Levels of PCDD/PCDFs and PCBs in edible marine 
species and human intake: A literature review. Environment International 33, 
397−405. 
Domingo, J.L., Perelló, G., Nadal, M., Schuhmacher, M., 2012. Dietary intake of 
polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) by a population 
living in the vicinity of a hazardous waste incinerator. Assessment of the temporal 
trend. Environment International 50, 22−30. 
European Commission. The Waste Incineration Directive, 2000. Available at: 
http://ec.europa.eu/environment/air/pollutants/stationary/wid/legislation.htm. 
Accessed in Jan 31, 2013. 
European Commission. Waste Statistics, 2012. Available at: 
http://epp.eurostat.ec.europa.eu/statistics_explained/index.php/Waste_statistics
. Accessed in Jan 31, 2013. 
Evans, R.G., Shadel, B.N., Roberts, D.W., Clardy, S., Jordan-Izaguirre, D., Patterson, 
D.G., Needham, L.L., 2000. Dioxin incinerator emissions exposure study Times 
Beach, Missouri. Chemosphere 40, 1063−1074. 
Fàbrega, F., Nadal, M., Schuhmacher, M., Domingo, J.L, 2011. PBPK modeling of PFOS 
and PFOA using a whole body pharmacokinetic model: A preliminary approach 
and validation test. Organohalogen Compounds 73, 1169−1172. 
Ferré-Huguet, N., Nadal, M., Schuhmacher, M., Domingo, J.L., 2006. Environmental 
impact and human health risks of polychlorinated dibenzo-p-dioxins and 
dibenzofurans in the vicinity of a new hazardous waste incinerator: A case study. 
Environmental Science & Technology 40, 61−66. 
Ferré-Huguet, N., Nadal, M., Schuhmacher, M., Domingo, J.L., 2009. Monitoring metals 
in blood and hair of the population living near a hazardous waste incinerator: 
Temporal trend. Biological Trace Element Research 128, 191−199. 
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CHAPTER 3 
A PBPK MODEL TO ESTIMATE PCDD/F LEVELS IN ADIPOSE 
TISSUE: COMPARISON WITH EXPERIMENTAL VALUES OF 
RESIDENTS NEAR A HAZARDOUS WASTE INCINERATOR 
Abstract 
This study was aimed at determining the concentrations of polychlorinated 
dibenzo-p-dioxins and polychlorinated dibenzofurans (PCDD/Fs) in 15 samples of 
adipose tissue from subjects who had been living in the vicinity of a hazardous waste 
incinerator (HWI). The results were compared with levels obtained in previous surveys 
carried out in 1998 (baseline study), 2002 and 2007. The current (2013) concentrations 
of PCDD/Fs in adipose tissue ranged from 2.8 to 46.3 pg WHO-TEQ/g fat (mean and 
median concentrations: 11.5 and 7.4 pg WHO-TEQ/g fat, respectively), being 
significantly lower (64%) than those observed in 1998.  In contrast, no significant 
differences in the mean PCDD/F concentrations were noted in the period 2002-2013. 
The significant decrease of the PCDD/F content in fat, also noted in other biological 
monitors such as plasma and breast milk, is in agreement with the reduction in the dietary 
intake of PCDD/Fs found in the same area of study. Similarly to other investigations 
across Europe, an increase of PCDD/F levels in adipose tissue in relation to age was 
observed, while no significant differences were noted according to gender. A 
multicompartmental physiologically-based pharmacokinetic (PBPK) model was also 
applied to estimate the levels of PCDD/Fs in adipose tissue. When comparing the 
modelled and experimental concentrations of PCDD/Fs in that tissue, very similar values 
were obtained for the four surveys, which indicates this can be a reliable tool to predict 
the internal dose of PCDD/Fs.  
 
1.Introduction 
Due to their toxic potential for humans and wildlife, as well as bioaccumulation 
and persistence capacity, contamination by polychlorinated dibenzo-p-dioxins and 
polychlorinated dibenzofurans (PCDD/Fs) is an environmental problem of global 
concern. PCDD/Fs are released to the environment from a number of sources, including 
traffic, chemical manufacturing, iron and steelmaking, as well as open burning of 
materials in forest fires, accidental fires and unintentional landfill fires (Schuhmacher and 
Domingo, 2006; Estrellan and Iino, 2010; Ooi and Lu, 2011). In the past, incinerators 
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were catalogued as important sources of toxic emissions, particularly PCDD/Fs and 
heavy metals (Hu et al., 2004). However, the installation of modern cleaning technologies 
to comply with maximum emission levels, according to European standards (0.1 ng I-
TEQ Nm3), has substantially reduced the environmental impact of these facilities, not 
only in terms of PCDD/Fs, but also other air pollutants (Glorennec et al., 2005; Vilavert 
et al., 2010).  
Incineration, also known as waste-to-energy, has become one of the most widely 
used alternatives for waste management, being considered as a serious option for the 
disposal of municipal solid, hazardous and medical wastes. In comparison to other waste 
treatments, incineration has a wide range of advantages, of which volume reduction, 
energetic recovery and microbial elimination are the most evident. Moreover, the 
incineration of hazardous waste is often selected as the most desirable disposal method, 
when these cannot be properly recycled (Ferré-Huguet et al., 2005; Mari et al., 2013). 
Unfortunately, this process may release a wide range of chemicals to air, therefore 
contaminating water, soil and biota by pollutant deposition, and ultimately affecting the 
human health of residents living in the surrounding of hazardous waste incinerators 
(HWIs). Despite of the heterogeneity of stack emissions, which include heavy metals, 
semivolatile and volatile organic compounds, especial attention has been paid to 
PCDD/Fs (Kulkarni et al., 2008; Mari and Domingo, 2010), becoming one of the 
chemicals of most scientific and social interest. Because of this, the European Union 
(EU) imposed strict operating conditions and technical requirements on waste 
incineration plants and co-incineration plants, according to the EU Directive 2000/76/EC. 
After application of this regulatory measures and implementation of Best Available 
Techniques (BAT), a gradual decrease in the concentrations of PCDD/Fs in human 
biological tissues has been noted worldwide (Hagmar et al., 2006; Nadal et al., 2013), 
being plasma and breast milk two of the most visible monitors. This fact has been 
associated to the parallel reduction in the dietary intake of these pollutants (Domingo et 
al., 2012). Notwithstanding, the potential health risks derived from HWI stack emissions 
still generate a considerable concern among the population (Liu et al., 2012; Bunsan et 
al., 2013). PCDD/Fs accumulate in human adipose tissues over lifetime. These 
contaminants are slowly metabolized in the human body and elicit adverse effects 
including developmental and reproductive toxicity, cancer, and endocrine disruption 
(Mocarelli et al., 2008; White and Birnbaum, 2009). The levels of contaminant residues 
in adipose tissue can provide valuable information on steady-state concentrations, as a 
way to integrate the body burdens of lipophilic chemicals accumulated overtime. For 
instance, the Stockholm convention (SC) of persistent organic pollutants (POPs) have 
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the goal to reduce the emissions of PCDD/Fs in a 50% in 10 years. To prove this, SC 
establishes a global monitoring system to prove the reduction of PCDD/Fs in 
environmental matrices as well as human tissues, like adipose tissue. 
The objective of this study was to determine the concentrations of PCDD/Fs in 
samples of adipose tissue of individuals living in the neighborhood of a HWI in Catalonia 
(Spain), 14 years after the facility started its regular operations. The results of this survey 
were compared with data from previous campaigns carried out before (1998) and after 
(2002 and 2007) the plant began to operate. Data from the biological monitoring study 
was also used to validate a multicompartment physiologically-based pharmacokinetic 
(PBPK) model to estimate the levels of PCDD/Fs in adipose tissue. 
 
2. Material and Methods 
2.1. Area of study 
The HWI herein studied is located in Constantí (Tarragona County, Catalonia, 
Spain), relatively close to other potential industrial sources of environmental pollutants, 
such as a big oil refinery, an important complex of chemical industries, and a municipal 
solid waste incinerator (MWSI), among others. In addition, an intense traffic is present in 
the zone, which is crossed by a highway, a motorway and a number of roads. The facility 
is located 5 km from the closest populated nuclei (Constantí and Reus), and 10 km from 
Tarragona downtown. Information about the HWI, as well as more characteristics of the 
surrounding area were described in detail elsewhere (Schuhmacher et al., 1999a,b,c). 
 
2.2. Sampling 
During 2012-2013, adipose tissue samples of 15 autopsied subjects living in 
zones of Tarragona County (Catalonia, Spain) under potential impact of the HWI were 
collected. At the time of death, all the individuals had lived for at least the last 10 years 
in the area under evaluation. All samples were obtained from the same body 
compartment (abdominal adipose tissue). Samples were stored in polyethylene 
containers and kept at -20 °C until analysis. Samples were classified according to sex (9 
men and 6 women) and age (mean age of the subjects was 52 years, ranging from 30 
to 74). Individual and medical information of the participants were collected by passing 
a questionnaire to the relatives. No occupational exposure to PCDD/F was found for any 
of the subjects. Sampling was conducted in collaboration with forensic physicians of the 
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Institute of Legal Medicine of Catalonia (Tarragona Division), whose Research 
Committee evaluated and approved the study. 
 
2.3. Analytical procedure 
Analysis of PCDD/Fs was done according to a procedure derived from the US 
EPA methods 1613 and 8290A. Samples were dissolved in hexane, and a mixture of 
13C12-PCDD/F standards was spiked in order to control potential losses during the 
extraction and clean-up processes. Lipids were destructed by adding acid silica. In order 
to remove interfering components, a multi-step clean-up was performed. The first step 
consisted on a multilayer silica column clean-up. Further, the extract was eluted on a 
basic alumina column by passing different solvents in order to separate PCDD/Fs from 
other compounds. The PCDD/F fraction was collected and concentrated to near dryness 
with a nitrogen flux. Finally, 25 μL of 13C12-PCDD/F injection standards were added. 
The analysis of PCDD/Fs was carried out by high resolution gas 
chromatography/high resolution mass spectrometry (HRGC/HRMS). The extract 
obtained after extraction and clean-up was injected on an Agilent 6890 gas 
chromatograph equipped with a ZB5-MS capillary column and coupled to a Waters 
Autospec Ultima mass spectrometer. The chromatographic process separated the 17 
toxic 2,3,7,8-substituted congeners from each other. The mass spectrometer measured 
(via “selected ion recording” at a resolution of >10 000) two selected ions per congener 
group for both the native and labelled compounds. The calculation of the concentrations 
was done by using the corresponding 13C congener level, automatically correcting 
according to the recovery percentage specific for each congener. In addition, the relative 
standard deviation (RSD) was calculated as a measure of the uncertainty. In all cases, 
the RSD of the control sample was lower than 10%. 
 
2.4. Data treatment 
The SPSS 19.0 statistical software package was used for data analysis. Total 
PCDD/F concentrations were calculated according to the 2005 WHO-TEFs (van den 
Berg et al., 2006). PCDD/F levels obtained in previous campaigns (1998, 2002 and 2007) 
were also recalculated according to the 2005 WHO-TEFs. The Levene test was applied 
to study the equality of variances. Furthermore, the ANOVA or Kruskal–Wallis tests were 
executed. A probability lower than 0.05 (p < 0.05) was considered as statistically 
significant. For calculations, when a PCDD/F congener presented a level below the 
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respective limit of detection (LOD), the concentration was assumed to be one-half of that 
limit (ND = 1/2 LOD). 
 
3. Results and Discussion 
3.1. Concentrations of PCDD/Fs in adipose tissue 
The individual PCDD/F concentrations in adipose tissue samples from 15 
subjects from Tarragona County, are summarized in Table 1. Age and sex of the 
individuals are also given. The mean levels of the 17 substituted-PCDD/F congeners, as 
well as the total PCDD/F concentration, in adipose tissue samples collected in the 
baseline (1998), previous (2002 and 2007) and current (2013) surveys, are summarized 
in Table 2. In the baseline (1998) study, a mean PCDD/F concentration in adipose tissue 
of 32.1  pg WHO-TEQ/g fat was found (median: 26.7 pg WHO-TEQ/g fat; range: 14.2-
70.1 pg WHO-TEQ/g fat) (Schuhmacher et al., 1999b). In the 2002 survey, the mean 
and median levels of PCDD/Fs were 9.9 and 6.8 pg WHO-TEQ/g fat, with minimum and 
maximum values of 1.4 and 36.1 pg WHO-TEQ/g fat, respectively (Schuhmacher et al., 
2004). In the immediately previous campaign (2007), the mean PCDD/F concentration 
in adipose tissue was 14.6 pg WHO-TEQ/g fat (median: 7.5 WHO-TEQ/g), with values 
ranging from 3.3 to 55.4 pg WHO-TEQ/g fat (Nadal et al., 2008).  
In the current (2013) survey, mean and median PCDD/F concentrations of 11.5 
and 7.4 pg WHO-TEQ/g fat, respectively, were observed, while minimum and maximum 
concentrations were 2.8 and 46.3 pg WHO-TEQ/g fat, respectively. Comparing the mean 
PCDD/F concentrations of the baseline (1998) study with those of the current (2013) 
survey, an important significant reduction was found (64%). However, during the period 
2002-2013 no significant differences in the mean PCDD/F concentrations were noted, 
being median levels very similar. This temporal trend is in agreement with the significant 
reduction of PCDD/Fs in other biological tissue samples from non-occupationally 
exposed people of the same area. 
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Table 1. Individual PCDD/F concentrations (pg WHO-TEQ/g fat) in adipose tissue 
samples of individuals who had been living for at least the last 10 years in Tarragona 
County, Spain. 
Sample Gender Age (years) pg WHO-TEQ/g fat 
1 M 56 10.2 
2 M 53 7.4 
3 F 74 21.4 
4 M 37 2.9 
5 F 40 6.7 
6 M 50 18.2 
7 M 59 11.3 
8 M 46 2.8 
9 M 56 12.8 
10 F 72 46.3 
11 F 40 5.1 
12 M 64 6.0 
13 M 36 2.9 
14 F 73 13.9 
15 F 30 5.1 
 M: Male; F: Female 
 
Table 2. Mean levels of PCDD/F congeners (in pg/g fat) in adipose tissue 
samples of residents near a HWI in Tarragona County (Catalonia, Spain). 
Congener 1998 2002 2007 2013 
2,3,7,8-TCDD 4.13 ± 3.03a 1.39 ± 1.53b 1.68 ± 1.86b 1.24 ± 1.14b 
1,2,3,7,8-PeCDD 11.37 ± 4.74a 3.73 ± 3.51b 5.28 ± 4.80b 4.11 ± 3.48b 
1,2,3,4,7,8-HxCDD 5.61 ± 2.86a 2.78 ± 1.73b 3.30 ± 3.61a,b 2.26 ± 2.26b 
1,2,3,6,7,8-HxCDD 59.4 ± 30.2a 19.2 ± 18.9b 28.1 ± 29.3b 25.3 ± 26.6b 
1,2,3,7,8,9-HxCDD 8.12 ± 6.45a 2.08 ± 2.03b 3.55 ± 4.47b 2.63 ± 4.37b 
1,2,3,4,6,7,8-HpCDD 84.9 ± 60.9a 10.2 ± 8.0b 20.0 ± 28.9b 20.3 ± 52.9b 
OCDD 477.5 ± 320.2a 53.6 ± 51.0b 151.9 ± 187.8b 113.3 ± 195.6b 
2,3,7,8-TCDF 0.94 ± 0.58a 0.34 ± 0.4b 0.40 ± 0.40b 0.35 ± 0.27b 
1,2,3,7,8-PeCDF 0.92 ± 0.47a,b 0.5 ± 0.45b 1.4 ± 1.33a 0.31 ± 0.26b 
2,3,4,7,8-PeCDF 21.1 ± 11.5a 5.71 ± 5.95b 9.94 ± 9.43b 7.43 ± 6.93b 
1,2,3,4,7,8-HxCDF 7.02 ± 3.33a 2.32 ± 1.75b 3.29 ± 3.25b 2.83 ± 2.97b 
1,2,3,6,7,8-HxCDF 8.22 ± 3.99a 2.03 ± 1.86b 3.31 ± 3.47b 2.69 ± 2.86b 
1,2,3,7,8,9-HxCDF 0.62 ± 0.35a 0.39 ± 0.41b 0.06 ± 0.05b 0.07 ± 0.05b 
2,3,4,6,7,8-HxCDF 2.2 ± 1.28a 0.38 ± 0.44a 0.88 ± 0.73a 0.69 ± 1.15a 
1,2,3,4,6,7,8-HpCDF 4.81 ± 2.17a 2.06 ± 0.65a 2.99 ± 2.54a,b 2.34 ± 3.13b 
1,2,3,4,7,8,9-HpCDF 0.39 ± 0.10a 0.31 ± 0.52a,b 0.10 ± 0.06b 0.11 ± 0.05b 
OCDF 0.72 ± 0.27a 2.59 ± 1.27b 0.49 ± 0.30a 0.31 ± 0.15a 
Total WHO-TEQ 32.1 ± 15.3a 9.9 ± 9.3b 14.6 ± 14.2b 11.5 ± 11.1b 
 a,bDifferent superscripts indicate statistically significant differences at p <0.05. In 
parenthesis, median values. 
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Between 1998 and 2012, a significant decrease of mean PCDD/F concentrations 
in plasma from residents in Tarragona County was found. Levels were reduced from 27.0 
to 6.18 pg I-TEQ/g lipid (77%; p<0.001) (Nadal et al., 2013). Similarly, the concentrations 
of PCDD/Fs in breast milk of women living in the same area were significantly lower in 
2012 than those obtained in the 1998 survey (12.2 and 4.8 pg WHO-TEQ/g fat, 
respectively; p<0.001). Although the overall assessment of the data indicate a similar 
decreasing trend of PCDD/F burdens in the 3 biomonitors (plasma, breast milk, and 
adipose tissue), the profile of this latter is slightly different from the remaining two. The 
temporal decline of PCDD/Fs in plasma and breast milk has been progressive, being the 
values of the intermediate sampling campaigns lower than that of the baseline survey 
(1998), but higher than that of the most recent study (2012-2013). Thus, mean plasma 
concentrations of 15.7 and 9.36 pg I-TEQ/g lipid were found in 2002 and 2007, 
respectively, while PCDD/F levels in breast milk in 2002 and 2007 were 10.6 and 7.6 pg 
WHO-TEQ/g fat, respectively. On the other hand, the most important reduction of 
PCDD/Fs in fat tissue was only detected in the period 1998-2002, while no significant 
changes have been found since then. This would indicate that fat tissue acts more as a 
storage compartment, when compared with plasma and breast milk. Anyhow, the 
significant reduction in the levels of PCDD/Fs in fat tissue is consistent with the 
decreasing trend in the dietary intake of PCDD/Fs observed in recent years. The intake 
of PCDD/Fs through food consumption for the adult population of Tarragona County was 
210.1 pg I-TEQ/day in the baseline survey (1998) (Domingo et al., 1999), while in 2012 
the dietary intake dropped to 33.1 pg WHO-TEQ/day (Domingo et al., 2012), being this 
intake similar to that previously found in 2006 (Martí-Cid et al., 2008). Although human 
exposure to PCDD/Fs may occur through a number of routes such as inhalation, dermal 
contact, and ingestion of soils and dust, it is well known that the diet is quantitatively the 
main exposure pathway for non-occupationally exposed individuals (Nadal et al., 2004; 
Passuello et al., 2010; Windal et al., 2010).  
The current concentrations of PCDD/Fs in samples of adipose tissue from 
individuals of Tarragona County are within the range of those reported in the scientific 
literature. Takenaka et al. (2002) found mean PCDD/F concentrations of 49.0 pg WHO-
TEQ/g fat in fat tissue of Japanese people, collected in 1999, being this level similar to 
the results of our baseline survey, conducted only one year before. In Turkey, Çok et al. 
(2007) observed that PCDD/F concentrations ranged from 3.2 to 19.7 pg WHO-TEQ/g 
fat (mean: 9.2 pg WHO-TEQ/g fat) in 23 adipose tissue samples collected from men in 
2004. In turn, Shen et al. (2009) reported that the mean PCDD/F level in 24 adipose 
tissue samples collected in 2006 in the Zhejiang Province (China) was 19 pg TEQ/g fat 
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(range: 2.5-56 pg TEQ/g fat). In general terms, these levels are quite similar to those 
found in the present survey. Furthermore, our results indicate that the incineration of 
hazardous wastes did not result in any detectable exposure of PCDD/Fs to the 
population surrounding the facility, as indicated by the TEQ levels in adipose tissue. The 
PCDD/F congener profile showed that OCDD was the predominant congener, followed 
by 1,2,3,6,7,8-HxCDD and 1,2,3,4,6,7,8-HpCDD (Table 2). On the other hand, all 
samples showed considerably higher levels of dioxins (PCDDs) than furans (PCDFs), 
which is in agreement with the results of our previous studies (Schuhmacher et al., 
1999b, 2004). Table 3 summarizes the PCDD/F concentrations in adipose tissue of each 
one of the sampling campaigns, classified according to gender. Similarly to previous 
surveys, in the current (2013) study women showed notable higher levels of PCDD/Fs 
than men (16.4 vs. 8.3 pg WHO-TEQ/g fat). However, the difference was not significant 
in any of the four studies.  
 
Table 3. Concentrations of PCDD/Fs (in pg WHO-TEQ/g fat) in adipose tissue of 
individuals who had lived in Tarragona County (Catalonia, Spain), according to gender.  
 
1998 2002 2007 2013 
Men 25.3 ± 9.4 7.2 ± 3.5 11.2 ± 8.1 8.3 ± 5.3 
Women 45.7 ± 16.7 17.4 ± 16.1 23.8 ± 23.9 16.4 ± 15.9 
Data given as mean ± standard deviation; n: number of samples 
 
An increase of PCDD/F levels in adipose tissue with age was observed (R2= 
0.4389) not only in the current (2013) survey but also in previous (1998, 2002 and 2007) 
studies. The concentrations of PCDD/Fs in 60 samples of adipose tissue collected 
between 1998 and 2012, according to the age at the time of death, are depicted in Fig. 
1. Additionally, in order to analyze the potential differences of the PCDD/F concentration 
in adipose tissue in the younger and older populations, samples were classified into two 
groups: people aged <55 years and ≥55 years. A separation point of 55 years old was 
selected because the average age of the individuals under study was 52.4 years old and 
the median was 53 years old. In 2013, PCDD/F concentrations of 5.85 and 17.40 pg 
WHO-TEQ/g fat were observed in the group of under and over 55 years, respectively, 
reaching this difference the level of statistical significance (p<0.05). Taking into account 
the global number of samples from the 4 campaigns (n=60), mean PCDD/F levels in 
adipose tissue of people who had died being <55 years and ≥55 years were 11.47 and 
25.52 pg WHO-TEQ/g fat, respectively (p<0.01). In Korea, Moon et al. (2011) found a 
mean concentration of PCDD/Fs of 3.4 pg TEQ/g fat in human adipose tissue from 
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women (aged between 40 and 68). No correlations were observed between the age of 
the subject and the burdens of dioxin-like contaminants. Similarly, no significant 
correlations between age and PCDD/F levels in human adipose tissue were found in 
China (Shen et al., 2008). In contrast, some European investigators have detected a 
positive association between PCDD/F levels in adipose tissue and age, in 420 individuals 
living in southern Finland (Kiviranta et al., 2005), and in 20 women living in southern 
Spain (López-Espinosa et al., 2008). Although notable differences in the PCDD/F body 
burdens have been noted in different geographical areas, mainly linked to fish 
consumption (Nadal et al., 2004b), the reasons of this should be studied in more detail. 
Age is likely an indicator of past cumulative exposures. People born in earlier times 
experienced higher environmental PCDD/F levels and thus they carry a higher body 
burden through life. There is evidence from human and animal studies that blood dioxin 
half-lives, in the absence of weight change or fat redistribution, increase with age. 
However, this effect is relatively minor compared to the birth cohort effect of historical 
exposures (Lorber and Phillips, 2002).  
 
 
Fig. 1. PCDD/F concentrations in samples of adipose tissue from individuals of 
Tarragona County in 1998, 2002, 2007 and 2013. 
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The accumulation of PCDD/Fs according to gender has also been assessed in a 
number of investigations. However, most of them have focused on blood and plasma.  
Fromme et al. (2009) did not find any significant difference in the blood concentration of 
PCDD/Fs between men and women. However, they observed a significant increase in 
the WHO-TEQ levels with age. In the city of Mataró (Catalonia, Spain), Parera et al. 
(2013) recently found that PCDD/F levels in blood were higher in women than in men, 
showing both gender groups a slight reduction in comparison to precedent campaigns. 
Reis et al. (2007) also noted slightly higher PCDD/F levels in blood of Portuguese 
women, although differences in dioxin blood levels between males and females were not 
statistically significant. These authors also found that age was also associated with total 
TEQs in blood, with a significant correlation in a way that elder individuals owned higher 
PCDD/F values.  
In recent years, the evaluation of several NHANES data sets have shown that a 
number of POPs are related to either body mass index (BMI) or waist circumference (Lee 
et al., 2007; Elobeid et al., 2010). BMI is physiologically related to the body’s capacity to 
eliminate PCDD/Fs (Schildkraut et al., 1999). The elimination capacity of PCDD/Fs is 
indirectly proportional to the content of body fat, as individuals with less fat may eliminate 
2,3,7,8-TCDD more easily (Emond et al., 2005; Collins et al., 2007). Since BMI tends to 
increase with age, it is difficult to study the effects of BMI independently of age. Collins 
et al. (2007) reported that age and BMI are both important factors for assessing 
background levels of 2,3,7,8-TCDD. Several studies indicate that body fat turnover is 
regulated at least, in part, by fat patterning, and that upper body fat turns over at a higher 
rate than peripheral fat located below the hips (Rodin, 1992). Therefore, measures other 
than BMI may provide further insight into the relationship between the amount and 
distribution of body fat and the capacity to store and eliminate PCDD/Fs. Although the 
amount of body fat has been also correlated with PCDD/F levels, it is rarely adjusted 
when comparing potentially exposed populations to a surveyed background (Landi et al., 
1998). Pharmacokinetic properties of POPs can explain the observed relationships. 
POPs are stored in lipid reservoirs, while their concentrations change predictably with 
changes in adipose tissue volume. Levels in blood are proportional to blood lipid content, 
and weight gain increases the POP half-life (Thomaseth and Salvan, 1998). Lim et al. 
(2011) observed that weight gain over 10 years resulted in lower levels of polychlorinated 
biphenyls (PCBs) compared with weight stable or weight-loss conditions. However, the 
pharmacokinetics is complex, and relationships between POPs and a number of factors, 
such as BMI or weight change, are difficult to evaluate. Temporal changes depend on 
the magnitude and time of exposure, ongoing exposure, body fat mass, and changes in 
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fat mass during the time between exposure and the time of blood sampling, among 
others.  
The pharmacokinetic characteristics of each PCDD/F congener determine the 
transport of chemicals, which pass from blood to the fat tissue. These characteristics 
include, for example, lipophilicity of the substance, molecular diameter, molecular weight, 
molar volume, and octanol-water partition coefficient (Kow). Some constitutional 
descriptors such as the number and position of attached halogens and the number of 
hydrogen-bond acceptors, have also some contribution. The position of the halogen 
substitutes will determine the rigidity of the molecular structure and, consequently, its 
ability to pass from blood to other tissues (Mannetje et al., 2012). Recent studies suggest 
that different PCDD/F congeners have different partition coefficients that are dependent 
on the properties listed above (Needham et al., 2011). In addition, this ratio can be 
modified by the half-life of each PCDD/F congener. The ratio between the concentration 
of each PCDD/F congener in fat tissue and human plasma, expressed on a lipid basis, 
for the non-occupationally exposed subjects of Tarragona County (Spain) is shown in 
Table 4. All PCDD congeners showed fat:blood ratios >1, being 2,3,7,8-TCDD and 
OCDD those presenting the highest and lowest relationships (3.7 and 1.5, respectively). 
In turn, PCDFs showed a completely different pattern of the fat:blood ratio, with values 
under the unity for most congeners. The higher ratio was noted for 2,3,4,6,7,8-HxCDF 
(3.3), while 2,3,4,7,8-PeCDF, 1,2,3,4,7,8-HxCDF, and 1,2,3,6,7,8-HxCDF showed 
values >1. The reasons behind these patterns need further investigations. These results 
have certain limitations because the samples of plasma and adipose tissue are not from 
the same individuals. Although studies did not differ in the timing of the sampling of both 
plasma and adipose tissue, being the mean age of subjects quite similar (52 and 50 
years for donors of fat tissue and blood, respectively), different dietary habits could have 
altered these ratios. 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF PCDD/FS AND PFASS IN HUMANS. 
Francesc Fabrega Bonadona 
Dipòsit Legal: T 1660-2014
Chapter 3. A PBPK model to estimate PCDD/F levels in adipose tissue 
 
76 
Table 4. Fat: blood ratio of PCDD/Fs in subjects living in Tarragona County (pg/g lipid).  
Congener PCDD/Fs in fat tissue (pg/g lipid)a 
PCDD/Fs in plasma 
(pg/g lipid) 
Fat:blood 
(unitless) 
2,3,7,8-TCDD  1.2 0.3 3.7 
1,2,3,7,8-PeCDD  4.1 2.1 1.9 
1,2,3,4,7,8-HxCDD  2.3 1.1 2.1 
1,2,3,6,7,8-HxCDD  25.3 10.2 2.5 
1,2,3,7,8,9-HxCDD  2.6 1.4 1.8 
1,2,3,4,6,7,8-HpCDD  20.3 9 2.3 
OCDD  113.3 75.8 1.5 
2,3,7,8-TCDF  0.3 4.4 0.07 
1,2,3,7,8-PeCDF  0.3 2.5 0.12 
2,3,4,7,8-PeCDF  7.4 4.4 1.7 
1,2,3,4,7,8-HxCDF  2.8 2.4 1.2 
1,2,3,6,7,8-HxCDF  2.7 1.9 1.4 
1,2,3,7,8,9-HxCDF  0.1 0.6 0.17 
2,3,4,6,7,8-HxCDF  0.7 0.2 3.3 
1,2,3,4,6,7,8-HpCDF  2.3 5.4 0.43 
1,2,3,4,7,8,9-HpCDF  0.1 0.5 0.2 
OCDF  0.3 6.5 0.05 
a From Nadal et al. (2013) 
 
3.2. Physiologically-based pharmacokinetic (PBPK) model 
Physiologically-based pharmacokinetic (PBPK) models are mathematical 
representations of the human body where the tissues are considered well-stirred 
compartments linked by the blood flow (Nestorov, 2007). The final result is a set of 
ordinary differential equations that can be mathematically solved to predict the 
concentration of chemicals in human tissues. In recent years, PBPK models have been 
used in human health risk assessment to estimate the burdens of chemicals in human 
tissues, thus avoiding the analysis of this kind of samples (Chiu et al., 2007; Clewell and 
Clewell III, 2008). In the present study, a previous PBPK model (Maruyama et al., 2003; 
Fàbrega et al., 2014) was adapted to assess the concentration of PCDD/Fs in adipose 
tissue in four temporal scenarios: 1998, 2002, 2007 and 2013. The simulations were run 
for adult individuals living in the same area of study. Oral intake was assumed to be the 
only exposure pathway. Data about dietary intake of PCDD/Fs were obtained from 
previous studies conducted in the same area (Domingo et al., 1999; Bocio and Domingo, 
2005; Martí-Cid et al., 2008; Domingo et al., 2012). Data of intakes and absorption rates 
were summarized in Table S1 (Annex 3). The characteristics and parameters of the 
model were previously described (Nadal et al., 2013). Briefly, 7 body compartments were 
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considered: blood, muscle, skin, richly perfused, adipose, kidney, and liver. The intake 
of PCDD/Fs, as well as other PBPK model parameters (e.g., volume, absorption, 
elimination and cardiac output of each tissue), were considered constant along time. The 
physical basis of the adipose tissue diffusion is related to the octanol:water partition 
coefficient (Kow). At steady state, the log Kow predicts the capacity of the chemical to 
diffuse into adipose tissue, being therefore accumulated in fat. 
PCDD/F concentrations in the flow limited compartments (muscle, skin, richly 
perfused, fat, kidney and liver) were estimated by applying the following equation: 
Vi
pKi
CiCaQi
dt
dCi 






−×
=
:
    (1) 
where Ci is the concentration of PCDD/Fs in the tissue i (pg/L), Qi is the blood 
flow in the tissue i (L/h), Ca is the arterial concentration (pg/L), Ki:p is the partition 
coefficient of tissue i, and Vi is the volume of the tissue i (L). 
The PCDD/F content in the blood compartment was assessed by using the 
following equation: 
Vblood
AbsDQiCblood
pKi
CiQi
dt
dCblood i i
×+





×−




 ×
=
∑ ∑
:
  (2) 
where Cblood is the concentration of PCDD/Fs in blood (pg/L), Qi is the blood 
flow in the tissue i (L/h), Ci is the concentration in the tissue i (pg/L), Ki:p is the partition 
coefficient of tissue i, D is the oral dose (pg/day), Abs is the gastrointestinal absorption 
(%), and Vblood is the volume of the tissue i (L).  
Since liver was considered as an elimination organ, the predicted concentration 
of PCDD/Fs in this tissue was estimated by the following equation: 
Vliver
KVliverCliver
pKl
CliverCaQliver
dt
dCliver 1:
××−





−×
=
  (3) 
where Cliver is the concentration of PCDD/Fs in blood (pg/L), Qliver is the blood 
flow in the liver, Ca is the arterial concentration, Kl:p is the partition coefficient in the liver, 
K1 is the elimination constant, partition coefficient (Kp) and Vliver is the volume in liver 
(L). Values of tissue volumes, cardiac output, absorption and elimination constants were 
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the same used in our previous models (Nadal et al., 2013), and were summarized in 
Table S2 and Table S3 (Annex 3). 
A density of 0.92 g/mL in adipose tissue was used to recalculate the final 
concentration in pg/g tissue (Brown et al., 1997). The final system was a set ordinary 
differential equations which was handled by using Berkeley Madonna v.8.3.18. Stiff was 
considered as the method to solve the differential equations, while the step size (SD) in 
the simulations was set at 0.0001. 
The measured and simulated concentrations of PCDD/Fs in fat tissue for the 
1998 (baseline), 2002, 2007 and 2013 (current) surveys are summarized in Table 5. 
When comparing the modelled and experimental concentrations of PCDD/Fs in fat 
tissue, expressed as total WHO-TEQ, it can be observed that similar values were 
obtained in the four scenarios. However, experimental results are slightly higher than 
those simulated for all the surveys. Analyzing PCDD/F congeners individually, the 
simulated concentrations of all PCDDs, excepting 1,2,3,7,8,9-HxCDD, tended to suffer 
an underestimation with respect to those observed levels. In turn, the simulated levels of 
PCDFs, excepting 2,3,4,7,8-PeCDF, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDF, were 
slightly higher than those experimentally obtained. OCDF showed the most important 
difference between simulated and measured concentrations of PCDD/Fs, being 2-3  
 
 
Fig. 2. Comparison between measured and simulated concentrations of 
PCDD/Fs in samples of adipose tissue collected in 1998, 2002, 2007 and 2013. 
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Table 5. Comparison between simulated (Sim) and measured (Exp) concentrations of 
PCDD/Fs found in adipose tissue of adults living near the HWI of Tarragona County 
(Spain).  
  1998  2002  2007  2013 
   Sim Exp  Sim Exp  Sim Exp  Sim Exp 
2,3,7,8-TCDD  3.40 4.13  0.81 1.39  0.48 1.68  0.88 1.24 
1,2,3,7,8-PeCDD  3.91 11.37  2.25 3.73  1.68 5.28  1.62 4.11 
1,2,3,4,7,8-HxCDD  0.89 5.61  0.74 2.78  0.35 3.30  0.22 2.26 
1,2,3,6,7,8-HxCDD  10.22 59.40  3.29 19.20  2.03 28.10  0.87 25.35 
1,2,3,7,8,9-HxCDD  9.07 8.12  4.37 2.08  2.19 3.55  5.32 2.63 
1,2,3,4,6,7,8-  64.24 84.90  8.04 10.20  3.10 20.00  3.80 20.29 
OCDD  114.52 477.50  7.85 53.60  2.67 151.90  3.53 113.27 
2,3,7,8-TCDF  8.21 0.94  2.10 0.34  1.08 0.40  1.86 0.35 
1,2,3,7,8-PeCDF  9.23 0.92  2.18 0.50  0.88 1.40  0.91 0.31 
2,3,4,7,8-PeCDF  11.52 21.10  4.76 5.71  1.81 9.94  2.62 7.43 
1,2,3,4,7,8-HxCDF  9.70 7.02  2.37 2.32  0.92 3.29  1.50 2.83 
1,2,3,6,7,8-HxCDF  4.53 8.22  1.34 2.03  0.60 3.31  0.62 2.69 
1,2,3,7,8,9-HxCDF  1.54 0.62  1.43 0.39  0.49 0.06  1.35 0.07 
2,3,4,6,7,8-HxCDF  3.93 2.20  3.14 0.38  0.53 0.88  1.14 0.69 
1,2,3,4,6,7,8-  45.72 4.81  5.98 2.06  4.99 2.99  9.63 2.34 
1,2,3,4,7,8,9-  9.11 0.39  1.67 0.31  1.32 0.10  3.12 0.11 
OCDF  376.86 0.72  9.59 2.59  40.67 0.49  21.78 0.31 
WHO-TEQ  17.19 32.1  6.59 9.94  3.66 14.6  4.77 11.5 
Concentrations are given in pg/g tissue. 
 
orders of magnitude higher than the modelled results (21.78 vs. 0.31 pg/g fat). Notable 
dissimilarities between estimated and observed concentrations of OCDF in adipose 
tissue were also reported in previous campaigns (1998, 2002, and 2007). The transfer 
of POPs from the vascular environment to other biological tissues is highly influence by 
pharmacokinetic factors, such as tissue volume, anatomical localization, and blood flow 
rate. The default approach assumes that the tissue is flow limited. It means that the 
distribution of chemicals contained in blood across the well-stirred tissue compartment 
is fast and homogenous. Although this assumption is valid for the distribution of many 
xenobiotic chemicals into many tissues, because of their diffusion-limited characteristics, 
it appears to be incorrect for the movement of several highly lipophilic POPs across the 
adipose tissue (Levitt, 2010; La Merrill et al., 2013). In this case, the distribution of the 
chemicals is slower and may be incomplete. A comparison between measured and 
simulated concentrations of PCDD/Fs in samples of human adipose tissue collected in 
1998, 2002, 2007 and 2013, is depicted in Fig. 2. Because food intake was assumed to 
be the only single exposure pathway, a significant reduction of fat concentrations of 
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PCDD/Fs was noted. This is in agreement with the significant decrease found in the 
dietary intake of PCDD/Fs (Domingo et al., 2012). An important uncertainty, represented 
by the high standard deviations, was observed in the experimental concentrations of 
PCDD/Fs. As abovementioned, age and BMI of individuals can affect PCDD/F 
accumulation in fat tissue. In addition, diverse dietary patterns may be also the reason 
of the differences found between individuals. Anyhow, simulated concentrations of 
PCDD/Fs in fat were within the range of experimental values, irrespectively of the 
sampling year. According to Berezhkovskiy (2011), the classical pharmacokinetic 
analysis of highly lipophilic POPs at low concentrations often leads to a substantial 
underestimation of the distribution volume during steady state (Vss) in obese people. 
Therefore, an accurate determination of Vss is required to assess the distribution and 
kinetics of environmental chemicals. In any case, further research to improve the 
understanding of the adipose tissue:blood partitioning mechanisms, and the differences 
according to the PCDD/F congener, is needed. Moreover, the histological and 
anatomical structure of different types of adipose tissue can influence their contribution 
to toxicokinetics (Sbarbati et al., 2010). Furthermore, age and BMI may be also important 
in epidemiology studies, where back-extrapolation from current PCDD/F levels is used. 
In order to improve the model, different partition ratios for each PCDD/F congener should 
be taken into account. Another issue for improvement is the inclusion of dynamic 
parameters of exposure, such as time varying lifetime exposure. 
 
4. Conclusions 
The PCDD/F concentrations in adipose tissue of 15 individuals who had been 
living for at least the last 10 years near a HWI located in Tarragona County (Spain), were 
here determined. A mean PCDD/F level of 11.5 pg WHO-TEQ/g fat was found, being 
significantly lower than the concentration observed in 1998 (32.1 pg WHO-TEQ/g fat), 
when the facility was still inactive (Schuhmacher et al., 1999b). Current values of 
PCDD/Fs in adipose tissue in Tarragona County are of the same order of magnitude 
than those recently observed in a number of industrialized countries. The important 
decrease, which was also noted in other biological monitors such as plasma and breast 
milk (Nadal et al., 2013; Schuhmacher et al., 2013), agrees well with the notable 
reduction in the dietary intake of PCDD/Fs recently found for the population living in the 
same area. Our findings confirm that, after 14 years of regular operations, air emissions 
of PCDD/Fs from the HWI do not mean a significant additional exposure to these organic 
pollutants for the population living near the facility. 
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On the other hand, our adapted PBPK model has demonstrated to be a reliable 
tool to predict the levels of PCDD/Fs in fat tissue, as it was also in plasma (Nadal et al., 
2013). Although the application of the model should be of great interest to estimate the 
long-term accumulation of PCDD/Fs, not only in fat, but also in other biological tissues, 
an improvement of the PBPK model is required to obtain more accurate results. 
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Discussion of Chapters II and III 
 
The PBPK model was firstly developed for PCDD/Fs, which show a relatively 
simple PK/PD behavior in the human body. PCDD/Fs are highly absorbed, while it was 
assumed they are not metabolized and the elimination mechanism is only through feces. 
PCDD/Fs were mainly chosen as a representative of classic POPs. The simulated results 
of PCDD/Fs in plasma and adipose tissue were very coincident with the experimental 
values, not only in terms of I-TEQ, but also in the profile of the 17 PCDD/F congeners. 
Measured mean level in plasma was 6.18 pg I-TEQ/g lipid, while modelled concentration 
was 7.9 pg I-TEQ/ g lipid. According to WHO (2010), a PBPK model may be considered 
as adequate if, on average, simulation results are inside the range within a factor of two 
of experimental data. Furthermore, for the first time adipose tissue has been validated 
demonstrating the reliability of PBPK to simulate fat. Due to their high octanol water 
partition coefficient (log Kow>4), adipose tissue is the main site of accumulation of 
PCDD/Fs. Hence, it is highly important to monitor this compartment. In adipose tissue, 
the simulated vs experimental levels of PCDD/Fs were also of the same order of 
magnitude (4.77 vs 11.15 pg I-TEQ/g lipid). Therefore, PBPK models have proven to be 
validated to estimate long-term concentrations of PCDD/Fs in human tissues.  
The PBPK model was also applied to evaluate temporal trends of PCDD/Fs in 
the human body. The simulation was carried out in four temporal scenarios: 1998, 2002, 
2007 and 2013. As a consequence of the reduction of PCDD/F emission sources, the 
levels of PCDD/Fs in human tissues have been decreasing over the last years in 
Tarragona County. In plasma, the concentration of PCDD/Fs were 27.0, 15.7, 9.36 and 
6.18 pg I-TEQ/g lipid in 1998, 2002, 2007 and 2013. In adipose tissue, the concentrations 
were 32.1, 9.9, 14.6 and 11.5 pg WHO-TEQ/g fat, respectively, in the same campaigns.  
According to our results, the use of PBPK models may notably reduce the cost 
of surveillance studies by minimizing the number of biological samples, something critical 
in the context of the current economic crisis. Moreover, the PBPK models are capable to 
make predictions of future scenarios of concentrations of PCDD/Fs in human tissues. 
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 CHAPTER 4 
PBPK MODELING FOR PFOS AND PFOA: VALIDATION WITH 
HUMAN EXPERIMENTAL DATA 
Abstract 
In recent years, because of the potential human toxicity, concern on 
perfluoroalkyl substances (PFASs) has increased notably with special attention to 
perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS). Unfortunately, 
there is currently an important knowledge gap on the burdens of these chemicals in most 
human tissues, as the reported studies have been mainly focused on plasma. In order 
to overcome these limitations, the use of physiologically-based pharmacokinetic (PBPK) 
models has been extended. The present study was aimed at testing an existing PBPK 
model for their predictability of PFOS and PFOA in a new case-study, and also to adapt 
it to estimate the PFAS content in human tissue compartments. Model validation was 
conducted by means of PFOA and PFOS concentrations in food and human drinking 
water from Tarragona County (Catalonia, Spain), and being the predicted results 
compared with those experimentally found in human tissues (blood, liver, kidney, liver 
and brain) of subjects from the same area of study. The use of human-derived partition 
coefficient (Pk) data was proven as more suitable for application to this PBPK model 
than rat-based Pk values. However, the uncertainty and variability of the data are still too 
high to get conclusive results. Consequently, further efforts should be carried out to 
reduce parametric uncertainty of PBPK models. More specifically, a deeper knowledge 
on the distribution of PFOA and PFOS within the human body should be obtained by 
enlarging the number of biological monitoring studies on PFASs.  
 
1. Introduction 
Perfluoroalkyl substances (PFASs) are a group of man-made substances, whose 
chemical structure is a carbon backbone, where the hydrogen has been substituted by 
fluorine. The carbon fluorine bound is among the strongest covalent bounds, conferring 
a high molecular stability. PFASs have widely used in consumer and industrial 
applications, including protective coatings for fabrics and carpets, paper coatings, 
insecticides, paints, cosmetics, and fire-fighting foams (Domingo, 2012). However, the 
properties making these chemicals useful, turns into environmental problems. Thus, 
PFASs show a high persistence and spreading capacity in the environment (Fujii et al., 
2007). Perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) are among 
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the most widely spread PFASs, having been detected in a number of environmental 
matrices, including water, sediments, soils and biota (Post et al., 2009; Rumsby et al., 
2009; Shi et al., 2012; Zareitalabad et al., 2013). Detectable concentrations of PFOA and 
PFOS have been found in food (Domingo et al., 2012a), while measurements in whole 
blood, plasma or serum samples from humans are also available from the scientific 
literature (Ehresman et al., 2007). Because of their low degradation, high 
bioaccumulation, potential toxicity and long-range transport capacity, both PFOS and 
PFOA are considered as persistent organic pollutants (POPs) (Chaemfa et al., 2010). In 
fact, PFOS was included as a POP under the Stockholm Convention in 2009, while 
PFOA remains a serious candidate to enter that list shortly. Very recently, PFOS was 
also identified as a priority hazardous substance according to the European Directive 
2013/39/EU, in the field of water policy (European Commission, 2013). Consequently, 
regulatory agencies are paying considerable attention to the presence of PFOA and 
PFOS in the environment, as well as to the human health risks associated to their 
exposure. 
Pharmacokinetic and pharmacodynamic characteristics of PFOA and PFOS 
have been studied in animals (Lau et al., 2007; Vanden Heuvel et al., 1991). These 
compounds are highly absorbed, not metabolized and poorly eliminated, being plasma, 
liver, kidney and lungs the main distribution tissues (Cui et al., 2009; Hundley et al., 
2006). Both compounds have a high affinity to albumin, being therefore accumulated in 
plasma. Specific PFOA half-lives in a number of animal species are known. Elimination 
half-lives of PFOA, ranging 2–6 h, 17–19 days, and 30–21 days, have been estimated 
for rats, mice, and monkeys, respectively (Lau et al., 2007; Lau, 2012). Contrastingly, 
PFOA half-life in the human body is markedly higher, with an estimated value of 3.8 
years. Regarding PFOS, half-lives have been established in 1-2 months, 4 months, and 
4.8 years in rodents, monkeys, and humans, respectively (Chang et al., 2012). Although 
the reasons of these differences are not conclusive, it has been hypothesized that it can 
be due to a saturable process of resorption of PFASs from urine to plasma (Andersen et 
al., 2006). In addition to bioaccumulation, toxicity of PFOS and PFOA has been also 
characterized in animals (Lau et al., 2004; Stahl et al., 2011). A number of developmental 
effects, such as reduction of fetal weight, edema, cardiac abnormalities, and delayed 
ossification, as well as behavioral effects, have been reported following acute exposure 
to PFOS (Fuentes et al., 2006, 2007a,b). Subchronic and subacute toxicities induce 
hepatotoxicity, reduction of body weight, reduction of the levels of triglycerides and 
cholesterol in serum, liver hypertrophy and thyroid hormones reduction, while the 
neuroendocrine system seems also to be affected in rats exposed to PFOS (Austin et 
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al., 2003). Recently, PFOA exposure has been suggested to be associated with kidney 
and testicular cancer in human populations (Barry et al., 2013).  
The time dependent concentration of a certain pollutant in human tissues can be 
predicted using physiologically-based pharmacokinetic (PBPK) models. These models 
consider the human body as a set of well stirred compartments linked by the blood flow. 
Physiological processes are represented by a set of ordinary differential equations 
describing the processes of administration, distribution, metabolism and elimination of a 
specific chemical (Loizou et al., 2008; Péry et al., 2013). The final result is a model that 
simulates the time course distribution of a substance in the human body (Nadal et al., 
2013), which helps to quantify the relationship between measures of external exposure 
and internal dose. Detailed species-specific physiological, chemical, and biochemical 
parameters have been obtained. It allows not only extrapolating data to humans, but also 
assessing the possible sources of variability and uncertainty in model parameterization 
(Huizer et al., 2012). Due to their potential power, PBPK models have been largely used 
in pharmacological development and health risk assessment (Chiu et al., 2007; Clewell 
and Clewell III, 2008).  
The objectives of the present study were the following: (1) to test an existing 
PBPK model for their predictability of PFOS and PFOA in a new case-study, and (2) to 
adapt the PBPK model to estimate the burdens in various human tissue compartments. 
The performance of this PBPK model, when using different partition coefficients (Pk), 
either from rats or humans, was studied in detail. In PBPK models, Pk is the main 
regulator parameter of the distribution of chemicals in the human body. Model validation 
was conducted using data on PFOS and PFOA levels in food and drinking water from 
Tarragona County (Tarragona, Spain). The model was calibrated and validated by using 
experimental data from autopsy tissues of subjects residing in the Tarragona County 
area. 
 
2. Materials and Methods 
A new PBPK model for PFOA and PFOS was developed based on a previously 
reported model (Loccisano et al., 2011, 2013). The key process adopted in the model is 
the kinetics of resorption by renal transporters in the filtrate compartment, where 
chemicals are reabsorbed back to plasma through a saturable process (Andersen et al., 
2006; Tan et al., 2008). This resorption mechanism could be responsible for the high 
persistence of PFOA and PFOS in human blood, compared to the low persistence found 
in other animal species (e.g., rat, monkey). In addition to plasma, gut, liver, fat, kidney, 
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filtrate, and the remaining body compartments, the adapted PBPK model included lungs 
and brain. However, since it is not a potential site of absorption/accumulation for PFASs, 
skin was removed. The final compartmental structure of the adapted PBPK model is 
depicted in Fig. 1. The human tissues were selected due to their toxicokinetic relevance: 
plasma as a carrier tissue of PFASs in the human body, gut as an absorption site, kidney 
for its role in elimination (Barry et al., 2013), brain as target organ of PFASs neurotoxic 
effects (Mariussen, 2012), liver as an accumulative tissue for organic chemicals, lungs 
because they may exhibit immaturity after PFOS exposure (Grasty et al., 2005), and fat 
as a main site of accumulation in lipophilic tissues. The rest of the body was considered 
as an independent compartment to include PFASs remaining in other tissues of the 
human body. In plasma, more than 90% of PFOA and PFOS is bound to albumin, while 
<10% is free to move to other tissues (Han et al., 2003). 
 
 
Fig. 1. Structure of the PBPK model for PFOA and PFOS. 
 
The PBPK model was based on a series of differential equations. The expression 
to estimate the levels of PFOA and PFOS in non-elimination tissues (fat, brain, lungs, 
and rest of the body) was the following: 
( )
Vi
pKiCiCafreeQi
dt
dCi :−××
=
    (1) 
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where Ci is the cellular concentration in each tissue (pg/mL), Qi is the blood flow 
(mL/h), free means the free amount of PFASs in plasma (unitless), Ca is the arterial 
concentration (pg/mL), Ki:p is the partition coefficient (unitless), and Vi is the tissue 
volume (mL). 
The cellular concentrations of PFOA and PFOS in gut were obtained by applying 
this equation:  
Vg
IntakepKg
CgCafreeQg
dt
dCg 



 +




−××
=
:
   (2) 
where Cg is the cellular concentration in gut (pg/mL), Qg is the blood flow to gut 
(mL/h), free means the free amount of PFASs in plasma (unitless), Ca is the arterial 
concentration (pg/mL), Kg:p is the gut partition coefficient (unitless), Intake is theoral 
daily intake (pg/h), and Vg is the gut volume (mL). 
With respect to the liver compartment, estimated values of PFASs were 
estimated by means of the following expression: 
Vl
pKl
ClQgQlpKg
CgQgCaQlfree
dt
dCl 








×+−×+××
=
:
)(
:
  (3) 
where Cl is the cellular concentration in liver (pg/mL), free means the free amount 
of PFASs in plasma (unitless), Ql is the blood flow to liver (mL/h), Ca is the arterial 
concentration (pg/mL), Qg is the blood flow to gut (mL/h), Cg is the cellular concentration 
in gut (pg/mL), Kg:p is the gut partition coefficient (unitless), Kl:p is the liver partition 
coefficient (unitless), and Vl is the liver volume (mL). 
For the kidney compartment the following equation was used:  
Vk
CfilKt
CfilTm
pkK
CkCafreeQk
dt
dCk 







+
×
+





−××
=
:
   (4) 
where Ck is the cellular concentration in kidney (pg/mL), Qk is the blood flow to 
kidney (mL/h), free is the free amount of PFASs in plasma (unitless), Ca is the arterial 
concentration (pg/mL), Kk:p is the gut partition coefficient (unitless), Tm is the resorption 
maximum (pg/h), Cfil is the cellular concentration in filtrate (pg/mL), Kt is the affinity 
constant (ng/mL), and Vk is the kidney volume (mL). 
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Finally, PFAS concentrations in the filtrate compartment were simulated by 
applying this equation:  
( )
Vfil
CfilKt
CfilTmCfilCafreeQfil
dt
dCfil 




+
×
−−××
=
   (5) 
where Cfil is the cellular concentration in filtrate (pg/mL), Qfil is the blood flow to 
filtrate (mL/h), free is the free amount of PFASs in plasma (unitless), Ca is the arterial 
concentration (pg/mL), Tm is the resorption maximum (pg/h), Kt is the affinity constant 
(ng/mL), and Vfil is the filtrate volume (mL). 
Flow limited PBPK equations were used in all tissues (Thompson et al., 2012). 
Physiological data of volumes and cardiac output, which were time-constant, were 
obtained from Brown et al. (1997) (Table 1). Plasma concentrations of PFOA and PFOS 
were adjusted by calibrating the elimination values to fit experimental values from a case-
study (Ericson et al., 2007). Thus, our PBPK model was applied to estimate the burdens 
of PFOS and PFOA for a population living in Tarragona County (Catalonia, NE of Spain), 
from which data on human intake and body burdens were available (Domingo et al., 
2012a,b; Ericson et al., 2007; Pérez et al., 2013). Human exposure to PFOA and PFOS 
was evaluated through two different pathways: water consumption and food intake. 
Water ingestion was calculated as the product of the concentration in human drinking 
water (2.40 and 1.81 ng/L for PFOA and PFOS, respectively) in Catalonia (Domingo et 
al., 2012b) and the most typical value of water daily intake (1.23 L/day), according to the 
US EPA (2011). Similarly, dietary exposure was estimated based on the mean PFAS 
concentration in 40 food items, which are representative of the Catalan diet, and the 
respective daily consumption by the general population (Domingo et al., 2012a). In 
agreement with previous findings (Ericson Jogsten et al., 2012; Fromme et al., 2009; Kim 
et al., 2013), food intake was found to be the most important contributive route to the 
exposure of PFOS and PFOA, with percentages of 97% and 98% of the total intake, 
respectively. Dietary exposure of PFOA and PFOS was estimated in 1.55 and 1.80 ng/kg 
body weight/day, respectively. Overall, the total daily intake of PFOA through water and 
food consumption was estimated to be 0.11 g/day for PFOA, while that of PFOS was 
found to be 0.13 g/day. 
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Table 1. Physiological parameters used in the PBPK model for PFOS and PFOA, and 
pharmacokinetic data. 
  
Volume Cardiac output 
Plasma 2.78 -  
Fat 1.43 19.03 
Brain 1.50 36.50 
Lungs 1.00 10.61 
Rest of the 61.59 64.27 
Gut  1.14 56.47 
Liver  1.64 58.97 
Kidney 0.29 55.22 
Filtrate 0.03 10.92 
Total  71.4 312 
  
 PFOA  PFOS  
Tmc 147.4 86.0 
Kt 0.116 0.0176 
Free 0.03 0.03 
Data taken from Brown et al. (1997) and Loccisano et al. (2011); Tmc: resorption 
maximum (µg/h); Kt: affinity constant (µg/L); Free: free fraction in plasma (unitless); Conversion 
from weight to volume was assumed to be 1. 
 
For validation purposes, data on PFOA and PFOS in human tissues from people 
living in the area of study (Tarragona County) were used. Ericson et al. (2007) reported 
the levels of 13 PFASs, including PFOA and PFOS, in blood samples of 48 residents in 
that same area. The mean PFOS concentration in blood was 7.64 ng/mL, while PFOA 
mean level was 1.80 ng/mL. Recently, Pérez et al. (2013) analyzed the concentrations 
of 21 PFASs in 99 samples of autopsy tissues (brain, liver, lung, bone, and kidney) from 
subjects who had been living in Tarragona County (Catalonia, Spain). At the time of 
death, the mean age of subjects was 57 years, with minimum and maximum values of 
28 and 86 years, respectively. A summary of the levels of PFOA and PFOS is shown in 
Fig. 2. Although PFASs have been largely monitored in human blood/plasma (Ehresman 
et al., 2007; Stahl et al., 2011), studies in other human tissues are certainly very limited, 
except some data on breast milk and liver (Kärrman et al., 2010; Lau et al., 2007; Yeung 
et al., 2013). To the best of our knowledge, to date only two studies have reported 
burdens of PFOS and PFOA in other human tissues. In Italy, Maestri et al. (2006) 
analyzed the concentrations of these compounds in samples of human liver, kidney, 
adipose tissue, brain, basal ganglia, hypophysis, thyroid, gonads, pancreas, lung, 
skeletal muscle, and blood. 
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Fig. 2. Concentrations of PFOA and PFOS in autopsy tissues of 20 residents 
from Tarragona County (Catalonia, Spain). Data from Pérez et al., (2013).  
 
In addition to the model validation, a particular study on the best Pk was 
conducted. Hence, the model was tested by using, as input data, Pk from studies 
conducted with either rats (Loccisano et al., 2011) or humans (Maestri et al., 2006). Data 
sets were compared to detect any improvement in the performance of both original and 
adapted PBPK models. In a flow limited equation, Pk is the main parameter governing 
the distribution of a chemical in the human body. However, this variable is usually 
obtained in animal experimentation studies without taking into account allometric scaling 
factors (Knaak et al., 1995), and assuming a steady state condition between tissue 
concentration and blood level. The final results by applying both data sets were 
compared with those previously observed in human tissues from people living in 
Tarragona County (Ericson et al., 2007; Pérez et al., 2013). The PBPK model was coded 
and simulated by using Berkeley Madona TM v8.3.18 (University of California at Berkeley, 
USA). 
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3. Results and Discussion 
3.1. Original PBPK model 
In the first stage, the PBPK model developed by Loccisano et al. (2011) was used 
to predict PFOA and PFOS concentrations in human tissues for the current case-study. 
Parameterization data were taken from Loccisano et al. (2011), excepting those values 
regarding oral intake of food and drinking water, which were obtained from Domingo et 
al. (2012a). Simulation results were compared with experimental values regarding PFOA 
and PFOS in autopsy tissues from residents in the area of Tarragona (Table 2). Based 
on the model, the presence of PFOA and PFOS in plasma was mostly overestimated. 
The steady-state concentration of PFOA was estimated in 28.7 ng/g, while that of PFOS 
was 21.3 ng/g. Experimental values of PFOS and PFOA in plasma were reported to be 
3.2 ± 1.2 and 13.6 ± 6.3 ng/g, respectively. Similarly, some disagreements were found 
for other human tissues when comparing modeled and monitored levels of both 
chemicals. In liver, the simulated PFOA concentration was 4.5-fold higher than the 
monitored mean value (13.6 ± 35.2 ng/g), while the predicted steady-state level of PFOS 
in liver was lower than empirical concentrations (79.6 vs. 102 ± 123 ng/g). Similar 
relationships were also detected in kidney, where simulated concentrations of PFOA and 
PFOS were 36.1 and 20.5 ng/g, respectively. By contrast, experimental mean levels of 
PFOA and PFOS in kidney were 2.0 ± 2.7 and 75.6 ± 61.2 pg/g. Consequently, the ratio 
of estimated: observed kidney PFOA concentration was 18, while that of PFOS was 0.27. 
According to the model outcomes, PFOA and PFOS concentrations in adipose tissue 
were 1.2 and 3.0 ng/g, respectively. Unfortunately, since no experimental values are 
available for this specific compartment, a comparison could not be carried out in adipose 
tissue. In general terms, the model simulation somehow overestimated the concentration 
for PFOA and PFOS, with the exception of PFOS in liver and kidney. Simulations results 
of PFOA in plasma, liver and kidney were >4-fold higher than the mean experimental 
values. However, predicted and empirical concentrations were of the same order of 
magnitude. Considering that analytical results were highly uncertain and variable, the 
results of the PBPK model should be considered as reasonably good. 
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Table 2. PFOS and PFOA concentration (in ng/g) found in human tissues. 
Experimental vs. simulated data after applying the original PBPK model. 
  
Tissue Experimental Simulated 
 
 Mean±SD Min-Max LOD  
PFOA Plasma 3.2±1.2 1.4-5.6 0.66 28.7 
 Liver 13.6±35.2 <3-98.9 3.0 63.1 
 Fat n.a. n.a. n.a. 1.15 
 Kidney 2.0±2.7 <3-11 3.0 36.1 
PFOS Plasma 13.6±6.3 1.4-28.9 0.09 21.3 
 Liver 102±123 <3-405 3.0 79.6 
 Fat n.a. n.a. n.a. 3.01 
  Kidney 75.6±61.2 <6-269 6.0 20.5 
LOD: limit of detection; SD: standard deviation; n.a.: not available. 
 
3.2. Adapted PBPK model 
Because of the toxicological significance of PFOS and PFOA (Huet al., 2012; 
Sato et al., 2009; Yahia et al., 2010), brain and lung were also included in the current 
model (Fig. 1). New Pk values coming from human autopsy tissues (Maestri et al., 2006) 
were also applied and compared with Pk data from rats (Loccisano et al., 2011) (Table 
3). As above mentioned, a constant oral intake of both PFOA and PFOS was considered. 
Descriptor parameters of the urinary elimination were calibrated by means of plasma 
concentrations (Ericson et al., 2007). Again, simulation results including the steady-state 
curve were compared with those recently reported in the same population group living in 
Tarragona County (Pérez et al.,2013). To understand the quality of experimental data, a 
statistical analysis was performed. Outliers (one for PFOA in liver and kidney, two for 
PFOS in brain, and one for PFOS in kidney) were eliminated from data treatment 
to avoid any potential distortion of the results. Predicted vs. observed 
concentrations of PFOA and PFOS, calculated by considering Pk values from 
human tissues are depicted in Fig. 3a and b, respectively. In the cases in which 
PFOA or PFOS levels were not detected in a sample, the concentration was 
assumed to be equal to the respective limit of detection (LOD). PFOA was not 
detected in brain, while it was only quantified in a single sample of kidney. 
Simulation results were clearly closer to empirical values when using Pk values 
from human autopsy tissues, rather than when applying Pk data coming from 
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experimental animal studies (Table 4). In general terms, simulated results were 
found inside the uncertainty range of experimental values, with the exception of 
PFOS in lung. This fact support the hypothesis that PFOS and PFOA are 
resorbed from urine back to plasma in a saturable process, as it was 
parameterized in the model. Although Pk is a key parameter in PBPK modelling, 
Pk values are usually obtained from studies in rodents. Our results highlight the 
importance to obtain Pk data from humans in order to estimate more accurately 
the body burdens of PFASs in particular, and chemical contaminants in general. 
For example, simulated liver concentrations for PFOA in steady-state were 7.03 
and 3.33 ng/g for rat- and human-derived Pk values, respectively, while the 
measured PFOA concentration was 13.6 ± 35.2 ng/g. Liver PFOS levels were 
estimated to be 50.7 and 36.4 ng/g, taking into account the rat- or human- derived 
Pk datum, respectively (observed value: 102 ± 122.9 ng/g). In brain, mean PFOS 
content ranged between 0.16 and 3.48 ng/g, depending on the use of Pk values 
from animal and human studies, respectively. According to the experimental 
investigation, brain contained PFOS in a concentration of 4.9 ± 6.6 ng/g. Simulation 
concentrations in lungs, using both Pk values from rats and humans, were notably lower 
than those experimentally obtained for PFOA (0.47and 4.06 ng/g vs. 29.2 ± 32.2 ng/g) 
and PFOS (2.04 and 2.11 ng/g vs. 29.1 ± 16.8 ng/g). Important disagreements were also 
observed when comparing PFAS concentrations in kidney from the modeling and 
monitoring studies. Overall, the results from our adjusted model seemed to 
underestimate the real concentrations of PFOA and PFOS in the steady-state, 
contrasting with the original PBPK model (Loccisano et al., 2011). Notwithstanding, the 
good performance of the latter model was validated by comparing only measurements 
of PFOA and PFOS in human serum. 
 
Table 3. Partition coefficients (Pk) used in the PBPK model.  
  PFOA PFOS 
 
Human-based Rat-based Human-based Rat-based 
Liver 1.03 2.20 2.67 3.72 
Fat 0.47 0.04 0.33 0.14 
Brain 0.17 0.01 0.26 0.01 
Lung 1.27 0.15 0.15 0.15 
Kidney 1.17 1.05 1.26 0.80 
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Fig. 3. Time course concentration of (a) PFOA and (b) PFOS in four human 
tissues from subjects who had been living in Tarragona County (Catalonia, Spain). 
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In the current study, validation was conducted by considering other tissue compartments, 
which increases the complexity in the model calibration. Although the use of data coming 
from studies with rodents or other animals (i.e., monkeys), is a common practice in PBPK 
modeling, the improvement in our model predictions confirms the World Health 
Organization (WHO) general guideline stating that the application of human data is 
always more desirable (WHO/IPCS,2010). 
 
Table 4. Steady-state concentration (in ng/g) of PFOA and PFOS. Experimental vs. 
simulated data after applying the adapted PBPK model, considering rat- and human-
derived Pk values. 
 Tissue Experimental Simulated 
Mean ± SD Min-Max Rat-based Human-based 
PFOA Liver 13.6 ± 35.2 <3-98.9 7.03 3.33 
Brain >1.5 <1.5 0.04 0.54 
Lung 29.2 ± 32.2 <6-87.9 0.47 4.06 
Kidney 2.0 ± 2.7 <3 -11.9 4.02 4.50 
PFOS Liver 102.3 ± 122.9 <3-405 50.7 36.4 
Brain 4.9 ± 6.6 <1.5-22.5 0.16 3.48 
Lung 29.1 ± 16.8 <3-61.8 2.04 2.11 
Kidney 75.6 ± 61.2 <6-269 13.1 20.5 
SD: standard deviation. 
 
The results obtained in the present work are in agreement with previous results 
where a resorption mechanism also presented a reasonably good matching in the 
plasma concentrations of PFOS and PFOA (Loccisano et al., 2011). Nonetheless, the 
high half-lives of both compounds cannot lay only on this fact, as protein binding maybe 
also a key process. In the present model, a high binding between PFAS and plasma 
proteins was taken into account, as suggested by Loccisano et al. (2011). However, the 
variation of the protein binding percentage can cause a variation in the plasma 
concentration. Therefore, further studies should demonstrate the weight of the protein 
binding and renal resorption in the long half-lives of some PFASs.  
The significance of the model prediction when using two different partition 
coefficients was tested by performing a two-sample t-test. In both cases (PFOA and 
PFOS), the tests failed in rejecting the null hypothesis at the alpha significance level. It 
means that both data sets came from independent random samples of normal 
distributions, with equal means and equal, although unknown, variances. Further high P-
values (0.92 and 0.95 for PFOA and PFOS, respectively) strongly validate the null 
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hypothesis. To test the significance of the results, the correlation coefficient (R), which 
measures the linearity of relationship between observed and predicted values, was 
calculated. Regarding PFOA, values of R = −0.12 and R = 0.44 were found for rat- and 
human- derived Kp data, respectively. On the other hand, regarding PFOS, R values 
were 0.88 and 0.95 considering rat- and human-Kp data, respectively. No significant 
difference was observed in the distribution mean of predicted values, clearly indicating 
that a better prediction may be achieved by using human partition coefficients. 
 
4. Conclusions 
In the current study, a previously developed PBPK model was modified by 
considering the main target tissues of toxicological relevance for PFOA and PFOS. In 
agreement with the original model (Loccisano et al., 2011), trends in the simulation 
results indicate that the urinary PFAS resorption-based PBPK model seems to be a 
reliable approach to explain the relatively longer half-life of PFOA and PFOS in human 
plasma. 
Although the model had been successfully validated by using experimental data 
in human blood, good validation results were not achieved for other human tissues. 
Anyhow, current knowledge on the levels of PFASs in human tissues, other than 
blood/plasma, is very limited. Uncertainty and variability of experimental data, together 
with that limited knowledge, means an additional difficulty to analyze those data. Despite 
only blood is commonly used for PBPK modeling validation, the comparability with other 
human compartments would ensure the reliability of the model with respect to target 
tissues (WHO/IPCS, 2010). The present results clearly indicate the need to acquire more 
information concerning body burdens of PFASs in general and those of PFOA and PFOS 
in particular. Biological monitoring of these POPs is necessary, as they provide 
fundamental support for the development of PBPK models as well as other in-silico tools. 
The parameterization of the partition coefficient was also validated by comparing values 
derived from animal and human experimental studies. The use of human-derived Pk data 
was more suitable for application to this PBPK model than rat-based values. The model 
simulation assessed in the present study showed a huge uncertainty. Although results 
from PBPK modeling are usually uncertain (Barton et al., 2007), the characterization of 
variability and uncertainty in PBPK models is not a common practice. The uncertainty in 
PBPK models can be predicted by using Monte Carlo simulations, but also applying 
Bayesian inferences, or even fuzzy simulations (Gueorguieva et al., 2004). In order to 
assess the impact of the parameterization uncertainty in the model, a sensitivity analysis 
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was not performed. The reduction of uncertainty can be done by using more precise 
measurements of the parameterization data (Huizer et al., 2012), while the variability 
cannot be reduced, but only described. Therefore, the separate characterization of 
variability and uncertainty should be considered to address more appropriately this issue 
(Kumar et al., 2009). Finally, further research must be carried out to improve the 
performance of the PBPK model by introducing temporal dynamics of exposure 
concentration and physiological parameters for the long-term exposure to PFASs. Being 
the most sensitive known target organ for PFOA toxicity in animals (Post et al., 2012), 
the inclusion of the mammary gland within the PBPK model should be also considered 
in future studies. On the other hand, as humans are really exposed to multiple chemicals, 
future studies should be focused on assessing the suitability of PBPK modelling for the 
evaluation of mixtures of PFASs, instead of individual compounds, assuming that 
different PFASs show a relatively comparable toxicological profile (Borg et al., 2013). 
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CHAPTER 5 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) 
MODELING OF PERFLUOROALKYL SUBSTANCES (PFASs) IN 
THE HUMAN BODY 
Abstract 
Nowadays, there are limited data on the levels of perfluoroalkyl substances 
(PFASs) other than perfluorooctane sulfonic acid (PFOS) and pefluorooctanoic acid 
(PFOA) in the human body. Moreover, most of this information has been extracted from 
the biological monitoring of plasma, while the occurrence of PFASs in other human 
tissues is not well studied. In silico research has emerged as an effective complement to 
biomonitoring, being physiologically-based pharmacokinetic (PBPK) modeling a reliable 
method. The objective of the present study was to develop a generic PBPK model to 
assess the concentration of PFASs in human tissues, based on an existing model 
previously validated for PFOS and PFOA. Experimental data on PFAS concentrations in 
human tissues from individuals in Tarragona County (NE of Spain) were used to estimate 
the values of some distribution and elimination parameters needed for the simulation. No 
significant correlations were found between these parameters and the PFAS chain 
length. The model was finally validated for 5 PFASs by using data of intake and plasma 
concentrations from residents in Andøya Island (Northern Norway). 
 
1. Introduction 
In recent years, perfluoroalkyl substances (PFASs), a group of organic 
compounds, have attracted an important social and scientific attention. PFASs are 
chemically characterized for the total or partial replacement of hydrogen atoms with 
fluorine, except those hydrogen atoms whose substitution affects the nature of any 
functional group. Common PFASs include perfluoroalkyl carboxylic acids (PFCAs), with 
a carboxylic acid (-COOH) in the extreme of the carbon chain, and perfluoroalkyl sulfonic 
acids (PFSAs), with a sulfonic acid (-SO3H) in that extreme of the molecule (Buck et al., 
2011). Because of their resistance to thermic and chemical degradation, PFASs have 
been widely used in a number of industrial applications. Since PFASs are highly 
persistent in environment, bioaccumulative in living organisms, potentially toxic, as well 
as subjected to long-range atmospheric transport capacity, these compounds have been 
labeled as persistent organic pollutants (POPs) (Wang et al., 2009). Furthermore, PFASs 
have been detected worldwide in a wide range of environmental and biological samples 
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(Yoo et al., 2009; Stahl et al., 2010; Domingo, 2012; Boiteux et al., 2012; Custer et al., 
2014; Vorkamp et al., 2014).  
Due to their high covalent carbon fluorine bond, PFASs are not metabolized, 
being poorly eliminated in the human body (Lau et al., 2004; Lau, 2012). PFASs are 
mainly distributed to well-perfussed tissues such as plasma, liver and kidney. Half-lives 
in human blood have been estimated in 5.4 years for perfluorooctane sulfonic acid 
(PFOS), between 2.3 and 3.8 years for pefluorooctanoic acid (PFOA), and 8.5 years for 
perfluorohexane sulfonic acid (PFHxS) (Lau, 2012). In contrast, shorter half-lives: 32, 30 
and 3 days, have been estimated for perfluorohexanoic acid (PFHxA), perfluorobutane 
sulfonic acid (PFBS) and perfluorobutanoic acid (PFBA), respectively (Olsen et al., 2009; 
Lau, 2012; Russell et al., 2013). Some PFASs show a notably capacity to bind to human 
proteins, such as those in plasma and liver. Hence, liver PFASs may interact with fatty 
acid binding proteins (FABPs), making easier its displacement (Zhang et al., 2013). In 
plasma, PFASs are strongly bound to serum albumin, with a bound fraction >90 % for 
rats and humans (Han et al., 2003). Different PFASs seem to elucidate similar 
toxicological properties regardless their molecular structure, being liver the target tissue 
(Yeung et al., 2013). Despite the lack of toxicological studies, most PFASs elucidate 
hepatoxicity and reproductive toxicity as well as toxic effects on body weight, 
development, cholesterol, thyroid hormone and immunotoxicity (Fuentes et al., 2006, 
2007; Lau et al., 2007; Stahl et al., 2011). 
The U.S. company 3M was the primary global manufacturer of PFASs. The POP 
properties of PFOS and PFOA, the two most largely studied PFASs, began to raise an 
important concern for the regulatory agencies in the 1990s. Consequently, 3M 
completely phased out the production of PFOS in 2002 (Wang et al., 2009; Taniyasu et 
al., 2013). In 2009, PFOS was included in the list of POPs under the Stockholm 
Convention, while PFOA is a serious candidate to enter the same list. After ceasing 
PFOS production, its concentration in human tissues and environmental matrices has 
been progressively reducing (Armitage et al., 2006; Furdui et al., 2008; Olsen et al., 
2008). In 2006, the U.S. EPA created the PFOA 2010/2015 Stewardship program aimed 
at reducing the 95% of the PFOA product releases and product content in 2010, as well 
as completely eliminate the production of PFOA in 2015 in western countries (U.S. EPA, 
2014). Due to these regulatory restrictions, the producers of PFASs started to search 
alternatives to PFOS and PFOA. The company 3M has been developing a new line of 
products based in PFBS chemistry (Renner, 2006). In turn, other companies were 
partnered in the Fluoro Council, aimed at developing a new line of products based on 
the perfluorohexanoic acid (PFHxA) chemistry (Buck et al., 2011). Due to the higher 
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environmental degradation, quicker elimination rates in humans and low toxicity of PFBS 
and PFHxA, PFOA has been progressively replaced in industrial applications (Olsen et 
al., 2009; Russell et al., 2013). However, although PFOS and PFOA have been 
extensively studied, there is an important lack of pharmacokinetic studies of PFASs other 
than PFOS and PFOA. Furthermore, investigations on PFAS mixtures are very scarce, 
limited to few approaches (Borg et al., 2013).  
Similarly to other substances, the use of experimental animals has been recurrent 
to identify the main toxic endpoints of PFASs and their distribution in the body (Inoue et 
al., 2012; Kowalczyk et al., 2012). Unfortunately, human data are particularly scarce 
because of the limitation to obtain tissue samples. Furthermore, alternatives to animal 
testing are being promoted at international level to avoid or minimize the use of live 
animals, being in silico tools one of the major promising alternatives (Benfenati et al., 
2010). Consequently, the development of physiologically-based pharmacokinetic 
(PBPK) models has progressively increased in recent years, being these not only applied 
to drugs, but also to environmental toxicants. PBPK models are mathematical 
representations of the human body, whose attempt is to describe the time course 
distribution of chemicals (Nestorov, 2007). PBPK models, which are often used in human 
health risk assessment (U.S. EPA 2006; WHO/IPCS 2010), may be used to elucidate 
the pharmacokinetics and pharmacodynamics (PK/PD) of chemicals in the human body 
(Medinsky, 1995; Wang et al., 2013). Recently, various PBPK models have been 
developed to estimate the distribution of PFOS and PFOA within the human body 
(Andersen et al., 2006; Tan et al., 2008; Loccisano et al., 2011, 2013; Fàbrega et al., 
2014). It has been suggested that the most important mechanism of removal of PFOS 
and PFOA in the human body is urinary elimination, with a renal resorption mechanism 
in the filtrate compartment (Andersen et al., 2006; Tan et al., 2008). The free fraction of 
PFOS and PFOA is also an important parameter to determine the distribution of PFOS 
and PFOA. However, there still exist some gaps and notable uncertainties around the 
pharmacokinetics and pharmacodynamics of PFASs different from PFOS and PFOA.  
The objective of the present study was to develop a generic PBPK model to 
assess the concentration of 11 PFASs in human tissues. A previous model (Fàbrega et 
al., 2014), validated for PFOS and PFOA, was here adjusted to other PFASs. 
Experimental data on PFAS concentrations in human tissues from individuals in 
Tarragona County (NE of Spain) were used to estimate the values of some distribution 
and elimination parameters needed for the simulation. The correlations with the chain 
length of each respective PFAS were also studied. Afterwards, the model was validated 
by using data of intake and plasma concentration from Andøya Island (Northern Norway).  
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2. Materials and Methods 
2.1. PBPK model for PFASs 
Based on previously obtained data for PFOS and PFOA (Fàbrega et al., 2014), 
a PBPK model to estimate the concentrations of 9 additional PFASs in different human 
tissues was here developed. Overall, up to 11 PFASs with different chain length were 
considered for the PBPK modeling (Table 1). The tissues studied in the present model 
were selected according to their pharmacokinetic relevance in the distribution and 
elimination of PFASs. Plasma, gut, liver, fat, kidney, filtrate, bone marrow, brain, lungs 
were selected as compartments of interest, while the rest of the body was integrated into 
an additional single compartment. The conceptual structure of the PBPK model is 
depicted in Fig. 1. The intake of chemicals was considered to occur only by food and 
water consumption through the gut. Kidney was selected because it is the organ where 
elimination takes place (Han et al., 2012). Liver, bone marrow, kidney, lungs and brain 
were chosen because quantifiable concentrations of PFASs have been found in autopsy 
tissues (Pérez et al., 2013). Finally, plasma was used as a descriptor of the systemic 
circulation. The PBPK model was based on flow-limited equations (Thompson and 
Beard, 2011). 
 
Fig. 1. Structure of the PBPK model 
 
 
Table 1. Structure of the selected PFASs 
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Compound name Abbreviation CAS  Structure Molecular 
weight 
Perfluorobutane sulfonic 
acid  PFBS 375-73-5 
 
300.1 
Perfluorohexane sulfonic 
acid  PFHxS 355-46-4 
 
400.1 
Perfluorooctane sulfonic 
acid  PFOS 1763-23-1 
 
500.1 
Perfluorodecane sulfonic 
acid  PFDS 335-77-3 
 
600.2 
Perfluorohexanoic acid  PFHxA 307-24-4 
 
314.1 
Perfluoroheptanoic acid  PFHpA 375-85-9 
 
364.1 
Pefluorooctanoic acid PFOA 335-67-1 
 
414.1 
Perfluorononanoic acid PFNA 375-95-1 
 
464.1 
Perfluorodecanoic acid PFDA 335-76-2  
 
514.1 
Perfluoroundecanoic 
acid  PFUnDA 2058-94-8 
 
564.1 
Perfluorotetradecanoic 
acid  PFTeDA 376-06-7 
 
714.1 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF PCDD/FS AND PFASS IN HUMANS. 
Francesc Fabrega Bonadona 
Dipòsit Legal: T 1660-2014
Chapter 5. PBPK modeling of PFASs in the human body 
 
112 
The concentrations of PFASs in non-eliminating tissues (bone marrow, fat, brain, 
lungs, and rest of the body) were estimated through the following mathematical equation:   
Vi
pKiCiCafreeQi
dt
dCi ):/( −××
=
   (1) 
where Ci is the concentration in tissue i (pg/mL), Qi is the blood flow to the tissue 
i (mL/h), free is the unbound fraction in plasma, Ca is the arterial concentration (pg/mL), 
Ki:p is the partition coefficient, and Vi is the volume of tissue i. 
PFAS concentration in gut was calculated by means of the following expression: 
Vg
IntakepKgCgCafreeQg
dt
dCg +−××
=
):/(
  (2) 
where Cg is the concentration in gut (pg/mL), Qg is the blood flow to gut (mL/h), 
free is the unbound fraction in plasma, Ca is the arterial concentration (pg/mL), Kg:p is 
the partition coefficient, Intake is the hourly ingestion of PFASs (pg/h), and Vg is the 
volume in gut compartment. 
For the liver compartment, the concentrations of PFASs were estimated by 
means of this equation: 
Vl
pKlClQgQlpKgCgQgCaQlfree
dt
dCl )):/()(:/( ×+−×+××
=
(3) 
where Cl is the concentration in liver (pg/mL), free is the unbound fraction in 
plasma, Ql is the blood flow to liver (mL/h), Ca is the arterial concentration (pg/mL), Qg 
is the blood flow to gut (mL/h), Cg is the concentration in gut (pg/mL), Kg:p is the partition 
coefficient in gut, Kl:p is the partition coefficient in liver, and Vl is the volume in liver 
compartment. 
For the kidney compartment, the used equation was: 
Vk
CfilKt
CfilTmpKkCkCafreeQk
dt
dCk +
×
+−××
=
):/((
 (4) 
where Ck is the concentration in kidney (pg/mL), Qk is the blood flow to the kidney 
(mL/h), free is the unbound fraction in plasma, Ca is the arterial concentration (pg/mL), 
Kk:p is the partition coefficient in kidney, Tm is the resorption maximum (pg/h), Kt is the 
affinity constant (pg/mL), and Vk is the volume of kidney. 
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Finally, the levels of PFASs in the filtrate compartment were estimated by means 
of the following mathematical expression: 
Vfil
CfilKt
CfilTmCfilCafreeQfil
dt
dCfil +
×
−−××
=
)(
   (5) 
where Cfil is the concentration in filtrate compartment (pg/mL), Qfil is the blood 
flow to filtrate (mL/h), free is the unbound fraction in plasma, Ca is the arterial 
concentration (pg/mL), Tm is the resorption maximum (pg/h), Kt is the affinity constant 
(ng/mL), and Vfil is the volume of filtrate compartment. 
All the variables, including volumes, cardiac output, partition coefficient (Pk), 
intake and elimination parameters, were considered to be constant along time. Data on 
time volumes and cardiac output were taken from Brown et al., (1997). Due to their high 
absorption rates observed in rats, PFASs were assumed to be completely absorbed 
(D'Eon and Mabury, 2011; Hundley et al., 2006). In turn, since PFASs are poorly 
metabolized in animals, metabolism was considered negligible (Ophaug and Singer, 
1980; Hundley et al. 2006). Although other exposure pathways, such as air inhalation 
and dermal absorption, might have a relevant contribution to the total intake of PFASs 
(D'Eon and Mabury., 2011; Ericson et al., 2012; Nadal and Domingo, 2014), water intake 
and food consumption were considered as the only routes of PFAS entrance to the 
human body. For confirmation purposes, values of dust ingestion of PFASs from the 
population living in the same area of study (Ericson et al., 2012) were compared with the 
dietary and water intake of PFASs, being the former considerably lower. In addition, 
since PFASs were not detected in air samples, air inhalation was considered negligible 
(Ericson et al., 2012). Calculations were performed for the adult population of Tarragona 
County. Water intake was assumed to be 1.022 L/day, while the mean body weight was 
set at 70 kg. The daily intake of PFASs through food and water for the population of 
Tarragona County (Table 2), was obtained elsewhere (Ericson et al., 2009; Domingo et 
al., 2012). A constant intake was considered for the lifespan of the individuals under 
study. The mean lifetime of the individuals was set to 80 years.  
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Table 2. Dust ingestion, water and food intake of PFASs in Tarragona County (Catalonia, 
Spain) (ng/day). Total exposure was assessed by considering only water intake and food 
consumption 
 
Dusta Waterb Foodc Total intake 
PFBS 0.05 1.64 (25.0) 4.90 (75.0) 6.54 
PFHxS 0.05 0.49 (10.5) 4.20 (89.5) 4.69 
PFOS 0.18 2.23 (1.4) 160.30 162.53 
PFDS 0.00 n.d. 1.40 (100) 1.40 
PFHxA 0.07 1.06 (3.1) 33.60 (96.9) 34.66 
PFHpA 0.08 1.33 (0.5) 261.10 262.43 
PFOA 0.48 2.95 (0.8) 385 (99.2) 387.95 
PFNA 0.34 1.51 (1.5) 97.30 (98.5) 98.81 
PFDA 0.49 0.57 (3.3) 16.80 (96.7) 17.37 
PFUnDA 0.17 0.38 (0.4) 95.20 (99.6) 95.58 
PFTDA 0.04 n.d. 32.90 (100) 32.90 
n.d.: Non detected. aEricson et al., (2012); bEricson et al., (2009); cDomingo et al., (2012). 
Between parentheses, percentage of water and food intake, respect to total exposure.  
 
The distribution of PFASs in the human body was described by the Pk, which is 
defined as the concentration of a chemical in a specific tissue in relation to its 
concentration in blood. To calculate Pk, the concentration of each PFAS found in autopsy 
tissues from subjects of Tarragona County was divided by the mean blood level of the 
same compound found in samples of donors from the same area of study (Ericson et al., 
2007; Pérez et al., 2013). Pks were assessed for liver, bone marrow, brain, lung and 
kidney. For the remaining tissues (adipose, gut, filtrate and rest of the body), a constant 
value of the Pks, coming from data on PFOA in rats, was used (Kudo et al., 2007).  
The elimination parameters of the PBPK model (Tm and Kt) and the free fraction 
of PFASs in plasma were also assessed for the case-study of Tarragona County. Data 
on the body burdens of PFASs in plasma, as well as those in a number of tissues (liver, 
bone, kidney, lungs, and brain) were available from previous investigations (Ericson et 
al., 2007; Pérez et al., 2013). PFASs were considered to be bound to serum albumin in 
a fraction of 97%, while the remaining fraction (3%) was available for accumulation in 
other tissues and elimination through urine (Han et al., 2003; Chen and Guo, 2009; 
Bischel et al., 2010). In order to assess the elimination parameters (Tm, Kt) and free 
fraction, the model was coded and parameterized, being the simulated plasma 
concentration fitted with experimental values of PFASs (Ericson et al., 2007). Values of 
Tm, Kt and free fraction constants were here obtained. The model was coded by using 
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Berkeley MadonnaTM v 8.3.18, using a Stiff method to solve the differential equations 
(Macey et al., 2009). 
 
2.2. Validation of the PBPK model 
The validation step consisted on executing the PBPK model for another 
population. Adults living in Andøya Island (Norway), for which data on intake and plasma 
concentrations of PFHxS, PFOS, PFHpA, PFOA and PFNA were available (Rylander et 
al., 2009; Haug et al., 2010), were chosen as case-study. To obtain minimum and 
maximum values, the PBPK simulation was conducted for the whole range of elimination 
and distribution parameters. As previously demonstrated (Huizer et al., 2012) and 
confirmed by sensitivity analysis (unpublished results), Tm, Kt and free fraction were the 
variables with the highest uncertainty in the PBPK model. Minimum and maximum values 
for Tm and Kt were set as 0.3 times the coefficient of variation (CV) (Allen et al., 1996). 
In turn, 0.1% and 3% were considered as the minimum and maximum percentages of 
the free fraction, respectively (Huizer et al., 2012). The daily intake of food and water 
consumption by the adult Norwegian population, was set at 1.2, 18, 8.2, 31 and 9.5 
ng/day for PFHxS, PFOS, PFHpA, PFOA and PFNA, respectively (Haug et al., 2010). 
Levels of PFASs in plasma were taken from a biological monitoring study of 44 women 
and 16 men living in the coastal population of Northern Norway, which was performed in 
September 2005 (Rylander et al., 2009). Mean plasma concentrations of PFHxS, PFOS, 
PFOA and PFNA were 1.8, 33, 4.4 and 0.95 ng/mL, respectively. Although PFHpA was 
not detected, the limit of detection (0.26 ng/mL) was used to validate the model. Finally, 
model validation was based on the comparison of experimental data on PFASs in plasma 
and the range of values predicted by the PBPK model. Since the human body is a system 
subjected to a number of biological processes, PBPK models averaging within a factor 
of 2 in comparison to experimental data may be considered as validated (WHO/IPCS 
2010). 
 
3. Results and Discussion 
3.1. PBPK models for PFASs 
A PBPK model was developed to estimate the concentration of 11 PFASs in 
human tissues. To simulate the internal distribution of PFASs, values of some 
physicochemical (Pks) and biochemical (Tm, Kt, and free fraction) parameters were 
needed. Pks were estimated by using data on PFAS concentration in plasma and 
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autopsy tissues from individuals of Tarragona County, Spain (Ericson et al., 2007; Pérez 
et al., 2013). The partition coefficients of 11 PFASs are summarized in Table 3. Pk values 
ranged from 0.001 for PFDS, PFDA and PFTeA in liver, as well as PFTeA in bone 
marrow, to 201.6 for PFHxA in brain. The correlation between the carbon chain length 
and those physicochemical and biochemical parameters of each respective PFAS was 
also studied. No significant correlations were noted between the PFAS chain length and 
Pk (Fig. 2). However, available experimental information is relatively scarce, since PFAS 
concentrations from only 20 individuals had been obtained.  
 
Table 3. Pks (unitless) of 11 PFASs obtained by using data on autopsy tissues  
  
Liver Bone Marrow Brain Lung Kidney 
PFBS 1.38 4.91 0.74 27.31 12.27 
PFHxS 0.72 0.28 0.50 1.27 3.27 
PFOS 7.48 0.11 0.36 2.13 5.54 
PFDS 0.001 3.28 0.58 5.99 9.46 
PFHxA 128.80 39.87 201.60 56.11 6.27 
PFHpA 47.82 110.71 1.94 24.98 11.20 
PFOA 4.23 18.73 0.37 9.08 0.62 
PFNA 1.65 2.66 37.80 19.47 36.02 
PFDA 0.001 0.28 43.68 31.92 11.57 
PFUnDA 0.002 0.25 14.82 4.61 11.69 
PFTeDA 0.001 0.001 63.13 24.95 15.78 
 Data from Pérez et al., (2013). 
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Fig. 2. Correlation between PFAS chain length and a number of parameters: Tm, Kt, free fraction and Pk. 
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Based on the results of animal studies (Andersen et al., 2006; Tan et al., 2008), 
the elimination of PFOS and PFOA is mainly urinary, with a resorption mechanism in the 
filtrate compartment. Once in the urine, the chemicals are resorbed back to the plasma 
in a saturable mechanism, driven by resorption maximum (Tm) and affinity constant (Kt). 
Tm and Kt are analogous constants to the kinetics of the Michaelis-Menten reactions for 
the enzymatic reactions. This mechanism was expected to be the responsible of the high 
half-lives of PFOS and PFOA in human blood. However, it has not been proved yet to 
be involved in the elimination of shorter chain PFASs. In the present study, a resorption 
mechanism was assumed for all the compounds, including C4 and C6 shorter chain 
PFASs (Han et al., 2012). The elimination constants (Tm and Kt), and the value of free 
fraction of PFASs in plasma, were calibrated by running multiple simulations of the PBPK 
model until fitting the simulation results with experimentally obtained PFAS 
concentrations in plasma. The elimination constants resulting from the PBPK modelling 
are summarized in Table 4. The final results for Tm ranged from 6.1 to 2456.3 µg/h, Kt 
ranged from 0.018 to 30 µg/L, and free fraction ratios ranged from 0.001 to 0.03. 
Significant correlations between the carbon chain length and any of these constants were 
not found (p>0.05) (Fig. 2). The model was able to simulate the pharmacokinetic 
behavior of PFASs with a shorter chain than PFOS and PFOS, such as PFBA or PFBS, 
whose half-lives in blood are considerably lower. To the best of our knowledge, this is 
the first attempt to develop in humans a PBPK model for PFASs other than PFOS and 
PFOA. According to the present PBPK model, the urinary elimination, the resorption 
mechanism and the strong protein binding are the hallmark of the absorption, distribution, 
metabolism, and excretion (ADME) of PFASs in the human body. Although other 
mechanisms of elimination may play an important role (Harada et al., 2007), data are 
currently too scarce to accurately evaluate their influence. Moreover, this is a generic 
model that should be improved by including more refined individual PK data of each 
individual chemical compound. Anyhow, it is undoubtedly of great interest as information 
on the body burdens of PFASs, other than plasma, is not available. 
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Table 4. Elimination constants coming from PBPK model simulation 
  
Tm (μg/h) Kt (μg/L) Free 
PFBS 2456.3 30 0.001 
PFHxS 2456.3 3 0.005 
PFOS 86.0 0.018 0.030 
PFDS 2456.3 15 0.001 
PFHxA 6.1 5 0.001 
PFHpA 368.4 7 0.015 
PFOA 147.4 0.116 0.030 
PFNA 491.3 4.5 0.010 
PFDA 245.6 0.6 0.010 
PFUnDA 2456.3 9 0.030 
PFTeDA 24.6 0.070 0.020 
Tm: resorption maximum (µg/h/); Kt: affinity constant (µg/L); Free: free fraction in 
plasma (unitless) 
 
The estimated steady-state concentration of PFASs in target tissues is shown in 
Table 5. The simulations followed a trend with a nearly lineal part at the beginning, 
reaching a plateau after 20-30 years. The result of the simulations found in tissues 
depends on the Pk, as well as on the elimination constants and the daily intake. In liver, 
the highest concentrations corresponded to PFOS, PFHxA, PFHpA, PFOA and PFNA, 
with values ranging from 1.32 to 127.6 ng/g (PFNA and PFOS, respectively). In contrast, 
the minimum values of other long-chain PFASs (PFDS, PFDA, PFTeDA, and PFUnDA) 
were also found in liver (0.0002, 0.0005, 0.0005, and 0.0016 ng/g, respectively). This 
fact is surprising, as liver is usually considered the main target organ where PFASs are 
accumulated. Furthermore, there are no evidences of low concentrations of long chain 
PFASs in liver (Karrman et al., 2010). PFOA was the predominant compound in bone 
marrow and lung (205.30 and 99.70 ng/g, respectively). Unexpectedly, the highest 
concentration of PFHxA (39.19 ng/g) was estimated in brain. Since PFHxA is rapidly 
cleared from biota, with elimination half-lives of 0.5-1.5 months in humans (Russell et al., 
2013), high levels of this compound should not be found in the human body. Kidney 
showed a similar profile of PFASs to those in plasma and liver, being PFOS the main 
contributor (113.40 ng/g).  
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Table 5. Simulated concentration of PFASs in target tissues of individuals from 
Tarragona County, Spain. 
  
Plasma Liver  Bone Marrow Brain Lung Kidney 
PFBS 0.65   0.55 1.92 0.29 10.70 5.70 
PFHxS 6.36   0.38 0.15 0.26 0.67 2.07 
PFOS 17.06 127.6 1.88 6.14 36.40 113.40 
PFDS 0.52   0.0002 0.53 0.09 0.98 1.85 
PFHxA 0.89   27.0 7.76 39.19 10.92 1.27 
PFHpA 0.70   34.5 79.25 1.39 17.86 9.40 
PFOA 10.97 46.5 205.30 4.06 99.70 8.19 
PFNA 0.79   1.32 2.08 29.60 15.20 33.40 
PFDA 0.54   0.0005 0.14 21.30 15.55 6.75 
PFUnDA 0.61   0.0016 0.15 8.97 2.79 8.50 
PFTeDA 0.39   0.0005 0.01 25.20 9.95 7.50 
Units: ng/g 
 
For model parameterization, data on PFAS concentrations in blood and other 
human tissues from two independent studies, performed in Tarragona County in 2007 
and 2008, were used (Ericson et al., 2007; Pérez et al., 2013). The number of analyzed 
autopsy samples was limited to 20, therefore contributing to a higher uncertainty of the 
PBPK model results. There is a lack of reliable experimental data for their use in model 
parameterization. Thus, limited available data may contribute to higher uncertainty in the 
PBPK model due to temporal variability (different years of sampling) and physiological 
variability (age group differences) associated with the experimental data. Moreover, 
sources of variability, like changes of body weight and cardiac output along time, which 
were not taken into account, should be explored in further investigations. 
 
3.2. Validation of the PBPK model 
For validation purposes, the current PBPK model was applied in a case-study in 
Norway, where information about dietary intake and plasma concentration of a number 
of PFASs was available (Haug et al., 2010; Rylander et al., 2009). The concentrations of 
PFHxS, PFOS, PFHpA, PFOA, and PFNA were assessed in 21 samples of selected 
foods and beverages, including meat, fish, vegetables, fruits, eggs, milk, cereals, bread 
and drinking water (Haug et al. 2010). The samples were purchased between 2008 and 
2009 in Norway, and the daily consumption of foodstuffs for the adult population was 
assessed by using statistical data. The total intake of PFASs for the adult Norwegian 
population was estimated in 1.2, 18, 8.2, 31 and 9.5 ng/day for PFHxS, PFOS, PFHpA, 
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PFOA and PFNA, respectively. In turn, plasma concentrations of PFASs for the 
Norwegian population were also obtained from the scientific literature (Rylander et al., 
2009). Samples from 44 men and 16 women (aged 26-60) living in Andøya Island 
(Northern Norway) were collected, and the PFAS content was determined. Mean 
concentrations of PFHxS, PFOS, PFOA and PFNA in plasma were 1.1, 29, 3.9 and 0.81 
ng/mL plasma, respectively. In turn, PFHpA was not detected in any sample. The 
experimental concentrations were compared with the results of the PBPK simulation. 
The ranges of experimental concentrations were reported for all the compounds, with the 
exception of PFHpA, which was not detected (Rylander et al., 2009). Since the limit of 
detection (LOD) for PFHpA was provided (0.26 ng/g), this value was used to validate the 
model. The minimum and maximum values for the simulation were assessed by running 
the model with the minimum and maximum values of Tm, Kt, and free fraction. These 
have been identified as the most uncertain parameters of the PBPK model (Allen et al., 
1996; Huizer et al., 2012), being also identified as the most sensitive (unpublished 
results). The comparison of the simulated and experimental concentrations of 5 different 
PFASs in plasma from people living in Norway is depicted in Fig. 3. Excepting for PFHpA, 
which was undetected in plasma, the experimental concentrations of PFASs were slightly 
higher than the modeled results, therefore underestimating the internal dose of PFASs. 
This fact could be linked to a potential interaction among PFASs, as well as between 
these and other chemicals present in blood. In the past, PBPK modeling has been 
increasingly used to assess the pharmacokinetics of chemical mixtures (El-Masri et al., 
2004; Dennison et al., 2004). These approaches are based on the comparison of the 
levels of simulated mixture responses with those anticipated from the individual response 
addition. The main objective is to determine the interaction threshold, which is defined 
as the combined total dose of chemicals at which interactions become significant in terms 
of joint toxicity of a mixture (Mumtaz et al., 2012). More specifically, complex interactive 
effects of PFOS and PFOA in zebrafish embryos have been observed, being additive, 
synergistic or antagonistic according to the mixture ratios of individual chemicals (Ding 
et al., 2013). Anyhow, since the range of experimental data fell within the range of 
simulation results, the PBPK model was confirmed to be validated and applicable to 
PFHxS, PFOS, PFHpA, PFOA and PFNA. However, further investigations are still 
needed in order to incorporate more refined PK/PD data in the model, as well as to 
reduce its uncertainty. 
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Fig. 3. Experimental and simulated concentrations of PFASs (ng/mL) in plasma 
from people living in Andøya Island (Norway). 
 
4. Conclusions 
A PBPK model was here developed and validated to simulate the body burdens 
of 9 PFASs, additionally to PFOS and PFOA. The model structure was characterized by 
owning a mechanism of urinary elimination, a mechanism of resorption of the chemicals 
from urine to plasma, and a strong protein binding for all the compounds. This generic 
PBPK model was able of simulating compounds with important pharmacokinetic 
differences, including half-lives in plasma (Lau et al., 2012). Our findings support that the 
regulation of both short- and long-chain PFASs is done by the abovementioned PK 
mechanism. Although further evidence is still necessary, this is a first and successful 
attempt to describe and simulate the PK of PFASs by using these mechanisms. 
Furthermore, the PBPK model was validated for 5 of the compounds by means of a case-
study in Norway. The relatively small differences between the experimental and the 
modeled results are a good indicator of the reliability of the model. However, some 
biochemical and mathematical aspects, such as the involvement of other elimination 
mechanisms and the uncertainty of parameterization data, deserve further research. 
Moreover, because of the scarcity of PK data for PFASs, other than PFOS and PFOA, 
differences among the compounds could not be studied in depth by PBPK modeling. 
Since the generation of quantitative time-course data sets is essential for the validation 
of PBPK models, an increase of well-conducted human biomonitoring investigations 
should be also enhanced to assure the validity of these models and their suitability for 
estimating PFAS body burdens. 
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Discussion of Chapters IV and V 
 
After the development of the PBPK model for PCDD/Fs, the model was adapted 
to a different group of POPs: PFASs. PFOS and PFOA, two of the most well known 
PFASs, were originally selected. The elimination mechanism was changed, and the role 
of the protein binding to plasma albumin was added. The mechanism of elimination was 
considered to occur by urine elimination with a saturable resorption mechanism from 
urine back to the plasma. In liver, the target tissue of PFOS and PFOA, the simulated 
concentration of PFOA was 3.33 ng/g, while the experimental value was 13.6±35.2 ng/g. 
For PFOS, the simulated and experimental concentrations were 36.4 ng/g and 
102.3±122.9 ng/g, respectively. Due to the coincidence of the simulated concentrations 
within the range of measured levels of PFOS and PFOA, the model was considered as 
validated. 
A comparison of Pks values obtained by using data from rats and humans, was 
conducted. As expected, the use of Pks coming from human data simulated better the 
concentration in human tissues. This clearly indicates the need to acquire more 
information regarding the body burdens of PFOS and PFOA to improve the accuracy of 
Pks. Although PBPK model validation is commonly carried out by using only blood data, 
this should be extended to other human tissues to ensure its reliability, with special 
emphasis on target tissues.  
Due to the regulatory restrictions for PFOS and PFOA, industrial producers are 
searching alternatives and developing new lines of products with lighter PFASs, such as 
PFBS or PFHxA. Thus, the PBPK model was extended to 9 PFASs more. For the first 
time, PFASs in human tissues other than PFOS and PFOA were simulated by using 
PBPK models. Although the mechanism of elimination of PFASs other than PFOS and 
PFOA is not well known, the PBPK model was capable to simulate PFASs through 
urinary elimination via resorption mechanism. This is not the proof of the resorption of all 
the PFASs but it is a successful first attempt to simulate PFASs using this mechanism. 
Notwithstanding, further evidence is still necessary. PBPK modeling demonstrates to be 
a reliable tool to elucidate the mechanism of elimination of different environmental 
pollutants, as well as other PK processes. Moreover, the parametric data of elimination 
(Tm and Kt), free fraction and Pk were also assessed using the PBPK model. Significant 
correlations between the carbon chain length of the PFASs and the elimination 
parameters were not found. However, this should be further explored, as these variables 
should be better calibrated using more experimental data. The number of analyzed 
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autopsy samples was limited to 20, therefore contributing to a higher uncertainty of the 
PBPK model results. Limited available data may contribute to a higher uncertainty in the 
PBPK model due to temporal variability (different years of sampling) and physiological 
variability (age group differences) associated with the experimental data. 
For validation purposes, the extended PBPK model was applied in a case-study 
in Andøya Island (Northern Norway), where information about dietary intake and plasma 
concentration was available for PFHxS, PFOS, PFHpA, PFOA and PFNA. The 
experimental concentrations were compared with the results of the PBPK simulation. 
The model was considered as validated because experimental concentrations were 
within the range of the PBPK simulation results. The relatively small differences between 
the experimental and the modeled results are a good indicator of the reliability of the 
model. 
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CHAPTER 6 
INFLUENCE OF THE UNCERTAINTY IN THE VALIDATION OF 
PBPK MODELS: A CASE-STUDY FOR PFOS AND PFOA.  
Abstract 
 Physiologically-based pharmacokinetic (PBPK) models are mathematical 
representations of the human body that aims to describe the time course distribution of 
chemicals in human tissues. PBPK models are developed using experimental data which 
may have an error associated with the measurements. The uncertainty associated with 
the parametric data used in PBPK modeling is huge, thus affecting the process and 
reliability of model validation. The objective of the present work was to assess the 
parametric uncertainty associated to a PBPK model developed for perfluorooctane 
sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA), and validated by using 
experimental data from people living in Tarragona County (NE of Spain). A sensitivity 
analysis was performed to understand the degree of influence of input parameters on 
the final outcomes. Data of partition coefficients (Pks), elimination constants (Tm and Kt) 
and unbound fraction in plasma (Free) were obtained from autopsy individuals in the 
area of Tarragona, while data on human intake of PFOS and PFOA were also compiled 
from previous studies in the same area. The uncertainty of the PBPK models were 
assessed by propagating the parametric uncertainty using Latin Hypercube Sampling 
(LHS) technique, and the uncertainty bound with mean concentrations of PFOS and 
PFOA in different tissue compartments, was estimated. Finally, the simulation results 
were compared with the experimental data and Student’s t-test was executed to assess 
the validity of the model. Significant differences were found when comparing the visual 
and statistical validation of the PBPK model. 
 
1. Introduction 
Physiologically-based pharmacokinetic (PBPK) models aim to simulate the time 
course concentration of chemical compounds in the human body (Nestorov, 2007). In 
PBPK modeling, tissues are considered compartments linked by the blood flow, and the 
time course concentration of chemicals are described by mathematical equations that 
can be solved computationally (Thompson and Beard, 2011, 2012). The complexity of 
the PBPK models depends on the administration, distribution, metabolism and 
elimination (ADME) properties of the chemicals in the human body. Although, the first 
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PBPK model was developed in 1937, it was impossible to compute the equations for the 
model resolution (Teorell, 1937). Later, in the 1970s, the development of computational 
tools allowed the resolution and the development of the PBPK modeling (Bischoff et al., 
1970; Jones and Rowland-Yeo, 2013). Nevertheless, the scarcity of pharmacokinetic 
and pharmacodynamic (PK/PD) data and the implementation of the in vivo and in silico 
tools to estimate PK/PD data, have delayed the extensive use of PBPK models until the 
last decade (Mumtaz et al., 2012; Rowland et al., 2011). Nowadays, PBPK modeling is 
extensively used in drug development and human health risk assessment (Chiu et al., 
2007; Rowland et al., 2011).  
PBPK modeling involves the use of input parameters that were generated by 
experimental assays. Consequently these variables own some variability and error 
associated with the measurements. The variability is the inter-individual differences in 
the anatomical and physiological characteristics among individuals, and cannot be 
eliminated but only reduced (Kumar et al., 2009). On the other hand, the uncertainty is 
due to the lack of knowledge in the parameter estimation, being this reducible (Bois et 
al., 2010a). To estimate the model variability and uncertainty several approaches have 
been used in PPBK modeling such as Monte-Carlo simulation, Fuzzy simulations and 
Bayesian Markov chain Monte Carlo (MCMC) (Bois et al., 2010b; Gueorguieva et al., 
2005; Hack, 2006; Sweeney et al., 2001; Woodruff et al., 1992). In the past, some studies 
characterized the differences between uncertainty and variability in PBPK models (Chiu 
et al., 2009; Huizer et al., 2012; Kumar et al., 2009; Mörk et al., 2009). The variability 
and uncertainty of input parameters affect the time course concentration, being 
dependent on the sensitivity of the parameters. A sensitivity analysis (SA) provides a 
quantitative assessment of the degree of influence of the input parameters on model 
results and have been used in PBPK models in the past (Loizou and McNally, 2010; 
McNally et al., 2011). Uncertainty plays a key role in the validation of the PBPK models. 
Validation is the process of evaluation of the model with the reliability and relevance of 
a particular approach (Chiu et al., 2007; WHO., 2010). PBPK models can be validated in 
many ways, and until now no single method has been accepted by the regulatory 
agencies. In general, the simulations whose results are within a factor of 2 of the 
experimental results may be considered as valid (WHO., 2010). The most common 
approach is the visual comparison of the experimental data with the simulated results 
(Chiu et al., 2007). This process of validation is highly affected by the structural and 
parametric error of the PBPK models. Instead, any model can be proven to be absolutely 
valid, the process of validation may be meaningless if the uncertainty of the PBPK model 
is excessively high. When high values of uncertainty are found in a PBPK model, any 
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experimental value may fall within the range of the model simulation, and thus the model 
can be easily considered valid. To improve the reliability of the PBPK models, a proper 
study of the model uncertainty is necessary for an accurate validation of the model 
(WHO., 2010). Until nowadays, the uncertainty in PBPK modeling has been poorly 
studied (WHO., 2010), and therefore case the process of model validation may be 
doubtful.  
The objective of the present work was to study the uncertainty associated to 
PBPK modeling parameterization, and the subsequent validation of the PBPK model. A 
previous PBPK model developed for perfluorooctanesulfonic acid (PFOS) and 
perfluorooctanoic acid (PFOA) in Tarragona County was used (Fàbrega et al., 2014). In 
a first step, a sensitivity analysis was performed, and the most sensitive parameters were 
selected for the uncertainty analysis. In the second step, the uncertainty of the PBPK 
models were assessed by propagating the parametric uncertainty using Latin Hypercube 
Sampling (LHS) technique and uncertainty bound along with mean concentrations of 
PFOS and PFOA in different tissue compartments. Finally, the uncertainty of PBPK 
model parameterization was compared with the experimental values from the area under 
study and a statistical analysis was performed to validate the result.  
 
2. Materials and Methods 
2.1. PBPK model for PFOS and PFOA 
In a previous study, a PBPK model was developed for two perfluoroalkyl 
substances (PFASs): PFOS and PFOA (Fàbrega et al., 2014). PFOS and PFOA are well 
absorbed via oral route, not metabolized in human body, and poorly eliminated. The 
mechanism of elimination for PFOS and PFOA has been proved to be mainly through 
urine elimination, with a resorption mechanism: once in the urine PFOS and PFOA are 
resorbed back from urine to plasma. (Andersen et al., 2006; Loccisano et al., 2011; Tan 
et al., 2008). Moreover, these compounds strongly bind to serum albumin, and only a 
small fraction is available to move to tissues and be eliminated (Bischel et al., 2010; 
Chen and Guo, 2009; Han et al., 2003). Model structure, parameterization data and 
equations were previously described in Fàbrega et al. (2014). In summary, the model 
structure includes plasma, gut, liver, kidney, filtrate, storage, fat, brain, lungs and rest of 
the body. Structure of the PBPK model is depicted in Figure 1. The model was carried 
out for a case study in Tarragona County (NE of Spain). The intake was considered to 
occur through ingestion of food and water (Domingo et al., 2012a; Domingo et al., 
2012b). The key parameter for the distribution is the partition coefficient (Pk), defined as 
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the concentration of a chemical in a tissue over its concentration in blood. Pks were 
assessed by using data of blood donors and autopsy tissues (Ericson et al., 2007; Pérez 
et al., 2013). Elimination was assumed to be through a resorption mechanism in kidney. 
The elimination constants are resorption maximum (Tm) and affinity constant (Kt), being 
previously assessed using data in human tissues (Fàbrega et al., 2014).Tm and Kt are 
analogous parameters to the maximum velocity (Vmax) and Michaelis-Menten constant 
(KM) in the Michaelis-Menten kinetics. Finally, PFOS and PFOA are strongly bound to 
plasma albumin. The remaining unbound fraction was called Free fraction, and is one of 
the key parameters in the distribution of PFOS and PFOA in PBPK modeling.  
 
 
Fig. 1. Structure of the PBPK model. 
 
2.2. Case-study  
The PBPK model for PFOS and PFOA was applied in a case study in Tarragona 
County (NE of Spain) (Fàbrega et al., 2014), where data of human intake (Domingo et 
al., 2012a; Domingo et al., 2012b) and human autopsy tissues were available (Ericson 
et al., 2007; Pérez et al., 2013). Data from the general population with no contact with 
industrial production or manufacture of PFASs (Ericsson et al., 2007; Pérez et al., 2013) 
were used. The ingestion of food was assessed by using data from Domingo et al. 
(2012b), data for all the population cohorts. For PFOS, the mean concentration in food 
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was 2.26 ng/kg body weight/day, and the minimum and maximum concentrations were 
1.57 and 4.48 ng/kg body weight/day, respectively. For PFOA, the mean concentration 
in food was 4.68 ng/ kg body weight/day, and the minimum and maximum concentrations 
were 0.83 and 19 ng/ kg body weight/day, respectively. The estimated concentrations in 
water were 1.8 ng/L and 2.4 ng/L for PFOS and PFOA, respectively (Domingo et al., 
2012a). Finally, considering a body weight of 70 kg and a water consumption of 1.23 L 
day (US EPA, 2011), the total intake of PFOS and PFOA in the adults of Tarragona 
County was estimated in 0.16 µg/day and 0.33 µg/day (Fàbrega et al., 2014). The 
minimum intake was assessed in the range 0.06-0.11 µg/day, and the maximum intake 
was considered to be within 0.32 and 1.33 µg/day, for PFOS and PFOA, respectively.  
The concentration of PFOS and PFOA in human tissues has been poorly 
analyzed in the past (Karrman et al., 2010; Maestri et al., 2006; Pérez et al., 2013). In 
Tarragona County, data of PFOS and PFOA were available for blood, liver, brain lung 
and kidney. These were used for validation purposes. PFOS and PFOA concentrations 
in blood were previously assessed for 48 blood donors, where the average age of the 
blood donors was 40 years old, with a range between 20 and 60 years old (Ericson et 
al., 2007). For PFOS, blood level was 7.64±3.54 ng/mL, while PFOA concentration was 
1.80±0.66 ng/mL. Similarly, the concentration of PFOS and PFOA were previously 
assessed in liver, brain, lung, bone marrow and kidney in 20 autopsies of individuals in 
Tarragona County (Pérez et al., 2013). The average concentration of PFOA was 
13.6±35.2, 29.2±32.2 and 2.00±2.70 ng/g wet weight for liver, lung and kidney, 
respectively. In brain, PFOA was under its respective detection limit (DL), being the mean 
concentration 1.50 ng/g wet weight (½ of the DL). For PFOS the concentrations found in 
human tissues were 102±123, 4.90±6.60, 29.1±16.9 and 75.6±61.2 ng/g wet weight for 
liver, brain, lung and kidney, respectively. At the time of death, the average age of the 
individuals was 57 years old, with a range of ages between 28 and 86 years old.  
 
2.3. Sensitive analysis (SA) 
A SA for the PBPK model parameterization was performed to study the 
parameters with the most important contribution to the final outcomes (Evans and 
Eklund, 2001). SA was performed using the method of sensitivity index (SI), which is 
based on the absolute value of the difference between the maximum and minimum value 
over the maximum value (Hamby, 1994): 
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To assess the SA in the PBPK model, the range of the parameters under study 
were used. PBPK parameters included body weight (BW), plasma volume, liver volume, 
brain volume, lung volume, kidney volume, cardiac output to liver, cardiac output to brain, 
cardiac output to lungs, cardiac output to kidney, Tm, Kt, Free fraction and Intake. 
Moreover, the partition coefficient (Pk) to gut, liver, kidney, fat, brain, lungs and rest of 
the body were also included. Physiological data and their ranges, came from Huizer et 
al. (2012) and Brown et al. (1997). The partition coefficients (Pk) of the different organs 
were previously assessed using experimental data found in human tissues (Fàbrega et 
al., 2014; Maestri et al., 2006). The mean and uncertainty range (minimum – maximum) 
for the parametric data are summarized in table 1. Data of Tm, Kt and Free fraction 
comes from our previous PBPK model (Fàbrega et al., 2014). For sensibility analysis of 
the different parameters a coefficient of variation (CV) of 0.3 was used (Allen et al., 1996; 
Brochot et al., 2007; Sweeney et al., 2001). The parametric uncertainty of intake was 
assessed for different population cohorts (Domingo et al., 2012b). Although, the intake 
has usually both uncertainty-variability components, we only assumed that a significant 
part of uncertainty comes from data treatment. 
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Table 1. Mean, range and sensitivity of the parameters used in the PBPK model, ranked according their sensitivity.  
PFOS  PFOA 
Parameter Mean Range Sensitivity  Parameter Mean Range Sensitivity 
Tmc  3.50 0.617-17.2 22.7  Free  0.03 9.46e-7-70.9 185696 
Q. kidney 0.17 0.118-0.265 3.82  Kt  0.116 1.12e-4-39.8 585 
Free  0.03 9.45e-7-70.9 1  Q. kidney 0.177 0.118-0.265 4.01 
Kt  0.018 3.30e-7-56.5 0.999  Intake 0.331 0.061-1.33 0.952 
Pk Rest body 0.2 0.0007-17.9 0.781  Tm  6.0 1.46-20.9 0.929 
Intake 0.161 0.112-0.316 0.624  Pk Rest body 0.12 0.0002-40.2 0.664 
Pk fat 0.033 0.004-15.0 0.438  BW  71.4 64.7-79.1 0.161 
BW  71.4 64.7-79.1 0.158  Pk fat 0.467 0.008-16.2 0.055 
Pk gut 0.57 0.013-17.7 0.073  Pk gut 0.05 9.97e-6-33.7 0.025 
Pk brain 0.255 0.002-16.8 0.017  Pk liver 1.03 0.077-14.1 0.002 
Pk lung 0.155 0.0003-24.8 0.017  Pk brain 0.17 0.0005-20.8 0.0008 
Pk liver 2.67 0.494-13.6 0.007  Pk kidney 1.17 0.096-11.5 0.0006 
Pk kidney 1.26 0.105-14.7 0.003  Volume plasma 0.04 0.026-0.059 0.0004 
Volume brain 0.021 0.014-0.032 0.001  Volume lung 0.014 0.009-0.021 0.0003 
Q. brain 0.117 0.078-0.176 0.0008  Volum liver 0.023 0.015-0.034 0.0003 
Volum liver 0.023 0.015-0.034 0.0007  Pk lung 1.27 0.105-13.72 0.0002 
Q. liver 0.189 0.126-0.283 0.0005  Q. liver 0.189 0.126-0.283 0.0002 
Q. lung 0.034 0.023-0.051 0.0002  Volum kidney 0.004 0.003-0.006 0.0002 
Volume plasma 0.04 0.026-0.059 0.0002  Q. brain 0.117 0.078-0.176 0.0002 
Volum kidney 0.004 0.003-0.006 0.0001  Q. lung 0.034 0.023-0.051 0.0002 
Volume lung 0.014 0.009-0.021 0.0001   Volume brain 0.021 0.014-0.032 0.0001 
BW: Body weight (kg); Tm: Resorption maximum (µg/h); Kt: Affinity constant (µg/L); Free: free fraction (unitless); Pk: partition coefficient (unitless); 
Intake (µg/day). Cardiac output to tissues and tissue volumes are given in the fraction of total cardiac output and total volume. 
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2.4. Uncertainty analysis  
The uncertainty of the PBPK model was assessed for those parameters with a 
higher contribution according to the SA. In a first step, the Latin Hypercube Sampling 
(LHS) method was used. LHS is a stratified sampling method to reduce the number of 
runs necessary for a Monte Carlo (MC) simulation and to achieve a distribution with a 
reasonable calculation (McKay et al., 1979). In LHS, the range of each variable is divided 
into N intervals, where N is the number of iterations of MC simulation. Then, a random 
value is obtained for each segment following a uniform distribution. After that, the 
variables are randomly grouped for each MC simulation. The outcomes were used to 
simulate the minimum and maximum concentration of PFOS and PFOA in the human 
tissues. The final results were the simulation of the concentration of PFOS and PFOA for 
plasma, liver, brain lung and kidney. The minimum and maximum simulation bands were 
used to validate the experimental results by comparing the experimental data with the 
simulation results obtained in the PBPK model (Chiu et al., 2007).  
 
2.5. Statistical analysis 
The t-test was applied to the results obtained for the PBPK model to assess the 
validity of the model simulation. T-test is used to determine if two populations means are 
equal (Snedecor and Cochran, 1989). The statistic test was assessed using:  
m
s
n
s
yx
t
yx
22
__
+
+
=
     (2) 
where x and y are the means, sx and sy are the standard deviation, and “n” and 
“m” are the size of the sample. When the variances of the data samples are different, the 
statistical test under the null hypothesis has Student’s distribution, and the sample 
standard deviation is replaced by the pooled standard deviation: 
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To test the significance, a level of significance calls alpha (α) need to be set. Alpha 
explains how the extreme observed results must be in order to reject the null hypothesis 
of the t-test. Alpha is associated to the confidence level of the t-test. Commonly, alpha 
has a value between 0.05 to 0.01, indicating a 95% and 99% of level of confidence, 
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respectively. On the other hand, p-value is the probability that the observed statistic 
occurred by chance alone. To test the significance α is compared with p-value to accept 
or reject the null hypothesis. 
 
3. Results and Discussion 
3.1 Sensitivity analysis (SA) 
SA was performed to identify how input uncertainty impacts the final outcomes. 
SA outcomes were ranked and summarized in Table 1. For PFOS, the highest values 
obtained in the SA were Tm, followed by cardiac output to kidney (Q. kidney), Free, Kt, 
Pk for the rest of the body and the oral intake. For PFOA, the main parameters according 
to the SA was for Free fraction, followed by Kt, Q. kidney, oral intake, Tm and Pk for the 
rest of the body. In general, cardiac output and volumes to tissues showed the smallest 
values of SA, with the only exception of Q. kidney. The reason of the high SA for Q. kidney 
may be that kidney is the elimination tissue, and elimination parameters, whose 
uncertainty is important, give a higher degree of influence to this parameter. SA in Q. 
kidney was not studied because it is a physiological parameter with natural variability, and 
the present study was limited to parametric uncertainty (Huizer et al., 2012). Similarly, the 
results of the SA for Pks were among the lower results with the exception of Pk for rest of 
the body that was considerably big. The most plausible explanation for the high value in 
the rest of the body is that this compartment is a lumped tissue that receives all the 
uncertainty of the other tissues together (Thompson and Beard, 2012). Using the result 
of SA, the study of the uncertainty was focused on the most sensitive parameters, namely 
Tm, Kt, Free and intake. For PFOA, more than the 99.9% of the contribution comes from 
these four parameters, whereas for PFOS, the contribution percentage for the selected 
parameters was 82.6%.  
 
3.2. Uncertainty assessment of parametric data  
The mean, minimum and maximum concentrations of PFOS and PFOA in plasma, 
liver, brain, lung and kidney were simulated, and compared with experimental data 
(Figures 2, 3, 4, 5 and 6). The parametric samples of the LHS were used to simulate the 
concentrations of PFOS and PFOA in human tissues. In many cases, the result was a set 
of simulations that were not converging. For those set of unconverged simulation, the 
values of Tm, Kt, Free and intake were adjusted by calibrating the value of the parameter 
to obtain the minimum and maximum results where the simulation trend converged. Table 
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2 summarizes the parametric data obtained for the Tm, Kt, Free and Intake for the PBPK 
model (Fàbrega et al., 2014). This process of calibration may underestimate the final 
value for the true range of uncertainty but allows to obtain simulations that converges with 
close aproximation to the true range of uncertainty. In the next paragraph, the behaviour 
of the parameters studied is discussed. 
 
Table 2. Values of Tm, Kt and Free fraction used in the PBPK model to assess the 
mean, minimum and maximum concentration of PFOS and PFOA.  
    
PFOS   PFOA 
  
Mean Minimum maximum  Mean Minimum  Maximum 
Tm  86 17.4 2456  147 35.9 245 
Kt  0.02 24.9 0.2  0.11 41.5 0.04 
Free  0.03 1.0 0.02  0.03 1.0 0.01 
Intake  0.17 0.11 0.32  0.33 0.06 1.33 
Tm: Resorption maximum (µg/h); Kt: Affinity constant (µg/L); Free: free fraction (unitless); 
Intake (µg/day).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UNIVERSITAT ROVIRA I VIRGILI 
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF PCDD/FS AND PFASS IN HUMANS. 
Francesc Fabrega Bonadona 
Dipòsit Legal: T 1660-2014
Chapter 6. Influence of the uncertinty in the validation of PBPK models: A case-study for PFOS and PFOA 
 
139 
 Fig. 2. Time course concentration of PFOS and PFOA in plasma. Simulated 
concentrations (mean, minimum and maximum) vs measured concentrations of PFOS 
and PFOA.  
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Fig. 3. Time course concentration of PFOS in liver, brain, lung and kidney. Simulated concentrations (mean, minimum and maximum) vs 
measured concentrations of PFOS. 
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Fig. 4. Time course concentration of PFOA in liver, brain, lung and kidney. Simulated concentrations (mean, minimum and maximum) vs 
measured concentrations of PFOA.  
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Fig. 5. Simulated vs experimental concentrations of PFOS and PFOA in plasma from two population groups, whose mean age is 25 and 54 
years old.  
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Fig. 6. Simulated vs experimental concentrations of PFOS in liver, brain, lung and kidney.  
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Fig. 7. Simulated vs experimental concentration of PFOA in liver, brain, lung and kidney. 
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Regarding the elimination process, the behaviour of the parameters Tm and Kt 
is analogous to the metabolic reaction of the Michaelis-Menten (Kou et al., 2005). Tm is 
the maximum amount of PFOS or PFOA that can be resorbed back from the urine to 
plasma compartment, being analogous to the maximum velocity of reaction (Vmax) in 
the Michaelis-Menten reactions. In turn, Kt is obtained when Vmax is equal to Vmax/2, 
and it is analogous to the Michaelis-Menten constant (Km). When Tm increases, the final 
values of concentration in tissues also increase. In contrast, when Kt increases the 
concentration in tissues decreases, because the increasing of Kt generates a decreasing 
of the slope of the trend, and subsequently the final result when the simulation 
converges. For Free fraction, the increasing of the parameter generates a decreasing of 
the final outcomes because the amount of free fraction is proportional to the tissue 
concentration. For the intake, the bigger the value the bigger the final concentration 
found in human tissues, because a higher amount of chemicals enter the human body. 
 
3.3. Model validation 
3.3.1 Visual validation 
The most usual process of model validation in PBPK models is the visual 
comparison of simulation results and experimental values (Chiu et al., 2007). The 
simulation of the mean, minimum and maximum was conducted in plasma, liver, brain, 
lung and kidney for PFOS and PFOA, and compared with the experimental values found 
in Tarragona County (Ericson et al., 2007; Pérez et al., 2013). The comparison of 
experimental data and the simulation trends is depicted in Figures 2, 3 and 4. The 
simulations were run for 90 years that is the maximum age of the experimental data 
available. All the simulations trends followed a hyperbolic profile similar to the Michaelis-
Menten saturation curve (Kou et al., 2005), that reach the convergence when the age of 
the population is close to 60 years old. The results for the most of the simulations were 
that the simulation trend was in between the data of experimental results. The differences 
between the minimum and maximum values of the experimental results were statistically 
significant. For PFOS, the minimum and maximum concentrations in the steady state 
ranged 3.0-405, 1.5-23.0, 3.0-61.8 and 6.0-269 ng/g in liver, brain, lung and kidney, 
respectively. For PFOA, the minimum and maximum concentration in the steady state 
ranged 3.0-99, 6.0-88 and 3.0-12 for liver, brain and kidney, respectively. The ranges 
found in experimental data imply that the range of simulation results would be bigger 
than the experimental ranges and thus a visual validation can be established. For 
plasma, all the experimental results were between the maximum and minimum for PFOS 
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and PFOA (Figure 2 and 5). The most part of the experimental results found in plasma 
were close to the median. For PFOA, the distribution of the experimental results in 
plasma was closer to the median in comparison to PFOS, where the dispersion was 
higher. In liver, all the experimental PFOA values were in the range of minimum and 
maximum concentration. In contrast, few outliers were found for PFOA, being out of the 
simulation range. In brain, all the experimental data were in the range for PFOA, but in 
PFOS two experimental points were out of simulation range. In lung, for PFOA five 
experimental points were out of the range and for PFOS all the experimental points were 
out of the range with only one exception. Finally, in kidney, for PFOA all the experimental 
points were in the range, but for PFOS seven experimental points were out of the range. 
Over all, visual inspections establish that the simulations results for PFOA were better 
than the simulations results for PFOS, thus validating the PBPK model.  
Furthermore, the box plot of experimental data and simulation results (in the 
steady state) is depicted in Figures 6 and 7. Two population groups according to age 
were studied: adults from 20 to 30 years old (average: 25 years old), and people aging 
from 50 to 60 years old (average: 54 years old). Many outliers were found in the 
simulation box plot, but the simulated and experimental box plot were very coincident in 
the ranges. Regarding the other tissues, the box plot showed a bigger dispersion of the 
results in the experimental tissue in comparison to the simulation. The most notably 
dispersion was in lungs and kidney, for PFOS, and in lung, for PFOA. The analysis of 
the box plot is in agreement with the simulation trends and improves the visual analysis 
of the results.  
However, the validation of the model depends also on the range of the simulation 
results. In a first step, the simulations generated by the LHS were not converging, and 
the concentration of PFOS and PFOA were out of the range. Afterwards, the values of 
Tm, Kt and Free were recalibrated to get the convergence of the simulations, obtaining 
its minimum and maximum values (Table 2). The values of Tm, Kt and Free were lower 
than those generated with the LHS and, therefore, the final simulations of PFOS and 
PFOA may be underestimated. Lung and kidney were the tissues with more experimental 
points out of the range, and the model may be considered useless to simulate PFOS in 
these of PFOS tissues. This fact evidences the necessity to include the uncertainty of 
the parameters for the evaluation of the validity of the PBPK models. The validity of the 
model in lungs, for PFOS and PFOA, and kidney, for PFOS, should be reconsidered.  
Concentration of PFOS and PFOA in tissues depends highly on Pk values. The 
Pks were previously assessed using data found in human tissues and plasma (Fàbrega 
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et al., 2014; Maestri et al., 2006). Whereas the simulated concentration in plasma was 
fitted with the experimental values for both PFOS and in PFOA, the simulation 
concentration found in some tissues were far from the experimental value. This fact 
demonstrated that these Pks should be better estimated using better experimental data. 
Mathematical algorithms used to provide a good estimation tool for the assessment of 
Pks in environmental contaminants, but for PFOS and PFOA the behaviour of these 
compounds makes it difficult to estimate due to the ambiphilic structure of PFASs (Peyret 
et al., 2010). Thus, the only way to estimate the Pks in PFOS and PFOA is the use of 
experimental data. Due to the relatively good fitting between simulation and experimental 
results in plasma, we can assume that one of the main factors responsible of the results 
obtained in tissues others than plasma were the PKs, besides of the parametric 
uncertainty.  
 
3.3.2. Statistical validation 
To assure the statistical validity of the final results, a student’s t-test was 
performed. Data are summarized in Tables 3 and 4. Plasma levels corresponding to two 
age groups were compared (25 and 45 years old). Probabilities (p values) ranged from 
0.69 to 0.86 for PFOS and PFOS, assuming equal variance. In consequence, there was 
no significant difference between experimental and simulated results. Assuming unequal 
variance, p values ranged from 0.53 to 0.73, and no significant differences were proved 
between experimental and simulation results. In other tissues, the validity of the model 
depends on the α value. For α=1% the results had significant differences for PFOA in 
brain and lung, and for PFOS in lung and kidney. Assuming α=5% significant differences 
were observed in liver, brain and lung in PFOA and in liver, lung and kidney in PFOS. 
The PBPK model is validated to simulate plasma, but in other tissues the model do not 
successfully simulates the concentration of PFOS and PFOA. The process of model 
validation differed depending on the fact of using visual analysis or statistical analysis for 
model validation. For visual analysis, all the simulation should be considered as a valid, 
since most experimental values fell in simulation ranges. In contrast, statistical analysis 
test statistical significance of two groups of data with clear set of criteria and avoid human 
biases in judgement. Althought, visual analysis are predominant in PBPK modeling, 
statistical analysis should be incorporated in the model validation to avoid biases in the 
visual validation. 
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Table 3: Two sample t- test of simulated and experimental concentration of PFOS and 
PFOA in plasma tissue for different age groups, assuming equal and unequal variances. 
     Equal variances   Unequal variances 
Age Group 
 Hα = 1% Hα = 5% P  Hα = 1% Hα = 5% P 
PFOS 25 years old  0 0 0.69  0 0 0.61 54 years old  0 0 0.69  0 0 0.53 
PFOA 25 years old  0 0 0.86  0 0 0.72 54 years old  0 0 0.85  0 0 0.73 
 
Table 4: Two sample t- test of simulated and experimental concentration of PFOS and 
PFOA.  
    PFOS   PFOA 
Tissue   Hα = 1% Hα = 5% P  Hα = 1% Hα = 5% P 
Liver  0 1 0.027  0 1 0.05 
Brain  0 0 0.34  1 1 1.56E-15 
Lung  1 1 5.42E-07  1 1 0.003 
Kidney  1 1 5.23E-04  0 0 0.162 
 
4. Conclusions  
The study of the uncertainty depends on the parametric data and the structure of 
the model. Thus, the study of the parametric uncertainty is model-dependent. 
Consequently, the conclusions are also model-dependent and cannot be extrapolated to 
all the PBPK models. The result of this study may help PBPK modelers to identify the 
most uncertain parameters and the influence of the uncertainty in PBPK modelling. The 
parameters studied were Tm, Kt, free and intake, since they had the highest contribution 
according to the SA. In fact, the SA contribution onto the variance of these four 
parameters was 82.6, for PFOS, and 99.9%, for PFOA. A greater confidence in 
uncertainty and variability analyses would result if parameter distributions and 
correlations among parameters etc. are based on the best available biological 
understanding of the systems. Therefore, the real uncertainty associated to the PBPK 
parameters may be underestimated. The validation of the PBPK model was performed 
visually and using statistical analysis (t-test). For plasma the model outcomes were 
considered as a validated for PFOS and PFOA, either by using visual analysis or the t-
test. In contrast, the visual validation of the PBPK model appeared to be suitable for the 
most part of the scenarios, but the statistical analysis showed that for many scenarios 
was not valid. The tissue simulations were not considered as valid for lungs and kidney 
in PFOS, and for brain and lungs in PFOA, according to the student’s t-test. Statistical 
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analysis should to be included in the validation process of PBPK modeling to avoid 
biases in the visual validation. Pk is the responsible of the distribution of PFOS and PFOA 
to tissues other than plasma. To adjust the simulations, more accurate Pks values should 
be found by using better experimental data. 
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Discussion of Chapter VI 
The uncertainty associated to the PBPK model was studied to the case-study of 
PFOS and PFOA. The visual validation of the model suggests that the PBPK model was 
able to simulate very precisely PFOS and PFOA in plasma, liver, kidney, brain and lungs. 
However, a deep statistical treatment, based on the Student’s t-test, revealed that 
models may not be fully validated. In general terms, there was a good fitting for plasma, 
while the statistical validation for the rest of the tissues was not so successful. Assuming 
a level of significance of the 1% (α=1%), significant differences were noted for PFOA in 
brain and lungs, and PFOS in lung and kidney. Assuming α=5%, significant differences 
were observed for PFOA in liver, brain and lung, and for PFOS in liver, lung and kidney. 
This means that the PBPK model can perfectly predict the concentration in plasma, but 
there is more uncertainty regarding its suitability for other body compartments. In liver, 
which is a target organ for both chemicals, the PBPK model may be considered as valid 
according to the visual validation, but not validated according to the statistical analysis. 
This uncertainties could be linked to the Pks, whose values were obtained by using 
experimental data coming from only 20 autopsy individuals. To adjust the simulations 
results, more accurete Pks should be found by using better experimental data. 
In conclusion, it is here confirmed that the visual study of the PBPK model 
outcomes must be complemented with some statistical treatment for a correct model 
validation. Although the statistic validation of PBPK models has been poorly used in the 
past, our results indicate that this should be an extended practice to avoid visual biases. 
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GENERAL DISCUSSION 
 
PCDD/Fs and PFASs are widely spread environmental contaminants. They are 
highly persistent in the environment and bioaccumulative in living organisms. Moreover, 
these pollutants are very toxic for human health, while they own a long-range transport 
capacity. PCDD/Fs were originally included in the Stockholm Convention as POPs, while 
PFOS was also added in 2009. In addition PFOA is a serious candidate to enter that list. 
Consequently, the human health risk associated to these two families of pollutants need 
to be carefully assessed.  
In silico techniques are receiving an important attention as alternative methods 
to classical toxicological methods. PBPK models may improve the assessment of human 
health risk, and therefore there is a need of reliable PBPK models. The use of PBPK 
models, as techniques to estimate the internal dose to environmental pollutants, has 
been incipient in the past. Even more, approaches on PCDD/Fs and PFASs are 
particularly scarce. Previous studies have been mainly focused on specific PCDD/F 
congeners, on one hand, and only on PFOS and PFOA, on the other one. PBPK models 
may improve the assessment of health risks by predicting the time-course concentration 
of pollutants in human tissues. The use of PBPK in human health risk assessment allows 
extrapolating the cross-species, cross-route, the dose and the time of the predictions, 
without the need of experimental analysis.  
The main objective of this thesis was to demonstrate the capability of PBPK 
models to estimate the body burdens of mixtures of environmental pollutants. The 
present work was focused on the development of a PBPK model to assess the time 
course concentration of PCDD/Fs and PFASs in human tissues, as a tool of potential 
use in health risk assessment. 
In the process of PBPK model development, PCDD/Fs were chosen as classic 
POPs, while there are also extensive PK data available in the scientific literature. 
Moreover, PCDD/Fs have a relatively simply PK for its high absorption, since they are 
not metabolized in humans and whose elimination mechanism takes place mainly 
through bile. On the other hand, PFASs were also selected as representative of “new” 
POPs. In order to prioritize chemicals, a SOM-based hazard index was here developed. 
PFASs are toxic chemicals whose hazard was compared to other pollutants, including 
pharmaceuticals, pesticides, and endocrine disruptors among others. In addition to 
PCDD/Fs, the PBPK model was applied to PFOS and PFOA, being the most well known 
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PFASs in the research literature. After that, the model was also extended to PFASs other 
than PFOS and PFOA, for the very first time. 
Extrapolation of the PBPK model to other groups of environmental pollutants is 
subject to PK/PD knowledge. For chemicals with similar PK/PD characteristics to 
PCDD/Fs and PFASs, the PBPK model may be extended by changing the parametric 
data (basically the Pks and elimination constants) and slightly modifying the mechanism 
of elimination and/or metabolism. Thus, POPs like polychlorinated biphenyls (PCBs) or 
polybrominated diphenyl ethers (PBDEs) are good candidates to be modelled by 
applying the present PBPK model. However, the robustness and accuracy of PBPK 
models should be improved in the future. For instance, temporal dynamics of exposure 
concentration and physiological parameters should be included to consider the long-term 
exposure to POPs. Furthermore, taking into account toxicity of POPs and related 
substances in the neonate development, PBPK models could incorporate the mammary 
gland in the model structure in order to assess the transfer of the chemicals. On the other 
hand, since humans are really exposed to chemical mixtures, future PBPK modeling 
studies should incorporate possible interactions among the chemical compounds.  
The simulations of both PCDD/Fs and PFASs were, in general terms, reasonably 
coincident with experimental results. Moreover, the uncertainty in the PBPK model was 
incorporated to improve the process of model validation. The PBPK model developed in 
the present thesis has been demonstrated to be a reliable tool to simulate the levels of 
PCDD/Fs and PFASs in human tissues. PBPK models are not only a promising tool, but 
also a reality to simulate the concentrations of environmental pollutants in human tissues, 
for their subsequent use in human health risk assessment.  
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CONCLUSIONS 
 
General conclusion 
The PBPK model here developed has proven to be a reliable tool to simulate 17 
PCDD/F congeners and 11 PFASs in human tissues. The model was successfully 
validated for PCDD/Fs in adipose tissue for the first time, being this the target tissue 
where PCDD/Fs accumulate. Moreover, the model was simulated for PFOS and PFOA 
as well as other PFASs, elucidating its mechanism of elimination. Finally, the statistical 
analysis carried out in the PBPK model for PFOS and PFOA demonstrates that statistical 
analysis of the final outcomes is a necessary practice to be integrated in PBPK modeling 
to ensure the reliability of the simulations.  
 
Specific conclusions 
1) A SOM-based hazard index (HI) have been able to create a ranking of 
environmental chemicals based on their PBT properties. The pollutants studied 
using HI were 205 pollutants, including pharmaceutic compounds, pesticides, 
illicit drugs, PFASs, endocrine disruptors and UV filters. According to the HI 
outcomes, PFASs are among the most hazardous environmental pollutants for 
human health. 
2) IRICAP may assess the human health risk associated to the exposure of 
chemical mixtures and its aggregate effect. Although chemical interactions have 
not been considered in the IRICAP, the ranking should be able to prioritize 
chemical mixtures in river water, being extensible to other environmental 
compounds. 
3) PBPK models have proven to be a reliable tool to assess the concentration of 
PCDD/Fs in plasma and adipose tissue. Values from PBPK model simulations 
and experimental results of PCDD/Fs in plasma and adipose tissue were very 
similar.  
4) PBPK models are a feasible tool to reduce the cost of biological surveillance 
studies by minimizing the number of biological samples (e.g., blood and adipose 
tissue) where PCDD/Fs must be analyzed. They also allow estimating the long-
term accumulation of PCDD/Fs in human tissues, highlighting adipose tissue as 
the target tissue where PCDD/Fs mainly accumulate. 
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5) For the first time, a generic PBPK model was developed for PFASs. The structure 
of the PBPK model simulated a mechanism of urinary elimination with a 
mechanism of resorption of PFASs from urine to plasma, and a strong protein 
binding for all the compounds. According to data from the population in Tarragona 
County (Spain), the model was able to successfully simulate the concentration of 
PFASs in plasma. Although it is not the definitive proof of the pharmacokinetics 
of the PFASs under study, it demonstrates that this mechanism is able to simulate 
PFASs in plasma. 
6) The PBPK model for PFASs was validated in a case study in Norway, where 
experimental data of 5 PFASs in blood were available for the PFAS exposure for 
general population. The model was validated for PFHxS, PFOS, PFHpA, PFOA 
and PFNA. 
7) The visual and the statistical validation of the PBPK model differed for some 
tissues depending on the level of significance (α). The visual validation seemed 
to be sufficient for validation purposes, being the most largely extended method 
of PBPK validation. However, the statistical tests showed that the visual 
validation may not be enough to assure the reliability of the model.  
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ANNEX 1 
Supporting Information in Chapter 1 
Integrated risk index of chemical aquatic pollution 
(IRICAP): Case studies in Iberian rivers 
 
Table S1 
Geographical distribution of 77 sampling points where IRICAP was applied. 
Code  River  River Basin  Coordinates UTM 
Zone X Y 
LLO1 Llobregat Llobregat 31 416304 4679359 
LLO2 Llobregat Llobregat 31 407020 4659392 
LLO3 Llobregat Llobregat 31 405907 4617415 
CAR1 Cardener Llobregat 31 381484 4656936 
CAR2 Cardener Llobregat 31 387429 4643298 
CAR3 Cardener Llobregat 31 397127 4629284 
CAR4 Cardener Llobregat 31 403881 4616871 
LLO4 Llobregat Llobregat 31 403792 4607459 
LLO5 Llobregat Llobregat 31 410078 4594291 
ANO1 Anoia Llobregat 31 378856 4606045 
ANO2 Anoia Llobregat 31 388339 4602206 
ANO3 Anoia Llobregat 31 401051 4586728 
LLO6 Llobregat Llobregat 31 411036 4592524 
LLO7 Llobregat Llobregat 31 420247 4577928 
EBR1 Ebro Ebro 30 405193 4761644 
OCA Oca Ebro 30 466118 4731520 
EBR2 Ebro Ebro 30 503672 4726140 
ZAD Zadorra Ebro 30 517732 4742302 
EBR3 Ebro Ebro 30 513141 4715725 
NAJ Nájerilla Ebro 30 523620 4703281 
ARG Arga Ebro 30 602161 4740847 
EBR4 Ebro Ebro 30 565335 4696194 
EBR5 Ebro Ebro 30 619147 4653811 
GAL1 Gállego Ebro 30 714638 4705571 
GAL2 Gállego Ebro 30 681725 4622524 
HUE Huerva Ebro 30 673724 4609044 
EBR6 Ebro Ebro 30 692418 4604252 
MAR Martín Ebro 30 693300 4535853 
ESE Ésera Ebro 30 280915 4676203 
CIN1 Cinca Ebro 31 271142 4667380 
CIN2 Cinca Ebro 31 264776 4642241 
continue on next page 
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Code River River Basin Zone X Y 
RS Ribera Salada Ebro 31 370389 4658269 
SEG Segre Ebro 31 292482 4601301 
MAT Matarranya Ebro 31 262933 4564305 
ALG Algars Ebro 31 265824 4554895 
EBR7 Ebro Ebro 31 299521 4559714 
EBR8 Ebro Ebro 31 294619 4513636 
EBR9 Ebro Ebro 31 306788 4509432 
JUC1 Júcar Júcar 30 598583 4453975 
JUC2 Júcar Júcar 30 573092 4436231 
JUC3 Júcar Júcar 30 562110 4414506 
JUC4 Júcar Júcar 30 601713 4336027 
JUC5 Júcar Júcar 30 665927 4340496 
CAB1 Cabriel Júcar 30 627162 4439354 
CAB2 Cabriel Júcar 30 612534 4422400 
CAB3 Cabriel Júcar 30 614272 4410987 
CAB4 Cabriel Júcar 30 628595 4376486 
CAB5 Cabriel Júcar 30 642129 4355758 
JUC6 Júcar Júcar 30 707741 4328283 
JUC7 Júcar Júcar 30 720584 4336933 
MAG1 Magro Júcar 30 667953 4362542 
MAG2 Magro Júcar 30 711245 4348964 
JUC8 Júcar Júcar 30 729360 4343192 
BOR Borosa Guadalquivir 30 512435 4207084 
GUA1 Guadalquivir Guadalquivir 30 497027 4214205 
GUAM Guadiana 
Menor 
Guadalquivir 30 481267 4192450 
GUA2 Guadalquivir Guadalquivir 30 452771 4200519 
MAG Magaña Guadalquivir 30 456338 4242400 
GUAN Guadabullón Guadalquivir 30 431850 4199348 
GUA3 Guadalquivir Guadalquivir 30 395434 4207864 
YEG Yeguas Guadalquivir 30 384664 4246754 
GUAL Guadalmoral Guadalquivir 30 375522 4166800 
GUA4 Guadalquivir Guadalquivir 30 334794 4189933 
PIC Picachos Guadalquivir 30 315008 4180807 
BEM Bembézar Guadalquivir 30 279446 4224770 
CAC Cacín Guadalquivir 30 423215 4086558 
GEN1 Genil Guadalquivir 30 396109 4116460 
GEN2 Genil Guadalquivir 30 314734 4161417 
GUA5 Guadalquivir Guadalquivir 30 294339 4174415 
COR Corbones Guadalquivir 30 272990 4153778 
HER Herreros Guadalquivir 30 235090 4156650 
GUAA Guadaira Guadalquivir 30 267816 4123619 
GUA6 Guadalquivir Guadalquivir 29 761545 4129986 
GUA7 Guadalquivir Guadalquivir 29 759226 4107247 
GUA8 Guadalquivir Guadalquivir 29 751405 4094029 
GUAR Guadiamar Guadalquivir 29 742717 4130496 
GUA9 Guadalquivir Guadalquivir 29 736448 4084204 
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Table S2. 
SOM input PBT values after normalization. 
 
Half-life Bioaccumulationn Toxicity 
Acetaminophen 0.066 0.117 0.268 
Acridone 0.089 0.045 0.346 
Albendazol 0.067 0.397 0.535 
Alprazolam 0.120 0.250 0.547 
Amlodipine 0.077 0.386 0.536 
Amoxicillin 0.033 0.117 0.238 
Atenolol 0.049 0.117 0.297 
Atorvastatin 0.050 0.410 0.684 
Azaperol 0.155 0.334 0.493 
Azaperone 0.179 0.295 0.506 
Azithromycin 0.274 0.544 0.466 
Bezafibrate 0.072 0.117 0.520 
Carazolol 0.066 0.417 0.472 
Carbamazepine 0.082 0.301 0.435 
Cefalexin 0.022 0.117 0.202 
Cimetidine 0.092 0.117 0.355 
Ciprofloxacin 0.115 0.117 0.177 
Citalopram 0.162 0.501 0.540 
Clarithromycin 0.218 0.411 0.462 
Clopidogrel 0.131 0.513 0.546 
Codeine 0.118 0.106 0.379 
Desloratadine 0.127 0.638 0.602 
Dexamethasone 0.161 0.221 0.307 
Diazepam 0.084 0.358 0.506 
Diclofenac 0.105 0.117 0.442 
Diltiazem 0.085 0.339 0.465 
Dimetridazole 0.086 0.117 0.411 
Enalapril 0.029 0.117 0.335 
Enalaprilat 0.014 0.117 0.112 
Erithromycin 0.212 0.395 0.416 
Famotidine 0.098 0.117 0.244 
Fluoxetine 0.111 0.513 0.603 
Fluvastatin 0.044 0.117 0.443 
Furosemide 0.129 0.117 0.354 
Gemfibrozil 0.067 0.117 0.524 
Glibenclamide 0.119 0.663 0.664 
Hydrochlrothiazide 0.124 0.117 0.258 
Hydrocodone 0.154 0.133 0.385 
Ibuprofen 0.054 0.117 0.438 
Indomethacine 0.083 0.117 0.602 
Iopromide 0.088 0.117 0.000 
Irbesartan 0.077 0.742 0.716 
Ketoprofen 0.055 0.117 0.350 
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Half-life Bioaccumulationn Toxicity 
Levamisol 0.077 0.207 0.459 
Loratadine 0.121 0.726 0.724 
Lorazepam 0.095 0.292 0.475 
Losartan 0.123 0.407 0.507 
Meloxicam 0.072 0.452 0.530 
Metformin 0.066 0.117 0.157 
Metoprolol 0.135 0.203 0.317 
Metronidazole 0.077 0.117 0.332 
Metronidazole-OH 0.060 0.117 0.203 
Nadolol 0.070 0.117 0.370 
Naproxen 0.044 0.117 0.365 
Norfluoxetine 0.108 0.569 0.574 
Ofloxacin 0.156 0.117 0.160 
Olanzapine 0.154 0.386 0.468 
Oxycodone 0.164 0.117 0.335 
Paroxetine 0.073 0.656 0.607 
Phenazone 0.074 0.117 0.557 
Piroxicam 0.077 0.117 0.326 
Pravastatin 0.019 0.117 0.381 
Propranolol 0.061 0.400 0.474 
Propyphenazone 0.080 0.222 0.619 
Ranitidine 0.118 0.117 0.311 
Ronidazole 0.068 0.117 0.308 
Salbutamol 0.064 0.117 0.347 
Sertraline 0.137 0.740 0.646 
Sotalol 0.070 0.117 0.323 
Sulfamethoxazole 0.104 0.117 0.357 
Tamsulosin 0.086 0.304 0.444 
Tenoxicam 0.100 0.000 0.272 
Tetracyclin 0.161 0.117 0.262 
Thiabendazole 0.077 0.304 0.467 
Torasemide 0.123 0.443 0.431 
Trazodone 0.215 0.419 0.498 
Trimethoprim 0.096 0.117 0.307 
Valsartan 0.030 0.117 0.458 
Venlafaxine 0.142 0.429 0.517 
Warfarin 0.065 0.339 0.554 
Xylazine 0.107 0.620 0.617 
9-Tetrahydrocannabinol  (THC) 0.084 1.000 0.886 
2-oxo-3-hydroxy-LSD 0.104 0.117 0.311 
1S,2R(+)Ephedrine 0.055 0.037 0.368 
11-hydri-9-THC 0.073 0.686 0.768 
11-nor-9-carboxy-9-THC 0.051 0.410 0.673 
6-acetylmorphine 0.116 0.162 0.404 
Amphetamine 0.069 0.194 0.449 
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Half-life Bioaccumulationn Toxicity 
Benzoilecgonine 0.057 0.117 0.095 
Cannabidiol 0.072 0.850 0.847 
Cannabinol 0.083 0.940 0.859 
Cocaethylene 0.076 0.333 0.469 
Cocaine 0.074 0.278 0.438 
EDDP perchlorate 0.141 0.686 0.628 
Heroin 0.100 0.166 0.404 
Lysergic acid diethylamide (LSD) 0.113 0.378 0.441 
MDMA 0.063 0.255 0.467 
Metaamphetamine 0.071 0.242 0.476 
Methadonehydrochloride 0.151 0.530 0.571 
Morphine 0.120 0.117 0.344 
1H-Benzotriazole (BT) 0.065 0.145 0.457 
Benzil paraben 0.054 0.473 0.561 
Bisphenol a (BPA) 0.089 0.436 0.578 
Caffeine 0.076 0.117 0.263 
Etilparaben 0.047 0.304 0.499 
Diethylstilbestrol (DES) 0.078 0.706 0.704 
Estradiol (E2) 0.101 0.542 0.598 
Estradiol 17-glucuronide (E2-17G) 0.062 0.117 0.448 
Estriol (E3) 0.089 0.301 0.434 
Estriol 16-glucuronide (E3-16G) 0.038 0.117 0.082 
Estriol 3-sulfate (E3-3S) 0.107 0.117 0.182 
Estrone (E1) 0.119 0.406 0.557 
Estrone 3-glucuronide (E1-3G) 0.072 0.117 0.318 
Estrone 3-sulfate (E1-3S) 0.140 0.117 0.245 
Ethinyl estradiol (EE2) 0.141 0.489 0.556 
Metilparaben 0.045 0.225 0.472 
Nonylphenol (NP) 0.056 0.491 0.776 
Nonylphenol diethoxylate (NP2EO) 0.054 0.360 0.678 
Nonylphenol monocarboxylate 
(NP1EC) 
0.028 0.234 0.621 
Nonylphenol monoethoxylate 
(NP1EO) 
0.047 0.402 0.712 
Octylphenol (OP) 0.054 0.450 0.738 
Octylphenol diethoxylate (OP2EO) 0.054 0.360 0.678 
Octylphenol monocarboxylate 
(OP1EC) 
0.070 0.234 0.553 
Octylphenol monoethoxylate 
(OP1EO) 
0.045 0.326 0.667 
Propilparaben 0.049 0.392 0.527 
Tolytriazon (TT) 0.106 0.117 0.393 
Triclocaraban 0.159 0.680 0.636 
Triclosan 0.137 0.658 0.654 
Tris (2-cloroetil) phosphate (TCEP) 0.072 0.000 0.419 
Tris (butoxietil) phosphate (TBEP) 0.000 0.308 0.489 
Tris (cloroisopropil) phosphate 
(TCCP) 
0.081 0.251 0.521 
3-hydroxycarbofuran 0.058 0.117 0.327 
Acethochlor 0.092 0.391 0.627 
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Half-life Bioaccumulationn Toxicity 
Alachlor 0.092 0.466 0.627 
Atrazine 0.130 0.204 0.511 
Azynphos ethyl 0.052 0.448 0.569 
Azinphos methyl 0.049 0.347 0.486 
Buprofezin 0.110 0.587 0.644 
Carbofuran 0.075 0.281 0.494 
Chlorfenvinphos 0.098 0.318 0.567 
Chlorpyriphos 0.106 0.689 0.666 
Deisopropylatrazine 0.122 0.000 0.426 
Desethylatrazine 0.125 0.034 0.447 
Diazinon 0.059 0.511 0.591 
Dichlofenthion 0.080 0.726 0.677 
Dimethoate 0.022 0.117 0.342 
Diuron 0.119 0.336 0.470 
Ethion 0.020 0.706 0.787 
Fenitrothion 0.059 0.432 0.558 
Fenoxon 0.048 0.086 0.466 
Fenoxon sulfone 0.052 0.117 0.331 
Fenoxon sulfoxide 0.050 0.117 0.326 
Fenthion 0.050 0.555 0.609 
Fenthion sulfone 0.054 0.239 0.471 
Fenthion sulfoxide 0.052 0.218 0.465 
Hexythiazox 0.120 0.784 0.706 
Imazalil 0.133 0.513 0.742 
Imdacloprid 0.105 0.117 0.688 
Isoproturon 0.085 0.366 0.490 
Malathion 0.015 0.287 0.453 
Methiocarb 0.074 0.374 0.536 
Metolachlor 0.094 0.370 0.621 
Molinate 0.056 0.418 0.514 
Omethoate 0.021 0.117 0.279 
Parathion ethyl 0.055 0.514 0.584 
Parathion methyl 0.051 0.364 0.525 
Prochloraz 0.161 0.556 0.589 
Propanil 0.093 0.397 0.535 
Propazine 0.133 0.254 0.564 
Pyriproxyphen 0.072 0.780 0.700 
Simazine 0.128 0.138 0.457 
Terbutryn 0.134 0.379 0.634 
Tolclofos methyl 0.085 0.627 0.651 
i,p-PFNA 0.329 0.234 0.583 
I,p PFNS 0.458 0.234 0.525 
L-PFBS 0.165 0.117 0.226 
L-PFDS 0.570 0.234 0.586 
L-PFHpS 0.305 0.117 0.404 
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Half-life Bioaccumulationn Toxicity 
L-PFHxS 0.249 0.117 0.344 
L-PFOS 0.373 0.117 0.464 
PFBA 0.066 0.117 0.289 
PFDA 0.276 0.234 0.567 
PFDoA 0.550 0.410 0.748 
PFHpA 0.197 0.117 0.445 
PFHxA 0.160 0.117 0.387 
PFHxDA 1.000 0.117 1.000 
PFNA 0.295 0.234 0.565 
PFOA 0.242 0.117 0.505 
PFODA 1.000 0.117 0.891 
PFOSA 0.438 0.819 0.689 
PFPeA 0.128 0.117 0.590 
PFTeDA 0.897 0.234 0.875 
PFTrDA 0.694 0.234 0.811 
PFUdA 0.550 0.410 0.748 
2,2'-dihydroxy-4-
methoxybenzophenone (DHMB) 
0.069 0.376 0.586 
4,4'-dih droxybenzophenone (4DHB) 0.073 0.123 0.486 
4-hydroxybenzophenone (4HB) 0.074 0.259 0.510 
4-methylbenzylidene camphor 
(4MBC) 
0.132 0.838 0.674 
Benzophenone-1 (BP1) 0.072 0.243 0.536 
Benzophenone-2 (BP2) 0.070 0.215 0.518 
Benzophenone-3 (BP3) 0.071 0.371 0.573 
Ethyl 4-aminobenzoate (Et-PABA) 0.060 0.210 0.454 
Ethylexyl dimethyl PABA (OD-PABA) 0.067 0.814 0.683 
Ethylexyl methoxycinnamate (EHMC) 0.036 0.819 0.653 
Octocrylene (OC) 0.056 0.986 0.672 
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Table S3. 
PBT properties of the studied compounds after SOM application.  
  
Half-life Bioaccumulation Toxicity 
PFHxDA 2.48 0.77 2.33 
PFODA 2.48 0.77 2.33 
PFTeDA 2.48 0.77 2.33 
PFTrDA 2.48 0.77 2.33 
PFDoA 2.11 0.93 2.53 
PFUdA 2.11 0.93 2.53 
THC 0.35 2.70 2.40 
Cannabidiol 0.35 2.70 2.40 
Cannabinol 0.35 2.70 2.40 
4MBC 0.35 2.70 2.40 
OD-PABA 0.35 2.70 2.40 
EHMC 0.35 2.70 2.40 
OC 0.35 2.70 2.40 
Hexythiazox 0.42 2.57 2.33 
PFOSA 0.42 2.57 2.33 
Irbesartan 0.30 2.57 2.40 
Pyriproxyphen 0.30 2.57 2.40 
Loratadine 0.36 2.47 2.30 
Sertraline 0.36 2.47 2.30 
Dichlofenthion 0.36 2.47 2.30 
L-PFDS 1.93 0.80 2.33 
Glibenclamide 0.41 2.30 2.20 
EDDPperchlorate 0.41 2.30 2.20 
Triclocaraban 0.41 2.30 2.20 
Triclosan 0.41 2.30 2.20 
Chlorpyriphos 0.41 2.30 2.20 
DES 0.29 2.27 2.30 
11-hydri-9-THC 0.25 2.20 2.40 
Ethion 0.25 2.20 2.40 
Paroxetine 0.34 2.13 2.17 
Tolclofos methyl 0.34 2.13 2.17 
Desloratadine 0.44 2.07 2.07 
Xylazine 0.44 2.07 2.07 
Buprofezin 0.37 1.97 2.03 
NP 0.24 1.70 2.40 
Inazalil 0.24 1.70 2.40 
Fenthion  0.26 1.87 2.13 
I,p PFNS 1.46 0.73 2.00 
L-PFOS 1.46 0.73 2.00 
Norfluoxetine 0.43 1.80 1.90 
Methadonehydrochloride 0.43 1.80 1.90 
Prochloraz 0.43 1.80 1.90 
Fluoxetine 0.29 1.77 2.00 
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Half-life Bioaccumulation Toxicity 
E2 0.29 1.77 2.00 
Diazinon 0.29 1.77 2.00 
Parathion ethyl 0.29 1.77 2.00 
i,p-PFNA 1.12 0.87 2.00 
Atorvastatin 0.24 1.47 2.27 
11-nor-9-carboxy-9-THC 0.24 1.47 2.27 
NP1EO 0.24 1.47 2.27 
OP 0.24 1.47 2.27 
Terbutryn 0.44 1.27 2.23 
Azithromycin 0.50 1.63 1.77 
Citalopram 0.50 1.63 1.77 
Clopidogrel 0.50 1.63 1.77 
EE2 0.50 1.63 1.77 
Alachlor 0.23 1.50 2.17 
NP2EO 0.27 1.30 2.17 
OP2EO 0.27 1.30 2.17 
OP1EO 0.27 1.30 2.17 
Acethochlor 0.27 1.30 2.17 
Meloxicam 0.26 1.50 1.87 
Benzilparaben 0.26 1.50 1.87 
BPA 0.26 1.50 1.87 
Azynphos ethyl 0.26 1.50 1.87 
Fenitrothion 0.26 1.50 1.87 
DHMB 0.24 1.33 2.03 
Venlafaxine 0.48 1.43 1.67 
PFDA 0.86 0.80 1.87 
PFNA 0.86 0.80 1.87 
Metolachlor 0.33 1.13 2.00 
E1 0.29 1.40 1.77 
Molinate 0.29 1.40 1.77 
Propanil 0.29 1.40 1.77 
Azaperone 0.58 0.93 1.93 
Clarithromycin 0.53 1.33 1.53 
Erithromycin 0.53 1.33 1.53 
Olanzapine 0.53 1.33 1.53 
Torasemide 0.53 1.33 1.53 
Trazodone 0.53 1.33 1.53 
Carazolol 0.35 1.30 1.67 
Losartan 0.35 1.30 1.67 
Warfarin 0.25 1.17 1.87 
BP3 0.25 1.17 1.87 
Albendazol 0.24 1.30 1.73 
Amlodipine 0.24 1.30 1.73 
Propilparaben 0.24 1.30 1.73 
Methiocarb 0.24 1.30 1.73 
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Half-life Bioaccumulation Toxicity 
Azaperol 0.43 1.23 1.57 
LSD 0.43 1.23 1.57 
Diazepam 0.27 1.23 1.67 
Propranolol 0.27 1.23 1.67 
Isoproturon 0.27 1.23 1.67 
Chlorfenvinphos 0.33 0.97 1.87 
Alprazolam 0.46 0.83 1.87 
Propazine 0.46 0.83 1.87 
Parathion_methyl 0.21 1.13 1.73 
Carbamazepine 0.32 1.13 1.57 
Diltiazem 0.32 1.13 1.57 
Lorazepam 0.32 1.13 1.57 
Tamsulosin 0.32 1.13 1.57 
Thiabendazole 0.32 1.13 1.57 
Cocaethylene 0.32 1.13 1.57 
Diuron 0.32 1.13 1.57 
Azinphos methyl 0.22 1.10 1.63 
NP1EC 0.29 0.80 1.83 
OP1EC 0.29 0.80 1.83 
BP1 0.29 0.80 1.83 
Propyphenazone 0.34 0.67 1.90 
Etilparaben 0.20 0.93 1.67 
TBEP 0.20 0.93 1.67 
Carbofuran  0.20 0.93 1.67 
Metaamphetamine 0.22 0.80 1.70 
Metilparaben 0.22 0.80 1.70 
TCCP 0.22 0.80 1.70 
Fenthion sulfone 0.22 0.80 1.70 
Fenthion sulfoxide 0.22 0.80 1.70 
4HB 0.22 0.80 1.70 
BP2 0.22 0.80 1.70 
E3 0.37 0.97 1.37 
MDMA 0.21 0.90 1.57 
Malathion 0.21 0.90 1.57 
Indomethacine 0.29 0.50 1.87 
Phenazone 0.29 0.50 1.87 
Imdacloprid 0.29 0.50 1.87 
PFPeA 0.29 0.50 1.87 
Atrazine  0.26 0.63 1.70 
Cocaine  0.28 0.87 1.40 
Bezafibrate 0.25 0.47 1.70 
Gemfibrozil 0.25 0.47 1.70 
Levamisol 0.22 0.67 1.47 
Amphetamine 0.22 0.67 1.47 
Et-PABA 0.22 0.67 1.47 
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Half-life Bioaccumulation Toxicity 
L-PFHpS 0.60 0.33 1.37 
L-PFHxS 0.60 0.33 1.37 
PFHpA 0.60 0.33 1.37 
PFOA 0.60 0.33 1.37 
Fenoxon 0.26 0.47 1.57 
4DHB 0.26 0.47 1.57 
Fluvastatin 0.24 0.43 1.53 
Ibuprofen 0.24 0.43 1.53 
Valsartan 0.24 0.43 1.53 
BT 0.24 0.43 1.53 
E2-17G 0.24 0.43 1.53 
Deisopropylatrazine 0.48 0.29 1.43 
Desethylatrazine 0.48 0.29 1.43 
Hydrocodone 0.49 0.37 1.30 
Oxycodone 0.49 0.37 1.30 
PFHxA 0.49 0.37 1.30 
Dimetridazole 0.30 0.43 1.40 
Diclofenac 0.32 0.33 1.47 
TCEP 0.32 0.33 1.47 
Simazine 0.32 0.33 1.47 
6-acetylmorphine 0.26 0.50 1.33 
Heroin 0.26 0.50 1.33 
Codeine 0.36 0.40 1.30 
TT 0.36 0.40 1.30 
Dexamethasone 0.42 0.67 0.93 
Pravastatin 0.22 0.50 1.27 
Cimetidine 0.34 0.37 1.20 
Furosemide 0.34 0.37 1.20 
Sulfamethoxazole 0.34 0.37 1.20 
Morphine 0.34 0.37 1.20 
Nadolol 0.26 0.40 1.20 
Naproxen 0.26 0.40 1.20 
Enalapril 0.23 0.40 1.13 
Ketoprofen 0.23 0.40 1.13 
Metronidazole 0.23 0.40 1.13 
Piroxicam 0.23 0.40 1.13 
Salbutamol 0.23 0.40 1.13 
3-hydrosycarbofuran 0.23 0.40 1.13 
Dimethoate 0.23 0.40 1.13 
Fenoxon sulfone 0.23 0.40 1.13 
Fenoxon sulfoxide 0.23 0.40 1.13 
Acridone 0.25 0.37 1.13 
1S,2R(+)Ephedrine  0.25 0.37 1.13 
Ranitidine 0.26 0.40 1.03 
Trimethoprim 0.26 0.40 1.03 
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Half-life Bioaccumulation Toxicity 
2-oxo-3-hydroxy-LSD 0.26 0.40 1.03 
Metoprolol 0.04 0.60 1.00 
Atenolol 0.24 0.37 1.03 
Ronidazole 0.24 0.37 1.03 
Sotalol 0.24 0.37 1.03 
E1-3G 0.24 0.37 1.03 
Famotidine 0.31 0.40 0.87 
Hydrochlrothiazide 0.31 0.40 0.87 
Tetracyclin 0.31 0.40 0.87 
E1-3S 0.31 0.40 0.87 
Acetaminophen 0.26 0.37 0.90 
Tenoxicam 0.26 0.37 0.90 
Caffeine 0.26 0.37 0.90 
Omethoate 0.26 0.37 0.90 
PFBA 0.26 0.37 0.90 
L-PFBS 0.32 0.43 0.70 
Amoxicillin 0.27 0.40 0.73 
Cefalexin 0.27 0.40 0.73 
Metronidazole-OH 0.27 0.40 0.73 
Ciprofloxacin 0.28 0.40 0.57 
Enalaprilat 0.28 0.40 0.57 
Iopromide 0.28 0.40 0.57 
Metformin 0.28 0.40 0.57 
Ofloxacin 0.28 0.40 0.57 
Benzoilecgonine 0.28 0.40 0.57 
E3-16G 0.28 0.40 0.57 
E3-3S 0.28 0.40 0.57 
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ANNEX 2 
Supporting Information in Chapter 2 
PCDD/Fs in plasma of individuals living near a 
hazardous waste incinerator. A comparison of measured 
levels and estimated concentrations by PBPK modeling 
 
 
 
 
Figure S1. Temporal trends of PCDD/Fs in plasma of residents near the HWI of 
Constantí, Tarragona County (Catalonia, Spain). 
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Figure S2. Conceptual representation of the PBPK model for PCDD/Fs in 
humans. 
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Table S1.  
PCDD/F concentrations (pg/g lipid) in plasma of 40 individuals living in the vicinity of the 
HWI. 
Sample Age Gender I-TEQ WHO-TEQ 
1 49 Male 7.47 5.91 
2 50 Male 13.3 12.7 
3 61 Male 18.8 25.4 
4 56 Female 7.67 6.73 
5 40 Male 8.89 7.54 
6 50 Female 7.67 7.14 
7 65 Female 17.5 16.1 
8 47 Male 8.12 7.73 
9 48 Female 5.26 5.25 
10 28 Female 6.54 5.5 
11 33 Female 9.21 7.8 
12 53 Male 4.4 4.6 
13 55 Male 4.86 4.53 
14 22 Female 3.83 3.88 
15 56 Female 7.68 7.99 
16 51 Male 11 10.7 
17 52 Female 6.89 6.81 
18 23 Male 3.82 4.05 
19 51 Female 4 4.15 
20 26 Male 12.1 11.9 
21 36 Female 3 3.29 
22 32 Female 2.04 2.16 
23 44 Male 6.02 5.33 
24 41 Male 8.05 7.5 
25 67 Female 5.72 6.63 
26 48 Male 2.67 2.87 
27 43 Female 4.14 4.46 
28 52 Male 5.08 5.62 
29 45 Male 2.7 3.03 
30 51 Female 2.35 2.51 
31 44 Male 2.75 2.95 
32 50 Female 2.03 2.59 
33 64 Female 5.93 7.38 
34 43 Female 2.5 2.77 
35 48 Male 2.21 2.52 
36 50 Male 2.56 2.87 
37 49 Male 2.67 2.7 
38 49 Female 3.8 4.04 
39 60 Female 9.75 10.5 
40 47 Male 2.11 2.17 
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   I-TEQ WHO-TEQ 
Mean 
  6.18 6.26 
Standard deviation 
  5.37 4.06 
Minimum 
  2.03 2.16 
Maximum 
    18.8 25.4 
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ANNEX 3 
Supporting Information in Chapter 3 
A PBPK model to estimate PCDD/F levels in adipose 
tissue: Comparison with experimental values of 
residents near a Hazardous Waste Incinerator. 
 
Table S1. 
Absorption and intake used in the PBPK model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Intake of PCCD/F (pg day-1) 
 
Absorption 
(%) 
 1998 2002 2007 2012 
2,3,7,8-TCDD 97  28.6 6.1 3.9 5.6 
1,2,3,7,8-PeCDD 99  14.9 9.6 8.5 7.6 
1,2,3,4,7,8-HxCDD 98  43.4 11.6 5.3 3.6 
1,2,3,6,7,8-HxCDD 97  114 21.5 7.1 10.9 
1,2,3,7,8,9-HxCDD 96  41.6 11.5 4.8 6.9 
1,2,3,4,6,7,8-HpCDD 86  1292 92.4 28.3 69.6 
OCDD 76  9623 525 141 297 
2,3,7,8-TCDF 97  192 48.9 25.2 40.6 
1,2,3,7,8-PeCDF 99  125 28.2 11.4 9.2 
2,3,4,7,8-PeCDF 98  109 46.8 12.4 25.7 
1,2,3,4,7,8-HxCDF 97  231 53.3 20.9 33.4 
1,2,3,6,7,8-HxCDF 97  107 27.6 12.3 13.9 
1,2,3,7,8,9-HxCDF 95  10.2 10.4 3.1 6.6 
2,3,4,6,7,8-HxCDF 96  42 32.7 5.8 9.3 
1,2,3,4,6,7,8-HpCDF 87  708 69.8 72.2 127 
1,2,3,4,7,8,9-HpCDF 99  89.7 15.8 13 23.9 
OCDF 95  4420 93.4 476 201 
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Table S2.  
Physiological parameters used in the PBPK model.  
Tissue Tissue volume 
(L) 
Cardiac output (L/h) 
Blood 4.5 - 
Liver 1.5 182.2 
Fat 10.3 11.1 
Kidney 0.3 3.5 
Muscle 24 43.2 
Richly perfused 1.8 51.1 
Skin 2.2 3.2 
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Table S3. 
Partition coefficients (Pk) used in the PBPK model (unitless).  
 Liver Kidney Fat Muscle Richly perfused Skin 
2,3,7,8-TCDD 9.8 3.1 247 17 4.1 2.5 
1,2,3,7,8-PeCDD 17 2.9 432 19 4.5 2 
1,2,3,4,7,8-HxCDD 30 1.2 117 5.1 2.4 2.6 
1,2,3,6,7,8-HxCDD 55 3 219 13 2.7 1.7 
1,2,3,7,8,9-HxCDD 297 11 1466 134 30 2.6 
1,2,3,4,6,7,8-HpCDD 34 2.3 143 39 14 14 
OCDD 56 2.8 55 26 16 14 
2,3,7,8-TCDF 18 0.97 55 4.7 2.3 9.4 
1,2,3,7,8-PeCDF 19 1.4 130 10 6.3 9.2 
2,3,4,7,8-PeCDF 45 2.1 336 38 3.5 2.6 
1,2,3,4,7,8-HxCDF 25 1.6 75 11 6 2.1 
1,2,3,6,7,8-HxCDF 45 1.7 130 25 2.2 2.4 
1,2,3,7,8,9-HxCDF 1.8 0.4 172 2.9 3.7 11 
2,3,4,6,7,8-HxCDF 3.8 0.9 48 3.1 3.5 6.2 
1,2,3,4,6,7,8-HpCDF 22 0.9 139 7.3 2.3 11 
1,2,3,4,7,8,9-HpCDF 8.7 0.3 113 3.1 1.9 11 
OCDF 15 1.7 144 5.5 4.5 14 
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